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Abstract 
Streptococcus pneumoniae is an important cause of morbidity and mortality worldwide. 
Acquisition of antimicrobial resistance, particularly to ~-lactams, by this pathogen has 
complicated treatment options. The prevalence of penicillin-resistant pneumococci in New 
Zealand has increased greatly since 1993. To investigate the population structure of resistant 
pneumococci, 200 isolates collected between 1997-2001 with reduced susceptibility to 
penicillin were obtained from a Christchurch clinical laboratory. Isolates were examined using 
DNA macro-restriction profiling (MRP) and analysis of pbp genes. Four major clonal lineages 
were identified, the largest and most homogenous containing 97 (48.5%) of the isolates. Two of 
the four major PFGE groups (MRPs 2 and 3), could tentatively be described as belonging to 
globally widespread epidemic clones; the Spain23F -1 clone and the France9v -3 clone 
respectively. 
To verify whether the New Zealand penicillin-resistant clones of S. pneumoniae had been 
recovered elsewhere in the world, 74 clinical isolates were chosen for analysis by multilocus 
sequence typing (MLST). These isolates were national samples, and represented pneumococci 
from multiple serotypes, multiple years, and from both invasive and non-invasive isolates. 
MLST is a technique based on nucleotide sequences of housekeeping genes. MLST permits 
strain identification by interrogation of a global database on the Internet. The isolates identified 
from throughout New Zealand were mainly found to belong to well-described international 
clonal lineages. The globally widespread Spain23F -1 and Spain9V -3 clones were represented by 
14 and 11 isolates, respectively. The most prolific group of antibiotic-resistant pneumococci in 
New Zealand were derived from a recently described Taiwan19F-14 clone, and represented by 26 
isolates. 
Although the Taiwanl9F-14 clone seemed genetically homogenous as assessed by MRP, the 
isolates varied in phenotype as observed by the range of ~-lactam MICs within the clonal 
population. Examination of ~-lactam resistance in New Zealand variant of the Taiwan19F_14 
clone was performed by pbp gene RFLP and DNA sequence analysis. Resistance was imparted 
at the molecular level by mosaic pbp genes. It appears that horizontal gene transfer from other 
resistant S. pneumoniae isolates has led to current pbp alleles observed in the Taiwan19F-14 
clone. 
The molecular mechanism of erythromycin resistancc was invcstigated in 150 pneumococcal 
isolates. On hundred and forty-onc isolatcs (94.0%) had high-level erythromycin resistance 
(MIC ~ 256 ~Lg/ml); the remaining 9 (6.0%) isolates had MICs bctween 2-8 f!g/ml. PCR 
detection of the macrolide resistance determinants was pcrformed on all 150 isolates. The 
mej(A) gene was detected in 105 (70.0%) isolates and thc erm(B) gene in 142 (94.7%) isolates. 
Both the mej(A) and erm(B) genes were detected in 97 (64.7%) isolates. The mef(A) erm(B) 
genotype was associated with the New Zealand variant of the Taiwan19F-14 clone. 
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Introduction 
1.1 History of Streptococcus pneumoniae 
The pneumococcus was fIrst identifIed in 1881 concurrently by Louis Pasteur in France, who 
named it Microbe septicemique du sa live, and George Sternberg in the United States who called 
it Micrococcus pasteuri. By the late 1880s the organism had become widely recognised as the 
most common cause of lobar pneumonia and consequently adopted the name pneumococcus. 
The name Diplococcus pneumoniae was assigned in 1920, which was eventually to be changed 
to its current name, Streptococcus pneumoniae, in 1974. The term pneumococcus still 
perseveres today as a common term for S. pneumoniae, and the two are used interchangeably in 
this text. A comprehensive review of the early classifIcation of S. pneumoniae is provided in 
Benajamin White's Biology of Pneumococcus, to which the interested reader is referred (White, 
1938). 
Few organis111S have contributed as much information to the understanding of bacterial disease 
and the biology of the cell as the pneumococcus (Watson et aI., 1993). For example, laboratory 
studies with S. pneumoniae led to the discovery of the fIrst polysaccharide antigen, when 
previously it had been supposed only proteins were antigenic. This discovery is attributed to 
Heidelberger and Avery who showed in 1928 that the polysaccharide capsule of the 
pneumococcus was antigenic and responsible for its type specificity (Austrian, 1971, Watson et 
aI., 1993). 
S. pneumoniae played an important role in the discovery of DNA. Griffith in the 1920s 
challenged mice with an intraperitoneal injection of living, unencapsulated ("rough"), avirulent 
type II pneumococci together with heat lalled, encapsulated ("smooth"), virulent type III 
pneumococci. The mice frequently developed a fatal infection. Culture of heart blood from 
dying animals recovered viable encapsulated type III pneumococci (GriffIth, 1928). This 
observation was dubbed "transformation". The exact nature of the transforming agent 
responsible remained a mystery until the 1940s when Avery, Macleod and McCarty provided 
evidence that DNA was in fact the "transfonning principle" capable of restoring the ability to 
produce a capsule (Avery et aL, 1944). 
The history of discovery attributed to the pneumococcus, and the researchers who have worked 
with this organism since its discovery, have facilitated some of the most influential findings in 
biological science over the last century. The above list is far from exhaustive; the history of the 
pneumococcus in biomedical research has been subject of several comprehensive reviews 
(Austrian, 1971, 1981, Watson et al., 1993), which do this field far more justice than pennitted 
herein. 
1.2 Description of S. pneumoniae 
The genus Streptococcus comprises a number of species from virulent pathogens to harmless 
commensals. Members of this genus are described as being Gram-positive, catalase-negative, 
facultative anaerobic bacteria that are spherical or ovoid and less than 2 ~tm in diameter, 
typically in pairs (Deibel and Seeley Jr, 1975). Streptococci are tillable to synthesize haem-
containing compounds and are consequently incapable of respiratory metabolism. 
Carbohydrates are metabolised fermentatively, with lactic acid being the main metabolic end 
product. Streptococci are nutritionally fastidious with variable and complex growth 
requirements. Blood or serum is often added to the culture medium to enhance growth. The 
growth of several streptococcal species (e.g., s. pneumoniae, Streptococcus mitis) is further 
stimulated in a CO2 enriched (5%) atmosphere. Growth of streptococci on blood agar provides a 
useful means of differentiation based on their haemolytic properties. Haemolysis is defined as 
a-haemolysis (incomplete lysis and "greening" of agar), ~-haemolysis (complete lysis of 
erythrocytes and clearing of agar) or x-haemolysis (no lysis). 
Many streptococci are human pathogens. Streptococcus pyogenes, the ~-haemolytic, Lancefield 
group A streptococcus, is an etiological agent of many types of infection, including pharyngitis, 
respiratory infections, glomonephritis, skin and soft tissue infections, endocarditis, meningitis 
and scarlet fever. S. pyogenes is a strictly human pathogen, spread from person to person via 
respiration, or saliva droplets. The ~-haemolytic, Lancefield group B streptococcus, 
Streptococcus algactiae, is an important cause of neonatal infection, characterised by sepsis and 
meningitis. Lancefield groups C and G are ~-haemolytic streptococci, and produce a range of 
infections similar to S. pyogenes. 
Like the ~-haemolytic streptoeocci, S. pneumoniae is also pathogenic to humans. However, by 
16S rDNA analysis S. pneumoniae is found to fall within the "mitis" group streptococci, 
whereas most of the other pathogenic streptococci cluster together in the "pyogenic" group 
(Kawamura et aI., 1995). The streptococci most closely related to the pneumococcus include S. 
mitis and S. oraits, both of which are components of the normal oral flora (Kawamura et aI., 
1995). 
On blood agar, S. pneumoniae produces colonies of characteristic appearance. Colonies are 
approximately 1 rom in diameter and surrounded by a green zone of a-haemolysis. 
Pneumococci produce polysaccharide capsules, which give colonies a moist glistening 
appearance. Serotype 3 pneumococci are particularly mucoid, and the colonies look 
correspondingly larger. The pneumococcal capsule is antigenic and is the basis of 
immunological typing. There are currently 90 different pneumococcal serotypes recognised ~ 
the last six (serotypes lOB, 10C, lID, 12B, 25A, and 33D) being recognised only recently 
(Henrichsen, 1995). Two nomenclature systems exist for pneumococcal serotypes. The Danish 
system that groups antigenically cross-reacting types into clusters, and the American system that 
lists serotypes in order of discovery. By comparison, the Danish serogroup 19 includes 
serotypes 19F, 19A, 19B and 19C (the letter F corresponds to the first member of the group to 
be identified, and is then followed A, B, C etc), under the American system these are types 19, 
57, 58 and 59 (Lund, 1960). The Danish nomenclature is currently the preferred of the two 
systems (Paton and Morona, 2000). The pneumococcal capsule is approximately 200-400 nm 
thick, and is attached to the cell wall peptidoglycan (Alonso De Velasco et aI., 1995). 
Structurally, the capsule consists of high molecular weight polymers comprised of repeating 
oligosaccharide units. The component oligosaccharide units vary in complexity from the very 
simple-linear polymers of two monosaccharides (such as the type 3 capsule) or more complex 
branching chain polysaccharides (Paton and Morona, 2000). The nature of the capsule as a 
virulence factor is addressed section 1.3.2.1. 
S. pneumoniae has the ability to bind and take up large pieces of DNA from the environment by 
a process called natural genetic competence. Natural genetic competence occurs in a variety of 
bacterial species, including Neisseria gonorrhoeae, Haemophilus injluenzae, Bacillus subtilis 
and S. pnewnoniae (Solomon and Grossman, 1996). The uptake mechanism in the Gram-
positive bacteria (s. pneumoniae and B, subtilis) are similar; DNA is bound without sequence 
specificity, the DNA undergoes double-stranded cleavage, one strand is taken into the cell while 
the other is degraded extracellularly (Dubnau and Provvedi, 2000). Slight differences have been 
noted with Gram-negative baeteria, presumably due to the presenee of an outer membrane. In 
most organisms natural genetic transformation is a regulated process (an exception being N. 
gonorrhoeae which is constitutively competent). In S. pneumoniae, cell-to-cell signalling 
induces competence. During exponential phase growth, the pneumococcus secretes a peptide 
pheromone. When this pheromone reaches a critical concentration in the culture media, 
competence is induced (Tomasz, 1966). The competence pheromone is a 17-residue 
oligopeptide, the product of the come gene (Havarstein et aI., 1995). 
Genome sequences of two pneumococcal strains have recently been made public; the complete 
genome sequence of the avirulent laboratory strain, R6, (Hoskins et aI., 2001); and the 
incomplete (>90%) genome sequence of virulent serotype 19F clinical strain, G54, (Dopazo et 
aI., 2001). The R6 and G54 genomes have been shown to be 2.038 and 2.066 Mbp in size 
respectively, both with 40% GC content. The pneumococcus R6 genome contains none of the 
18 genes encoding enzymes that comprise the tricarboxylic acid cycle (Hoskins et aI., 2001). As 
a result, S. pneumoniae R6 is incapable of synthesizing amino aeids from TCA cycle 
intennediates. This is consistent with the nutritionally fastidious nature of the pneumococcus 
(Deibel and Seeley Jr, 1975). S. pneumoniae cannot synthesize aspartate, aspargine, lysine, 
methionine, threonine and isoleucine (ultimately derived from oxaloacetate) or glutamate and 
arginine (derived from a-ketoglutarate). Furthermore, complete pathways for the synthesis of 
glycine, histidine and leucine could not be identified with the genome. Not surprisingly, these 
amino acids are included within a defined chemical media specifically designed for the 
cultivation of the pneumococcus (Tomasz arid Hotchkiss, 1964). Many genes for the synthesis 
of various cofactors are also absent. Scattered within the R6 genome are numerous genes that 
are apparently derived from other bacteria (Hoskins et aI., 2001). Presumably this has occurred 
as a consequence of natural competence in the pneumococcus. There are 40 ORFs present 
similar to those found in Gram-negative bacteria and that have no known homolog in Gram-
positive species. FUltheml0re, approximately 2% of the R6 genes are truncated (particularly at 
the 5' ends) relative to orthologous genes in other bacteria. This again could be attributed to 
promiscuous horizontal gene transfer in the pneumococcus. No less than 60 complete or partial 
IS elements were also found the R6 genome, representing ten different IS families. 
Determination of the genome sequence of at least one other pneumococcal strain is currently in 
progress. A serotype 4 strain, KNR.7/87 has been sequenced as an ongoing project initiated by 
The Institute of Genomic Research (TIGR). Although unfinished, TIGR have made the partial 
sequence accessible to researchers for some time (http://www.tigr.org). 
A brief description is worthy of pneumococcal strain R36 and its derivatives. All 
nonencapsulated isolates currently used in genetic studies of S. pneumoniae are derived from a 
single type 2 clinical isolate (D39) and its nonencapsulated derivative, used in the 1944 studies 
of Avery and colleagues; strain R36 (Avery et al., 1944). This strain has been exhaustively 
studied since its iuitial isolation in 1928. Subsequently, many derivatives of this strain have 
been documented, including R36A, R6, Rx and Rxl. These strain names; particularly R6 and 
Rxl are used throughout this work. For a more detailed ancestry of these strains, see 
descriptions of Yother (Yother, 2000). 
1.3 S. pneumoniae : Host - Pathogen Interactions 
1.3.1 Pathology of pneumococcal infections 
S. pneumoniae is the leading cause of potentially life threatening community-acquired disease. 
In the Uuited States the estimated annual number of pneumococcal infections includes 0.5 
million cases of community acquired pneumonia, 50 000 cases of bacteraemia, 3 000 cases of 
meningitis, and up to 6 million cases of otitis'media (Tomasz, 1997). Pncumococcal infection is 
most frequent at the extremes of age, in infants up to two years and in adults over 65 years. This 
is illustrated in a study from Temuco, Chile (Inostroza et al., 2001) in which the incidence of 
invasive pneumococcal disease was 348, 54 and 234 per 100 000 persons in infants «2 years), 
children/adults (5-65 years) and the elderly (>65 years) respectively. 
Supeljicial infections 
Deep infections 
Atypical infections 
Conjunctivitis 
Otitis media 
Pneumonia 
Bacteraernia 
Meningitis 
Endocarditis 
Necrotizing Fasciitis 
Table 1.1 Sites of potential pneumococcal infection 
Middle ear 
Lung 
Blood stream 
CSFfBrain 
Heart valve 
Skin, deep tissue 
S. pneumoniae is a component of the nomlal bacterial flora of the nasopharyx. In the absence of 
injury to the respiratory tract pneumococci exist in a commensal state with humans, however the 
pneumococcus has the potential to infect and cause disease in a large number of uiches in the 
human body (Table 1.1). This ability has lead to a huge array of infections that may be 
attributed to the pneumococcus (Taylor and Sanders, 1999). Factors which predispose 
individuals to pneumococcal infection in an adult population include; alcoholism, HIV 
infection, splenectomy, multiple myeloma, connective tissue disease, steroid use, diabetes 
mellitus, and intravenous drug use (Taylor and Sanders, 1999). 
Disruption of the cells lining the respiratory tract, by viral, physical, or chemical challenge 
predisposes the host to bacterial infection. Such disruption causes congestion throughout the 
respiratory tract, including the nose, nasopharynx, eustachian tube and middle ear. Congestion 
of the eustachian tube results in obstruction of its narrowest portion, the isthmus. This prevents 
drainage of secretions from the middle ear, which accumulate. If pathogenic bacteria from the 
nasopharynx are present in the middle ear after such an obstruction, otitis media infection of 
the middle ear - will result (Klein and Bluestone, 1998). In most instances when an etiological 
agent is isolated, S. pneumoniae is the organism most frequently recovered, or is second only to 
H injluenzae (Klein and Bluestone, 1998). 
Disturbance of the lower respiratory tract of healthy individuals may be followed by infection of 
the lungs. Bacteria reaching the alveoli of the lungs are usually rapidly cleared. Injury of the 
alveolar lining cells by viral (e.g., influenza) infection or other means will delay bacteria 
clearance (Hament et aI., 1999). The prolonged presence of bacteria allows the establishment of 
infection and results in pneumococcal pneumonia. This may be complicated further by the 
presence of alcohol, anaesthetics or corticosteroids, which retard the movement of 
polymorphonuclear leukocytes, and thus facilitates the spread of pneumonia. 
If the host immune system fails to contain the infection, bacteria may extend from the lungs to 
the hilar lymph node. From the lymph node bacteria may gain access to the systemic circulatory 
system via the thoracic duct, resulting in pneumococcal bacteraemia. Once bacteraemia is 
established, the invading pneumococcus is capable of evading host immune systems by virtue of 
its polysaccharide capsule (Tunkel and Scheid, 1993). Meningitis may follow if the bacteria 
traverses the blood-brain barrier, and establishes a focus of infection. The cerebral spinal fluid 
(CSF) provides the infecting organism with a sanctuary, devoid of many of the host's immune 
defences, in which the invading bacteria may replicate rapidly (Tunkel and ScheId, 1993, Feigin 
and Pearlman, 1998). Inflammation of the meninges occurs as a result of the presence of 
bacteria and their associated products in the CSF. Pneumococcal lysis, whether autolysis by 
pneumolysin or antibiotic mediated, directly attracts and activates phagocytes. The resulting 
inflammation is thought to be responsible for the morbidity and mortality associated with 
pneuomoeoecal meningitis (Alonso De Velasco et aI., 1995). 
1.3.2 Pneumococcal pathogenicity 
Pneumococcal pathogenicity has been attributed to a number of structures, mostly associated 
with the surface of the cell. Although a great number of virulence factors have been proposed 
(see Alonso De Velasco and Jedrzejas for reviews (Alonso De Velasco et aI., 1995, Jedrzejas, 
2001» it is likely there are more yet to be identified. The following sections relate to two of the 
best described of the pneumococcal virulence factors; the polysaccharide capsule, and the 
cytotoxin pneumolysin. 
1.3.2.1 The pneumococcal capsule 
The pneumococcus is enveloped by a polysaccharide capsule that forms the outermost layer of 
all fresh clinical isolates. The pneumococcal capsule is considered the primary virulence factor 
based on the observation that loss of the caps~le renders an isolate significantly less efficient at 
causing disease than the encapsulated parent from which it was derived (Griffith, 1928, Watson 
and Musher, 1990). Although an important virulence factor, the precise role played by the 
capsule during infection is not completely understood. It is well documented that some capsular 
types are more adept at causing invasive disease than others. For example, of 1477 isolates 
serotyped in Brazil over a 16-year period, 51.9% of the isolates belonged to eight serotypes (1, 
6B, 14, 6A, 18C, 3, 5, 23F) of the 64 different capsular types identified (Brandileone et aI., 
1995). The differential association of serotypes causing invasive disease seems to be a function 
of the chemical composition of the capsule (Alonso De Velasco et aL, 1995). The capsule has 
been shown to be required for colonization of the nasopharynx of mice, which is necessary 
prerequisite for pathogenesis (Magee and Yother, 2001). The major mechanism of virulence 
attributed to the pneumococcal capsule is its resistance to phagocytosis and lack of activation of 
the alternative complement pathway (Alonso De Velasco et aI., 1995). 
1.3.2.2 Pneumolysin 
Pneumolysin is a 53 kDa cytotoxic protein that belongs to the family of thiol-activated toxins, 
and shares sequence identity with streptolysin 0 (s. pyogenes) and lysteriolysin 0 (Listeria 
mOl1ocytogenes) (Billington et a1., 2000). Unlike cytotoxins from other bacterial species, 
pneumolysin is cytoplasmic and is released from the pneumococcal cell upon lysis (Jedrzejas, 
2001). Pneumolysin has at least two biological activities that contribute to virulence in animal 
models; cytolytic activity and the ability to activate complement (Mitchell et a1., 1991, 
Jedrzejas, 2001). The cytotoxic nature ofpneumolysin is due to the toxin binding cholesterol in 
host cell membranes, with subsequent disruption of membranes by forming large oligomeric 
pores (Rossjohn et ai., 1998). This activity inhibits the action of ciliated mucosal cells, and aids 
colonisation by preventing the host from clearing bacteria. Pneumolysin has also been shown to 
activate the complement pathway (Mitchell et aI., 1991). In vivo, this activity would stimulate 
an inflammatory response, a characteristic and key component of pneumococcal infection. 
Evidence for pneumolysin as an important virulence factor is supported by the fact that strains 
with a deleted pneumolysin have greatly attenuated virulence in mouse models (Berry and 
Paton, 2000). 
1.4 Treatment of Pneumococcal Infections 
Historically, the management of pneumococcal infections can be divided into three phases; the 
pre-antibiotic era and immunotherapy, the clinical introduction of antibiotics, and the current 
phase of increasing resistance to antibiotics. 
1.4.1 Pre-penicillin treatment 
Shortly after the elucidation of the pneumococcus as a major cause of lobar pneumonia, there 
was a period of active interest in the immunology of the organism. It was soon noted that 
animals could be immunised with cell-free pneumococcal filtrates, and this would protect the 
animal against subsequent pneumococcal infection. Furthermore, serum taken from an 
immunised animal could be used to protect naIve animals from experimental pneumococcal 
infection (Austrian, 1981). This observation spawned the first and only successful treatment 
option (immunotherapy) for pneumococcal infection until the advent of antibiotic 
chemotherapy. Immunotherapy was initially hampered by the fact that different capsular types 
had not yet been distinguished. However, by 1910 different capsular types had been recognised, 
and four groups described; types I, II, III and N (type IV essentially being everything which did 
not fall into the first three). Subsequently, using antisera to treat pneumococcal pneumonia 
proved to be quite effective (Dubos, 1976). 
Immunotherapy has two major drawbacks. Firstly, immunotherapy is dependant on the serotype 
of the infecting organism and subsequent administration of the corresponding antisera as early 
as possible. This process is time consuming, and the efficacy of the antisera diminishes with 
delayed treatment. Secondly, treatment with antisera provides no advantage for localised 
infections such as meningitis. Consequently the focus management of pneumococcal infections 
shifted from the treatment of the disease, to prevention. Research into the use of pneumococcal 
vaccines coincided with the use of antisera for treatment, however the efficacy of vaccines was 
more difficult to judge. The most persuasive report showing the effectiveness of a vaccine was 
published in 1945 on recruits at a US air force base (MacLeod et aI., 1945). MacLeod and 
colleagues administered a pneumococcal vaccine, containing capsular polysaccharides from 
types 1, 2, 5 and 7, to a group of 8586 men. Over the course of the study, only four cases of 
pneumonia caused by a type included in the vaccine was observed in the treated population, 
compared to 26 cases in the control population (8449 men). Pneumonia caused by types not 
included in the vaccine was similar for both immunized and non-immunized groups (56 and 59 
cases respectively). 
Although by 1945 considerable progress had been made in the formulations of vaccines for 
preventing pneumococcal disease, this also coincided with the introduction of antibiotics. 
Antibiotics have the advantage of being effective against all isolates of pneumococci, regardless 
of serotype. They are also able to clear localised infection, which were previously non-treatable. 
Interest in pneumococcal immunology subsequently diminished rapidly, and with the exception 
of some serotype surveillance, such research was effectively halted. 
1.4.2 The antibiotic era 
In 1928 Alexander Fleming described the antibacterial properties of a compound produced by a 
member of the Penicillium genus of fungus (Fleming, 1929). lne compound, dubbed penicillin, 
inhibited a variety of microorganisms, particularly Staphylococci and Streptococci; "It is on the 
pyogenic cocci and on bacilli of the diptheria group that the action is most manifest". Chain 
and co-workers (1940) followed up the work of Fleming and investigated the potential of 
penicillin as a chemotherapeutic agent. The experiments described provide the first evidence of 
penicillin's efficacy in treating bacterial infections. Penicillin was shown to be effective in the 
treatment and clearance of three pathogenic bacterial species, including S. pyogenes, in a mouse 
model. Thus was borne the antibiotic era. To this day ~-lactams, including penicillins and 
cephalosporins, have remained the most effective antibiotics in the treatment of streptococcal 
discase. 
The introduction of antibiotics greatly reduced the mortality associated with pneumococcal 
infection. Prior to antibiotic chemotherapy, the mortality associated with pneumococcal 
pneumonia, bacteraemia and meningitis was 20%, 50% and 80-100% respectively. Appropriate 
antibiotic treatment, predominantly with penicillin, has reduced these statistics to 5%, 20% and 
30% respectively (Tomasz, 1997). Although penicillin, due to its low toxicity, low cost and high 
efficacy, is considered the antibiotic of choice for anti-pneumococcal chemotherapy, many other 
agents are also highly effective. In some instances (e.g., allergy to penicillin), treatment with 
penicillin may not be an option. In such cases antibiotics such as erythromycin, tetracycline, co-
trimoxazole and chloramphenicol are suitable alternatives for treatment. 
1.4.3 Post-penicillin era 
1.4.3.1 Antibiotic resistance and new antibiotics 
In recent years, the spectre of increasing antibiotic resistance in many bacterial pathogens, 
including the pneumococcus, has become a serious therapeutic concern (Neu, 1992). 
Consequently, much research has been conducted in formulating new anti-pneumococcal 
treatment regimes in a bid to eurb rising antibiotic resistance in the pneumococeus (Appelbaum, 
1995). The unmet need for new antibiotic agents has prompted pharmaceutical companies to 
attempt to uncover novel agents effective in treating bacterial disease caused by resistant 
organisms. Data generated from microbial genomics is being exploited in a bid to idcntify new 
cellular targets, in order to bypass existing resistance mechanisms. To this end, the US 
pharmaceutical industry spent $2.8 billion on research of infectious disease in 1997 (Bax et aI., 
2000). 
Although not a new class of antibiotic, fluoroquinolones, particularly the more modern 
members (e.g., moxifloxacin) have gained popularity in the treatment of pneumococcal 
infections. Other options for anti-pneumococcal chemotherapy include novel antimicrobial 
compounds such as the ketolides (telithromycin), quinupristinldalfopristin (Synercid) and 
oxazolidinones (linezolid). Comparative activities of some of these agents are listed in Table 1.2 
(adapted from Ball (Ball, 1999». 
The fluoroquinolone antibiotic, ciprofloxacin, was shown to have fairly good clinical efficacy in 
the treatment of pneumonia. Krumpe and colleagues (1999) showed ciprofloxacin mono-therapy 
had a clinical success rate (defmed as dissipation of symptoms) of 85%, compared to 83% for 
standard therapy (p-Iactam) when treating pneumonia. Howcver, ciprofloxacin appeared less 
effective than standard thcrapy for bacteriological cradication (82% and 100%, respectively). 
Furthermore, in vitro susceptibility data on the susceptibility of pneumococci to 
fluoroquinolones have shown older agents such as ciprofloxacin have MICs that tend to cluster 
around their respective breakpoints (2.0 f!g/ml) (Visalli et aI., 1996, Ednie et a1., 1998, 
HocHman et aI., 1999). The introduction of newer fluoroquinolones such as levofloxacin, 
trovafloxacin and moxifloxacin, which have greater activity against Gram-positive organisms, 
has renewed interest in using these agents for treating S. pneumoniae infections (Appelbaum 
and Hunter, 2000). 
Ketolides are novel, 14-membered-ring, semi-synthetic macrolides (Hunter, 1998). They are 
active against S. pneumoniae including isolates that are resistant to conventional macrolide 
antibiotics (Chu, 1999). Morosini and colleagues (2001) showed the activity of one such 
ketolide, telithromycin, against erythromycin-resistant pneumococci. Telithromycin was active 
against 98.9% (MICs ~ 0.5 )lg/mI) of 203 Spanish pneumococcal isolates, while erythromycin 
was active against 61.0% (MICs ~ 0.25 ~Lg/mI). MIC90 values were 0.06 )lg/mI and >64 ~Lg/mI 
for telithromycin and erythromycin respectively. Furthermore, in a Canadian study (Hoban et 
aI., 2001) of 215 macrolide-resistance pneumococcal isolates, the MIC90 of two ketolides, 
telithromycin and ABT -773 were determined to be 0.06 and 0.03 )lg/ml respectively, regardless 
of the macrolide-resistance genotype. Ketolides may well be a useful alternative therapy for 
pneumococci resistant to other macrolides. 
f3-1actams 
Penicillin 0.06 LO 4 
Ceftriaxone 0.03 0.5-LO 1-2 
Vancomycin 0.25 0.5 0.5-1.0 
Fluoroquinolones 
Trovafloxacin 0.12 0.12 0.06 
Moxifloxacin 0.12 0.12 0.12 
Sparfloxacin 0.5 0.5 0.5 
Levofloxacin 1 1 1 
Ciprofloxacin 1 1 1-2 
Other Novel Agents 
Ketolides 0.12 0.12 0.12 
Quinupristinl dalfopristin 1 1 1 
Oxazolidinones 0.5-1.0 0.5-1.0 0.5-1.0 
Table 1.2 Comparative activities of antibiotic agents on penicillin-susceptible, intermediate, and 
resistant pneumococci. 
Quinupristinldalfopristin is a two component antibiotic consisting of quinupristin (streptogramin 
B) and dalfopristin (strcptogramin A) in the ratio of 30:70 (w/w) (Nadler et al., 1999). The two 
eomponents have a synergistic mode of action, both targeting the bacterial ribosome. The drug 
is currently reserved for treatment of serious infections by Gram-positive organisms including 
isolates that currently available drugs are ineffective. The quinupristinldalfopristin MICso and 
MIC90 for S. pneumoniae is typically 0.25 ~g/ml and 0.5 ~lg/m1 respectively, regardless of the 
level of penicillin resistance (Doem et al., 2001). 
Linezolid is a member of a new class of synthetic antibiotics, named the oxazolidinones, 
unrelated to any other currently available agent. Linezolid binds to the 50S ribosomal subunit 
near the interfaee with the 30S subunit, which results in the inhibition of the initiation of protein 
synthesis (Corti et al., 2000). Linezolid is active against Gram-positive cocci, including multi-
resistant isolates. A Taiwanese study found linezolid to have a MIC range of 0.125-0.5 ~lg/m1 
when tested against 54 pneumococcal isolates (Fang et al., 2001). No cross-resistance to other 
antimicrobials was noted. 
1.4.3.2 Pneumococcal vaccine 
The recent emergence of antibiotic resistance in S. pneumoniae has emphasized the importance 
of prevention and control of pneumococcal disease, most practically achieved by vaccination. 
Unfortunately, complacency derived from the introduction of antibiotic chemotherapy for 
treating pneumococcal infection has significantly set back vaccine development for this 
organism. In 1946 commercial hexavalent pneumococeal vaccines were produced, but were 
subsequently withdrawn because of the wide availability and efficacy of penicillin (Lee et al., 
1991). However, Austrian and Goldman (1964) found that antibiotic therapy had little effect on 
the mortality of pneumococeal pneumonia within the first five days of treatment (Austrian and 
Gold, 1964). This was a startling insight, as at the time many were of " ... the impression that 
pneumococcal disease no longer constitutes a serious medical problem JJ (Austrian and Gold, 
1964). 
Renewed interest in vaecination against pneumococcal infections saw FDA approval of a 14-
valent vaecine in 1977, which was followed by a 23-valent vaecine six years later (Lee et al., 
1991). The 23-valent vaccine contains purified capsular polysaccharides of types 1, 2, 3, 4, 5, 
6B, 8, 9N, 9V, lOA, 11 A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. 
Efficacy of the 14-valent and 23-valent vaccines for prcventing invasive disease due to 
serotypes covered by the vaccine were 53% and 60%, respectively (Butler et al., 1993). 
Unfortunately the currently available 23-valent pneumococcal vaccine does not provide 
adequate protection to children less than two years old, who are at greatest risk of disease 
(Klein, 1999). Subsequently alternative vaccine candidates are being pursued. A seven-valent 
pneumococcal vaccine has recently been licensed for use in the United States (Mulholland, 
2000). It is hoped this may reach the success achieved with the Haemophilus irif/uenza type b 
vaccine, introduced in 1990. 
1.5 Antibiotic Resistance in S. pneumoniae 
1.5.1 Development and spread of pneumococcal resistance 
S. pneumoniae was thought to be consistently sensitive to penicillin (MIC 0.006 Ilglml), and for 
at least two decades this was the case. Possibly the fIrst documented account of penicillin 
resistance in the pneumococcus occurred in 1965. Investigators in Boston noted that among 200 
clinical isolates of S. pneumoniae, two isolates had MICs in the 0.1-0.2 Ilg/ml range (Kislak et 
aI., 1965). However, these investigators failed to recognise the signifIcance of their 
observations. It was not until 1967 that' Hansman & co-workers identifIed a resistant 
pneumococcus in Sydney, Australia (Hansman and Bullen, 1967). In this instance the resistance 
strain had a penicillin MIC of 0.6 )lg/ml. 
Following these initial observations, sporadic descriptions of penicillin-resistant pneumococci 
began to surface in the literature. Fifteen serotype 4 penicillin insensitive (MIC 0.5 ~Lg/ml) 
pneumococci were recovered from a village in New Guinea (Hansman et aI., 1971a, Hansman et 
aI., 1971b). The fIrst clinical description of a resistant pneumococcus from North America was 
an isolate recovered from a 68-year-old man in Albelta, Canada (Dixon, 1974). The isolate was 
serotype 9 and had a penicillin MIC of 0.32 )lglml. In the same year, a report of relapsing 
pneumococcal meningitis was described in Chicago (Naraqi et aI., 1974). In this instance a 
serotype 23 pneumococcus was recovered with a penicillin MIC of 0.25 Ilglml. This case was 
also notable in that it pointed out pneumococcal infections in diffIcult to treat sites (e.g., CSF), 
may require higher than recommended doses of penicillin to successfully eradicate infection. 
fIrst isolation of a penicillin-resistant pneumococcus in Britain was recovered from a 10-
month-old girl presenting with meningitis (Howes and Mitchell, 1976). The isolate was serotype 
14 and had a penicillinMIC of 0.37 ~Lglml. 
Around the same time pneumococcal penicillin resistance was noted, resistance to non-f)-lactam 
antibiotics was also being described. To many at the time, the increased resistance to non-f)-
lactam antibiotics was more concerning than those of penicillin itself, as the increases were 
more dramatic and absolute (Gunnison et aL, 1968, Finland, 1971). While increased penicillin 
resistance was certainly significant when compared to sensitive isolates, the MICs were still 
well below the therapeutic levels of antibiotic that could be achieved in serum. Furthermore, the 
initial descriptions of penicillin resistance were deemed too geographically isolated to be 
considered significant, as cited in a report by Finland (1971); 
"It [the 1971 Hansman et al report] raises the spectre of a new and increasing problem of 
resistance to penicillin in the treatment of pneumonia and other serious pneumococcal 
infections. Although such a possibility cannot be completely dismissed, the particular 
epidemiologic circumstances in the report from New Guinea, and the special properties of 
the strain of pneumococcus involved, make such a prospect extremely remote" 
The same report goes on to dismiss the potential need for diagnostic screening of pneumococcal 
resistance to penicillin, but does suggest a need to investigate resistance to other classes of 
antibiotics. Consequently, a brief review of pneumococcal resistance to several other clinically 
useful antibiotics, in particular; tetracycline, erythromycin, co-trimoxazole and 
chloramphenicol, is included here. 
Tetracycline-resistance was first noted in Australia by Evans and Hansman (1963). A resistant 
isolate was recovered from a 10-month infant with meningitis. The tetracycline MIC of this 
strain was determined to be 11 ~Lg/ml. The isolate was susceptible to other non-related 
antimicrobial compounds, and was eventually cleared with penicillin. Over the following two 
years, an additional 37 tetracycline-resistant isolates were recovered in an Australian hospital, 
with MICs ranging from 15-100 ~g/ml (Hansman and Andrews, 1967). Within two weeks of the 
initial observation, Richards and Rycroft (1963) reported on the culture of four similar isolates 
from St. Pacras hospital in London. Of these four strains, three belonged to serogroup 9 and the 
other to serotype 11. In all four cases patients had been treated with tetracycline shortly (one 
week - two months) before the recovery of the resistant organism. Later the same year in a 
Liverpool hospital, tetracycline-resistant pneumococci were isolated from ten patients (Turner, 
1963). In this instance all ten organisms were capsular type 7, suggesting cross-infection may 
have occurred within the hospital. Of the ten patients, five had received tetracycline a minimum 
of 12 days before the isolation of the resistant pneumococcus. 
The macrolide antibiotic, erythromycin, is considered second only to penicillin for treating 
pneunlOcoccal infections. Resistance to erythromycin, as well as lincomycin, was first repOlied 
in 1967 (Kislak, 1967). A type 6 pneumococcus was isolated from a lO-year-old boy in New 
York. The patient had been treated within the two months previous with both erythromycin and 
lincomycin. A further report from Australia of a serotype 11, erythromycin-resistant 
pneumococcus appeared later that year (Cooper et aI., 1968). 
Cotrimoxazole is a combination of two agents; trimethoprim and sulfamethoxazole. 
Trimethoprim inhibits dihydrofolate reductase (DHFR), and subsequently blocks the reduction 
of dihydrofolate to tetrahydrofolate. This deprives the cell of a vital precursor for the synthesis 
of purines, thymidylate and various amino acids and vitamins. The first pneumococcal isolate 
with resistance to co-trimoxazole was described in 1972 (Howe and Wilson, 1972). In this 
instance a 58-year-old woman was admitted to hospital with acute exacerbation of chronic 
bronchitis. Culture of a sputum specimen recovered a serogroup 23 pneumococcus resistant to 
co-trimoxazole, but sensitive to non-related antibiotics. The patient had received a course of eo-
trimoxazole one month previously. 
Chloramphenicol is a broad-spectrum antibiotic which owes its activity to its strong inhibitory 
effeet upon the peptidyl transferase activity of the 50S ribosomal subunit. Chloramphenicol is a 
baeteriostatic agent, but may exert a bactericidal effect at two to four times the MIC towards 
Gram positive cocci. Pneumococci resistant to chloramphenicol were first described by 
Cybulska in Poland (Cybulska et aI., 1970). A survey of pneumococcal carriage in Nigeria in 
1977 found 14% of isolates resistant to ehloramphenicol (Hansman, 1978). 
In 1977 the first report of multi-drug resistant pneumococci emerged from Durban, South 
Africa. Resistant pneumococci were isolated from five patients with systemic infection, 
including three cases of meningitis. These isolates were highly resistant to penicillin (MIC 4-8 
~lg/ml) and also exhibited resistance to chloramphenicol and streptomycin (Appelbaum et aI., 
1977). All isolates were capsular type 19A. At a similar time, 300 miles away in 
Johmmesburg, similar resistant pneumococci were isolated. The first case was from a three year 
old boy who developed pneumonia post-operatively. A serotype 19A pneumococcus was 
recovered. The isolate was resistant to penicillin, erythromycin, tetracycline, chloramphenicol, 
co-trimoxazole and various aminoglycosides (Anonymous, 1977). Following this index case, 
potential carriers of the resistant pneumococcus were surveyed at two Johannesburg hospitals 
(Jacobs et aI., 1978). Cultures from 427 patients and 363 staff members of Baragwanath hospital 
were performed yielding penicillin-resistant pneumococci in 83 patients (19%) and eight staff 
members (2%). Of these, 51 were multi-drug resistant 19A, and the remaining 32 were serotype 
6A or 19A, and were resistant to penicillin, tetracycline and chloramphenicol either singly or in 
combination. At the second hospital a type 19A multi-resistant pneumococcus was isolated from 
77 patients. 
Thus began the South African epidemic of penicillin-resistant pneumococci an ongoing 
problem in this country today (Koomhof et aI., 1992, Klugman and Saunders, 1993). Unlike 
previous sporadic reports of resistance, epidemiological links could be made, and it appeared as 
if the epidemic was being caused by the dissemination and spread of distinct pneumococcal 
lineages. Surveillance of penicillin-resistant pneumococci in South Africa between 1979 and 
1986 showed an increase in prevalence among isolates from invasive disease from 4.9% in 1979 
to 14.1% in 1986 (Klugman and Koomhof, 1988). The most frequently recovered serogroups 
during this period were; 6 (59%), 19 (25.9%), and 14 (12.7%). Throughout the 1970s-80s, 
reports of pneumococcal resistance were published from all parts of the world. These have been 
summarised in several reviews (Appelbaum, 1987, Klugman, 1990, Appelbaum, 1992). A 
summary of the worldwide distribution of resistant pneumococci is shown in Figure l.l(a) 
(adapted from Appelbaum (Appelbaum, 1992». This figure illustrates prevalence data that was 
accurate until around 1990. A more current approximation of worldwide prevalence is shown 
for comparison in Figure 1.1 (b), based on the data in Table 1.3. 
Africa 
Ivory Coast 1996-97 311138 (22.5) Clinical (Benbachir et aI., 2001) 
Kenya 1991-92 58/223 (26) Clinical (Ken et a1., 1993) 
Morocco 1996-97 9/98 (9.2) Clinical (Benbachir et aI., 2001) 
Senegal 1996-97 50/81 (61.7) Clinical (Benbachir et aI., 2001) 
South Africa 1997 20/66 (30.3) Clinical (Felmingham and 
Gruneberg, 2000) 
Tunisia 1996-97 24/58 (41.4) Clinical (Benbachir et aI., 2001) 
Zambia 1994 7/126 (5.5) Carriage (Woolf son et aI., 1997) 
Asia 
Bangladesh 1993-97 46/362 (12.7) Clinical (Saha et aI., 1999) 
China 1996-97 5/51 (9.8) Clinical (Song et aI., 1999) 
Hong Kong 1997 33/54 (61.1) Clinical (Felmingham and 
Gruneberg, 2000) 
India 1996-97 7/183 (3.8) Clinical (Song et aI., 1999) 
Indonesia 1996-97 7/33 (21) Clinical (Song et aI., 1999) 
Japan 1996-97 55/84 (65.3) Clinical (Song et aI., 1999) 
Korea 1996-97 1411177 (79.7) Clinical (Song et aI., 1999) 
Malaysia 1996-97 3/34 (9.0) Clinical (Song et aI., 1999) 
1995-96 19/273 (7.0) Clinical (Rohani et aI., 1999) 
Pakistan 1993-94 118/229 (51.5) Clinical (Qazi, 1999) 
Saudi Arabia 1997 15/31 (48.4) Clinical (Felmingham and 
Gruneberg, 2000) 
Singapore 1997-99 114/180 (63) Clinical/Carriage (Soh et aI., 2000) 
1996-97 19/84 (23.1) Clinical (Song et aI., 1999) 
Sri Lanka 1996-97 17/41 (41.2) Clinical (Song et aI., 1999) 
Taiwan 1996-97 120/200 (60) Clinical (Hsueh et aI., 1999) 
1996-97 310/550 (56.4) Clinical (Fung et aI., 2000) 
Thailand 1996-97 73/126 (57.9) Clinical (Song et aI., 1999) 
Vietnam 1996-97 28/46 (60.8) Clinical (Song et aI., 1999) 
?-1997 212/399 (51) Carriage (Parry et aI., 2000) 
Oceania 
Australia 1997 259/1020 (25.4) Clinical (Turnidge et aI., 1999) 
New Zealand 1999-97 2085/10976 (19) Clinical (Brett and Ellis-Pegler, 
2001) 
2000 1498/5830 (25.7) Clinical (Anonymous, 2001) 
Enrope 
Austria 1994-96 68/l385 (4.9) Clinical (Georgopoulos et aI., 1998) 
Belgium 1994-98 542/5486 (9.9) Clinical (Verhaegen et aI., 2000) 
Czech Republic 1997 5/93 (5.4) Clinical (Felmingham and 
Gruneberg, 2000) 
France 1993-94 207/363 (57) Clinical (Moissenet et aI., 1997) 
1997 90/181 (49.7) Clinical (Felmingham and 
Gruneberg,2000) 
Germany 1998-99 62/961 (6.6) Clinical (Reinert et aI., 2001) 
Greece 1997 15/132 (11.4) Carriers (Tsolia et aI., 1999) 
Hungary 1996 . 46/127 (36.2) Clinical (Felmingham and 
Gruneberg, 2000) 
1997 17/121 Carriers et 
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Netherlands 1996 3/65 (4.6) Clinical (Felmingham and 
Gruneberg, 2000) 
Poland 1997 (14.4) Clinical (Overweg et al., 1999) 
Portugal 1996 661277 (24) Carriers (De Lencastre et aI., 1999) 
Rep. Ireland 1997 21187 (24.1) Clinical (Felmingham and 
Gruneberg, 2000) 
Scotland 1993-95 1198 (1) Clinical (McKenzie et aI., 2000) 
Slovak Republic 1997 16/60 (26.7) Clinical (Felmingham and 
Gruneberg, 2000) 
Spain 1999-2000 197/300 (65.6) Clinical (Oteo et al., 2001) 
1996-97 669/1113 (60.1) Clinical (Baquero et aI., 1999) 
1990-96 4527/9243 (49) Clinical/Carriage (Fenoll et aI., 1998) 
Sweden 1993-97 694/10735 (6.5) Carriers (Kamme et aI., 1999) 
Switzerland 1993-94 25/351 (7.1) Clinical (Wust et al., 1995) 
UK 1997 14/111 (12.6) Clinical (Felrningham and 
Gruneberg, 2000) 
North America 
Alaska 1991-98 10911037 (10.5) Clinical (Rudolph et al., 2000) 
Canada 1991-98 104/1538 (6.7) Clinical (Greenberg et aI., 2002) 
US 1999-2000 524/1531 (34.2) Clinical (Doern et aI., 2001) 
1998-99 63214296 (14.7.) Clinical (Sahm et aI., 2001) 
1997-98 47211601 (29.5) Clinical (Doern et aI., 1999) 
Mexico 1997 31163 (49.2) Clinical (Felmingham and 
Gruneberg, 2000) 
1993-95 106/220 (48.2) Clinical (Echaniz-Aviles et aI., 
1998) 
South America 
Argentina 1993-96 123/505 (24.4) Clinical (Rossi et aI., 1998) 
Brazil 1993-96 19011525 (I5.1) Clinical (Brandileone et at, 1998) 
Chile 1997 31199 (31.3) Clinical (Jacobs and Appelbaum, 
2000) 
Columbia 1994-96 64/409 (15.6) Clinical (Castaneda et a1., 1998) 
Panama 1997 14/61 (23.0) Clinical (Jacobs and Appelbaum, 
2000) 
Venezuela 1997 16173 (21.9) Clinical (Jacobs and Appelbaum, 
2000) 
West Indies 1997 6/84 (7.1) Clinical (Jacobs and Appelbaum, 
2000) 
Table 1.3 Worldwide prevalence of penicillin-resistant isolates of S. pneumoniae. 
The proportion of resistant isolates includes all isolates of intermediate resistance (~ 0.12 Jlg/ml). Preference was 
given to reports presenting clinically relevant data, rather than those of asymptomatic calTiage. 
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Figure 1.1 Worldwide prevalence of penicillin non-susceptible pneumococci. 
Based on; (a) global prevalence data, accurate until around 1990 (adapted from Appelbaum (Appelbaum, 1992»; (b) 
a current approximation of worldwide prevalence of non-susceptible pneumococci (based on the data in table 1.3). 
Unshaded regions represent areas where current prevalence data was unavailable. 
1.5.1.1 Nomenclature ojpeniciJlin resistance 
It is worth a brief mention of the nomenclature involved in pneumococcal penicillin resistance. 
The pneumococcus acquires penicillin resistance in a stepwise fashion, rather than obtaining 
absolute resistance imparted by a f3-lactamase. Consequently, there has been a potential need to 
distinguish between intennediate resistance (MIC 0.1-1.0 I-Lg/ml) and full resistance (MIC 
I-Lg/ml). This distinction is particularly relevant for the management of pneumococcal 
meningitis, which may be complicated by moderate increases in penicillin resistance. This has 
led to a veritable plethora of acronyms having been introduced in the literature to describe 
resistant pneumococci, some of which include; PN(S)SP (nenicillin non-~usceptible 
{itreptococcus J!neumoniae; (McEllistrem et a1., 2000a, Greenberg et a1., 2002», PRSP 
(nenicillin-resistant {itreptococcus J!neumoniae; (Bryan, 1999», (M)DRSP (multi-grog resistant 
{itreptococcus J!neumoniae; (Ball, 1999, Greenberg et a1., 2002) and RRP (relatively resistant 
nneumococcus; (Saah et a1., 1980». For a more exhaustive list of related terms, see the 1990 
review of Klugman (Klugman, 1990). 
For the purposes of the current text, many of the above tenns have been employed, although the 
use of the corresponding acronyms has been avoided to minimise confusion. Unless otherwise 
stated, resistance refers to isolates with a penicillin MIC of ;:::0.1 I-Lg/ml (i.e. both intennediate 
and highly resistant organisms). Wherever possible throughout this text, it has been 
cndeavoured to also include actual MICs to further avoid confusion. 
1.5.2 Penicillin resistance in S. pneumoniae 
In many bacteria, a ~-lactamase enzyme mediates resistance to ~-lactams. Such enzymes cleave 
the J3-lactam ring of penicillins rendering them inactive (Ghuysen, 1991, Bush and Miller, 
1998). The pneumococcus differs from most bacteria in this regard as a J3-lactarnase has never 
been detected (Robins-Brown et aI., 1979). Resistance has instead been identified to be due to 
changes in the affinity of the target molecules, the penicillin-binding proteins (PBPs), toward 
penicillin. This section serves as a background review of the function of PBPs and their role in 
peptidoglycan biosynthesis (for reviews see (Blumberg and Strominger, 1974, 
Georgopapadakou, 1993, Goffin and Ghuysen, 1998». The pcnicillin resistance mechanism will 
be covered in more detail in Chapter 5. 
1.5.2.1 Biologicalfimction ofPBPs 
PBPs are enzymes that selectively bind and are inhibited by penicillin. They are membrane 
bound enzymes, and involved in cell wall synthesis and maintenance. PBPs are readily 
visualised after incubating cell wall extracts in the presence of radioactively labelled penicillin 
after separation by SDS-PAGE; the binding of penicillin to the enzymes facilitated their 
discovery. PBPs are a group of enzymes common to all bacteria, with the exception of non-
peptidoglycan containing bacteria (e.g., mycoplasmas). 
Penicillin binding proteins themselves are classified as high or low molecular weight proteins. 
The high molecular weight PBPs are multimodular; that is they have at least two catalytic 
functions encoded in the same polypeptide; the low molecular weight PBPs are monofunctional. 
S. pneumoniae contains six PBPs; five high-molecular weight (PBPs 1 a, 1 b, 2a, 2b and 2x) and 
one low molecular weight (PBP 3). The high molecular weight PBPs are further subdivided into 
classes. The differentiation into classes is based upon comparison of amino acid sequences 
(Goffin and Ghuysen, 1998). The pneumococcal PBPs la, 1b and 2a belong to class A and 
PBPs 2b and 2x belong to class B. 
All PBPs possess a common penicillin-binding domain, which is responsible for the enzymatic 
inactivation of these enzymes by the covalent binding of the drug to the active site serine 
residue. In the high-molecular-weight PBPs this penicillin-binding domain is the C-terminal 
portion of the enzyme. Structurally, PBPs contain a transmembrane "anchor" fused to the amino 
end of a transglycosylase (non-penicillin binding) module, which is in tum fused to the amino 
end of a D, D-transpeptidase (penicillin bincling) module. The transpeptidase module contains 
conserved amino acid motifs of SXXK, SXN and KT(S)G. The first of these motifs contains the 
active-site serine residue, the target of ~-lactam antibiotics. 
1.5.2.2 Biological fimction of peptidoglycan 
The cell envelope is an indispensable structural feature of many prokaryotes. It is responsible 
for providing cellular support and maintenance of morphology (Koch, 2000a, Koch, 2000b). 
Bacteria lacking cell walls are typically not free living, and must be maintained in an 
environment where the extemal osmotic pressure equals the cell intemal osmotic pressure. The 
cell walls of all bacterial species have common aspects (Schleifer and Kandler, 1972). Both 
Gram-positive and Gram-negative bacteria have a membrane that surrounds the cytoplasm. The 
peptidoglycan is located extemal to this membrane. Gram-negative bacteria also have a second, 
outer membrane (Figure 1.2). In each case, the peptidoglycan layer provides the cell structural 
stability and shape. 
Peptidoglycan is a continuous, covalently linked network of muropeptides that surround the 
cell. Peptidoglycan is structurally similar amongst all eubacterial species. It consists of glycan 
strands, made up of altemating ~-1 ,4-linked units of N-acetylglucosamine and N-acetylmuramic 
acid, which are cross-linked by short peptides (Figure 1.3). These cross-linking peptides are 
typically 4-5 residues in length, with an alternating series of L- and D- amino acids. The peptide 
units are linked to the carboxyl group of the N-acetylmuramic acid residue by an amide bond. 
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Figure 1.2 Diagramatic representation of Gram-positive and Gram-negative cell walls 
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The amino-acid composition of the peptide bridges, and degree of cross-linking, varies between 
bacterial species and consequently has been used for taxonomic purposes (Schleifer and 
Kandler, 1972). The typical composition of these peptide bridges is L-alanyl-y-D-glutamyl-L-
diaminoacyl-D-alanine. The third residue is diamino acid, however exact composition varies 
between bacterial species. In Escherichia coli, this residue is meso-diaminopimelic acid, in the 
pneumococcus (and S. pyogenes) it is L-Iysine (Deibel and Seeley Jr, 1975, Severin and 
Tomasz, 2000). Adjacent glycan chains are cross-linked via these peptide bridges. Extracelluar 
peptide bonds are formed between the carboxyl group of the terminal D-alanine of one peptide, 
to an amino group of the diamino acid residue of an adjacent peptide. The energy required to 
catalyse this reaction comes from the cleavage of the terminal D-alanine residue. This is the 
penicillin-sensitive step in peptidoglycan biosynthesis (Wise Jr. and Park, 1965). 
1.5.2.3 Peptidoglycan biosynthesis 
Peptidoglycan synthesis can be divided into four stages (Goffm and Ghuysen, 1998), occurring 
in two locations. The first occurs in the cytoplasm. This is the formation of the peptidoglycan 
precursor UDP-N-acetylmuramyl-pentapeptide and UDP-N-acetylglucosarnine. The second step 
involves the formation of the disaccharide-pentapeptide via a pyrophosphate bridge from the C] 
of N-acetylmuramic acid to a C55Hs9 undecaprenyl lipid U carrier. This intermediate facilitates 
the transfer of the precursor to the extracellular matrix (Koch, 2000a). The transport of the lipid-
bound precursor occurs at a rate which matches nascent peptidoglycan synthesis, suggesting 
catalysis by as of yet unidentified proteins, suggested to be fl ippases (Holtje, 1998). Once 
external to the cytoplasmic membrane, the third stage of peptidoglycan biosynthesis takes place. 
This involves the transfer of the disaccharide penta peptide from the lipid carrier to the growing 
glycan chain. This is the transglycosylation, which can occur by either of two mechanisms: (1) 
fnlr(lduct ion 
dispi<tccll1ent or pyrophusphate or the lipid II carrier by the 4-hydroxyl group or the terminal N-
acetylglucusal11ine, or (2) displacement or the pyrophosphate ur all existing glycan chain by the 
4-hydroxyl group of the N-acelylglucos,lllline (Cionin ,md Ghuysen, 10():-; , Iloltjc, 1 09X). These 
reactions arc catalysed oy glycosyl transfCrases , ;:md result in rhe linear gruw·th or the glyc,\Il 
chain "",ith repe,lled addition or disaccharide units (Ci()1lin and Cihuysell , 1l)9S). 
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transkrases ,Ire so e,llled due to their [ilrm,ltiol1 or an active site serine peptidyl cllIyme 
complex. /\ ssembly of thi s intermediate involves the lioeration of the carboxy terminal D-
alanine . The peptidylmoiety is next tntllsferred to the diaminu acid lysine residue ur an adjacent 
peptide - ,llld the cross-link is Limned. The reactioll eatalysed by tlte I), D- transpeptidasc is ,t\ so 
the penicillin-sens itive stage or the process. Penicillin is structurally similar to the tenninal ])-
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Because of the important role these enzymes play in the construction of the cell envelop, their 
inhibition is lethal to the cell. Penicillin is an analog of the natural substrate of these enzymes 
and consequently acts as an efficient inhibitor of their function (Wise Jr. and Park, 1965). 
Resistance to p-Iactams in pneumococci has arisen due to alterations of the target PBPs that 
result in a reduction of their affinity toward the drugs, yet not impairing their biological 
function. Overall, pneumococcal resistance has been shown to be a function of the individual 
penicillin affinities of its PBPs (Zighelboim and Tomasz, 1980). 
1.6 Epidemiology of Penicillin-Resistant S. pneumoniae 
Strain identification is the process of analysing multiple isolates of a given species to identify 
whether they represent a single strain (clonal), or comprise of multiple strains (non-clonal). 
Identification systems are based on the premise that related isolates will share characteristics by 
which they can be differentiated from unrelated isolates. Such analyses are useful in several 
clinical settings. For example, a series of ba'Cterial isolates from an individual patient may be 
examined to determine whether a relapsing condition is due to a recurring infection by a single 
isolate, or by sequential infections by different isolates. Bacterial strain identification also has 
utility in nosocomial infection control, when it is important to control outbreaks rapidly. In such 
a situation strain identification can help monitor the spread of the infection and identify the 
outbreak foci, allowing appropriate control measures to be taken. Outside the clinical milieu, 
strain identification is used to monitor the population dynamics of disease causing organisms in 
the community. 
Strain identification systems can be conveniently grouped into phenotypic techniques, i.e., those 
that detect characteristics expressed by a microorganism, and genotypic techniques, i.e., those 
based on direct analysis of DNA. 
1.6.1 Phenotypic identification techniques 
Phenotypic methods vary in complexity and include techniques such as antimicrobial 
susceptibility, biotyping, phage typing, serotyping (Finland and Barnes, 1977), fatty acid 
profiling, SDS-PAGE (pease et aI., 1986), and multilocus enzyme electrophoresis (MLEE) 
(McDougal et a1., 1992). Of these only serotyping has been vigorously utilized as an 
identification system for the pneumococcus. Although today serotyping has been largely 
superseded by molecular techniques, it still has a great deal of utility; especially when 
formulating vaccines which are currently based upon capsular polysaccharide types (Butler et 
aI., 1993). Furthermore, investigation of serotype prevalence has provided many important 
observations, for example: the prevalence of various serotypes shows temporal variation 
(Finland and Barnes, 1977); certain serotypes are responsible for the larger burden of invasive 
disease (Shapiro and Austrian, 1994); and that antibiotic resistance occurs most frequently in a 
narrow range of serotypes (Wust et a1., 1995, Castaneda et aI., 1997, Marchese et a1., 2000, Soh 
et aI., 2000, Maraki ct a1., 2001). For detailed epidemiological studies however, serotyping does 
not provide adequate diseriminatory power. Isolates that share a common serotype may have 
quite different genetic backgrounds (Hall et aI., 1996), consequently relatedncss of isolates 
cannot necessarily be inferred from their serotype. Serotyping also has some short-faIlings in 
that not all pneumococcal isolates have a distinguishable capsular typc. Non-typable 
pneumococci are those that fail to produce a capsule. This is particularly common in 
pneumococci isolatcd from eye infections (Pease et aI., 1986). Furthermore, on subculture in the 
laboratory, pneumococci have been shown to spontaneously stop capsule production, producing 
characteristic "rough" colonies. 
1.6.2 Genotypic identification techniques 
The worldwide emergence and dissemination of penicillin-resistant pneumococci during the 
1980s and 1990s coincided with development of novel molecular biology techniques. The 
massive geographic spread of such resistance organisms was in fact a major motivation for the 
development of molecular surveillance techniques (Tomasz, 1999). Genotypic techniques of 
strain identification attempt to overcome some of the shortcomings of conventional phenotypic 
typing systems. Phenotypic techniques are based upon expressed cellular characteristics and 
traits; consequently they may yield variable or inconsistent results (e.g., an encapsulated 
pneumococcus that halts capsule production cannot be serotyped). Genotypic methods differ in 
that they utilise the bacterial genome itself as a molecular marker. Variations in the genomic 
DNA sequence of bacterial isolates are exploited to discriminate between individuals. Methods 
based on thc DNA sequence of bacterial isolates have the advantage that all prokaryotic 
organisms have a DNA genome and are all therefore theoretically distinguishable. 
The number of molecular typing methods that have been employed for the typing of prokaryotes 
is extensive. Some of the techniques used for typing of pneumococci include; amplified 
fragment lcngth polymorphism (AFLP) (van Eldere et aI., 1999), BOX PCR (van Belkum et aI., 
1996), enterobacterial repetitive intergeneric consensus (ERIC) based PCR (Hermans et aI., 
1995), multilocus restriction typing (MLRT) (Muller-Graf et aI., 1999), multilocus sequence 
typing (MLST) (Enright and Spratt, 1998, Zhou et aI., 2000) and chromosomal macro-
restriction profiling (MRP) using pulsed field gel electrophorcsis (PFGE) (McEllistrem et aI., 
2000b) or field inversion gel electrophoresis (FIGE) (Lefevre et aI., 1993). Each of the 
molecular typing methods described has it's own utility. Several reports have compared 
molecular methods based on typability, reproducibility, ease of use, cost and discriminatory 
power (Olive and Bean, 1999, van Belkum et aI., 2001). 
1.6.3 Molecular epidemiology of penicillin-resistant S. plleulltolliae 
Regardless of the choice of typing method, molecular typing can provide useful information, 
especially when considered in light of other phenotypic techniques. Most obviously, molecular 
typing of pneumococci has shown that within most serotypes therc may be many genetically 
diverse organisms (Hall et aI., 1996). These may be quite distinct bacterial lineages, although 
having in common the genes necessary for production of their given capsular type. 
Thc application of molecular typing has done much to increase understanding of the evolution 
and dissemination of penicillin-resistant pnel,lmococci. From such work it is evident that three 
distinct processes occur when resistance is developed within pneumococcal populations: (1) the 
acquisition of the resistance trait, and consequent "fine-tuning" of this trait; (2) the expansion of 
resistant clones; and (3) the transfer of the resistance trait between bacteria. Examples of each 
process are numerous in the literature. Analysis of resistant isolates of a discrete pneumococcal 
population from any given geographical area may aid in elucidating how such a resistant 
population developed (Hall, 1998). 
In the first process, dubbed the "de novo" scenario (Tomasz, 1997), an organism sequentially 
acquires resistance determinants (altered pbp genes) resulting in a baseline increase in MIC 
This eventually leads to the evolution of a small number of successful resistant clones, such as 
those documented by the pneumococcal molecular epidemiology network (PMEN) (McGee et 
aI., 2001b). This is noted by the gradual increase of pneumococcal resistance in a given 
geographical area. The emergence of intermediate resistance strains will precede the highly 
resistant strains. 
A sudden increase in the prevalence of resistant pneumococci in any geographically distinct 
region is characteristic of the second process. In contrast to the "de novo" scenario, the 
prevalence of resistance may jump from essentially zero to fairly high in a very short period of 
time. Such situations can usually be attributed to the importation and spread of a successful 
resistant clone. This is well demonstrated by the situation in Iceland documented in 1993 
(Soares et a1., 1993). In Iceland, the first penicillin-resistant pneumocoeeus was deteeted in 
December 1988. In the five years prior to this, no penicillin-resistant isolates had been detected. 
In the three years following the first isolation, the frequency of penicillin resistance isolates rose 
to 2.3%, 2.7% and 8.4% respectively. By the first quarter of 1992, 17% of isolates exhibited 
penicillin resistance (Kristinsson et a1., 1992). Of these resistant-isolates, almost 70% belonged 
to serogroup 6 and had identieal multi-resistant phenotypes. Fifty-seven such isolates were 
characterised by genomic MRP, MLEE, serotyping and PBP patterns. The Icelandic isolates 
were indistinguishable from a multi-resistant serotype 6B, which had been circulating in Spain 
for a decade previous. 
The third process is the transfer of resistance between pneumococci and other streptococcal 
species. Oral streptococci have long been thought the most likely candidates for the transfer of 
DNA into the pneumococcus (Challdey and Koornhof, 1990, Reichmann et aI., 1997). Evidence 
suggests that resistant pneumococci may also donate DNA to viridans streptococci and impart 
resistance (Dowson et a1., 1990). Analysis of the pbp2b gene nucleotide sequence of penicillin-
resistant viridans streptococci identified a typical "mosaic" structure, of resistant blocks 
interspersed with sensitive blocks with high sequence identity to sensitive pneumococcal strain, 
R6 (Dowson et aI., 1990). This supports the notion that a gene pool exists between streptococcal 
species, and that intra- and interspecies gene exchange may occur frequently Streptococcus 
pneumoniae (Reichmann et a1., 1997, Hakenbcck et a1., 2001). 
1.6.4 Major penicillin-resistant pneumococcal clones 
Perhaps the most successful resistant pneumococcal clones are those that originated in Spain, 
and subsequently began to disseminate worldwide. The intercontinental spread of a multi-
resistant pneumococcal clone was first demonstrated by Munoz and colleagues (Munoz et a1., 
1991) in 1991. A serotype 23F clone resistant to penicillin reeovered from children attending a 
day care centre in Cleveland, Ohio, was indistinguishable from a multi-resistant Spanish clone. 
Both strains were serotype 23F, had identical MLEE profiles, indistinguishable genomic MRPs 
and RFLP profiles of pbp genes. The Spanish clone was resistant to penicillin (MIC 1-2 ~glm1), 
chloramphenicol, co-trimoxazole and tetracycline. The Spanish 23F multi-resistant clone has 
subsequently been reported in many other parts of the world, including; France (Ferroni et a1., 
1996), Greece (Bogaert et a1., 2000), Hong Kong (Ip et a1., 1999), Korea (McGee et a1., 1997, 
Tarasi et a1., 1997), Taiwan (Shi et a1., 1998), Columbia (Castaneda et a1., 1998) and Mexico 
(Echaniz-Aviles et a1., 1998). 
Resistant pneumococcal clones have disseminated and spread throughout the world. PMEN is a 
group which was recently established to monitor the most globally widespread antibiotic-
resistant pneumococcal clones (McGee et aL, 2001b). To date 16 internationally spread resistant 
clones have been identified by PMEN, as listed in Table 104. These isolates have been defined 
by PFGE, BOX-PCR and MLST. Criteria for inclusion into the PMEN list includes; wide 
geographic distribution; strain well established over time; resistance to at least one clinically 
relevant antibiotic and description of the clone in international journals. Information regarding 
PMEN and the recognised clones can be acquired online (http://www.pneumo.com). 
~(~lone ilesignation ¥ean ~f Senot~pe Penicilllii:Mlt£ ~ t£efotaxime Mm 
:!~ " : Reporting (!:+giml) (!:+g/ml) 
Spain23F_1 1991 23FI19F 2 0.5 
Spain6B-2 1992 6B 2 1 
France9V-3 1991 9V 2 1 
Tennesse23F -4 1995 23F 0.12 32 
Spainl4-5 1996 14 2 1 
Hungaryl9A-6 1991 19A 2 0.5 
South Africal9A-7 1997 19A 0.5 0.5 
South Africa6B-8 1997 6B 0.5 0.25 
England14-9 1996 14 0.03 0.03 
S1ovakial4-10 1995 14 8 
S1ovakial9A-ll 1995 19A 4 1 
F inland6B -12 1992 6B 1 
South Africa!9A-13 1997 19A 8 2 
Taiwanl9F-14 1998 19F 2 1 
Taiwan23F-15 1998 23F 1-2 1 
Poland23F-16 1999 23F 8 8 
Table 1.4 recognised pneumococcal clones as defined by PMEN. 
The strain designations suggested by PMEN are not official strain designations, but rather the 
nomenclature of clonal groups as recommended by PMEN. However, as the PMEN group is 
eomprised of many of the world's top pneumoeoecal researchers, it is likely these terms will 
reeeive widespread acceptance. Consequently these terms have been employed throughout this 
work to describe established international clonal groups. 
1.7 Penicillin Resistance in S. pneumoniae in New Zealand 
1.7.1 Penicillin resistance in invasive pneumococci 
Pneumococci with reduced susceptibility to penicillin were first described in New Zealand in 
1978 (Thornley et a1., 1983). Co-ordinated nationwide surveillance of pneumococcal antibiotic 
resistance began at ESR in 1988 (Brett, 1996), although invasive isolates were screened for 
resistance prior to this (Heffernan, 1986). Among 233 invasive isolates submitted to ESR 
between 1981-1987, only intennediate resistance (MIC 0.l-1.0 ~g/rn1) was observed, with a 
prevalence of 1.3% during this period. Penicillin resistance (MIC ~2.0 ~g/ml) was first noted 
among invasive isolates in 1988. Between 1987 and 1995, penicillin resistance was noted in 
0.4%, and intennediate penicillin resistance 1.1 %, of submitted isolates. 
1.7.2 Penicillin resistance in community acquired pneumococci 
As with invasive isolates, penicillin-resistant pneumococci have remained uncommon in the 
community until relatively recently. A study perfonned at Green Lane hospital, Auckland, over 
eight months in 1974 yielded no penicillin-resistant pneumococci out of l30 isolates examined 
(Wood, 1976). However, low incidences of tetracycline and co-trimoxazole resistance were 
noted (6.9% and 3.9% respectively). 
The proportion of penicillin-resistant pneumococci recovered in the community has been 
increasing yearly during the 1990s with a particularly striking increase around 1993-94. This 
increase is best demonstrated by 1997 data from Riley et al (Riley et aI., 1997), this group 
observed an increase in resistance among Auckland isolates from 0.8% in 1993 to 17% in 1994. 
This was accompanied by resistance increases in non-related antibiotics at the same time. From 
1993-94, erythromycin, tetracycline and co-trimoxazole rose from 3 to 16%, 5 to 16% and 10 to 
22% respectively. Other studies in 1997 suggest the overall rate of resistance (MIC ~ 0.l2 
~lg/ml) in New Zealand to be 17%, with Christchurch and Auckland having the highest 
prevalence (19%) (Brett et aL, 1999). 
1.8 Hypothesis and Aims 
The incidence of pneumococci with reduced penicillin susceptibility has increased in New 
Zealand steadily since 1995. Based on this, the following hypotheses were considered; 
(a) Observations and published reports from other parts of the world suggest that the rapid 
onset and spread of penicillin-resistant pneumococci are due to the introduction and 
proliferation of a single successful clone. It is believed that this has occurred in New Zealand. 
Thus the fIrst hypothesis tested was; 
A single penicillin-resistant pneumococcal clone is responsible jor the increased 
prevalence in resistance observed since 1995. 
(b) The predominant clone is likely to have either developed de novo in New Zealand, or 
originated elsewhere in the world, and subsequently has been imported into New Zealand. The 
rapid emergence and increase in prevalence supports the latter scenario. 
The prominent New Zealand resistant pneumococcal clone has been imported into 
the country from an exogenous source. 
(c) A high level of resistance to cephalosporins is noted among New Zealand isolates. This 
may be associated with the major New Ze~land clone, and if so, it may to have developed 
unique combinations of penicillin binding protein genes to impart this resistance. 
The high-level cefotaxime-resistance is imparted by novel modifications within 
penicillin binding protein genes. 
(d) Most resistant pneumococcal isolates recovered in New Zealand tend to be associated 
with very high-level resistance to macrolides, typically imparted by the erm(B) gene. The major 
New Zealand clone, therefore, is likely to harbour the erm(B) gene. 
The high-level erythromycin resistance is imparted by the erm(B) gene within New 
Zealand isolates. 
The aim of this thesis is to test each of these four hypotheses. 
Chapter 2 
Materials and Methods 
Bacterial Strains and Growth Conditions 
All clinical pneumococcal isolates used in this study were obtained from Medlab South, 
Christchurch, and the Institute of Environmental Science and Research Limited (ESR), 
Kenepuru Science Centre (KSC). A list of clinical isolates and their relevant phenotypes is 
given in appendix I. All reference strains are listed in Table 2.1. Descriptions of all media used 
are listed in appendix II. 
ATCC 49619 NCCLS recommended Medlab South Ltd, 
antibiotic control strain Christchurch. 
ATCC 700669 Spain23F_l KSC,ESR. 
ATCC 700670 Spain6B_2 KSC,ESR. 
ATCC 700671 9V Spain -3 KSC, ESR. 
ATCC 51916 Tennessee23F -4 KSC, ESR. 
ATCC 700902 Spainl4-5 KSC,ESR. 
ATCC 700673 Hungaryl9A -6 KSC,ESR. 
ATCC 700674 South Africa19A-7 KSC,ESR. 
ATCC 700675 South Africa6B-8 KSC,ESR. 
ATCC 700676 England14-9 KSC,ESR. 
ATCC 700677 Czech Republic 14_10 KSC,ESR. 
RX1 R36A derivative Dr Ann Holmes, Otago 
R800 R3 6A derivative Dental School. 
Table 2.1 Reference and strains used in this study. 
2.1.1 Cultivation and storage of bacterial strains 
(NCCLS, 1999) 
(McGee et al., 
2001b) 
" 
Pneumococcal strains were routinely cultivated on tryptic soya agar (TSA) supplemented with 
5% sheep's blood. Samples were cultured for 18-24 h at 37°C in a 10% CO2 incubator (primary 
isolation was perfonned under the same conditions 5% CO2). For long tenn storage cells 
were removed after 18 h growth with a sterile eotton swab and suspended in brain-heart infusion 
(BHI) broth supplemented with 10% glycerol, and stored at -80°C. 
2.2 Sample Isolation and Identification 
Pneumococcal isolates were identified from clinical specimens using standard teclmiques. In all 
instances the following tests were performed for the identification of S. pneumoniae. As such, 
these tests were performed at either Medlab South (in the case of the Christchurch strains), or 
within the respective submitting laboratory (in the case of strains from KSC). Descriptions of 
these tests are included here for completion. Typically, colonies exhibiting characteristic 
pneumococcal morphology and a-haemolysis on TSA sheep's blood agar would be subcultured 
and tested to differentiate from other a-haemolytic streptococci. Differentiation consists of 
testing optochin sensitivity and bile solubility. 
2.2.1 Optochin (Ethylhydrocupreine hydrochloride) sensitivity 
A single pneumococcal colony was suspended in 1m! of Todd Hewitt broth. The cell suspension 
was spread three ways on to a pre-dried TSA plate containing 5% sheep's blood using a sterile 
cotton swab. The agar was allowed to dry for approximately 10 min before application of a 5 ~lg 
optochin disc (Oxoid, Hampshire, England). Plates were inverted and incubated for 18 h at 37°C 
in a 5% CO2 incubator. After incubation the zones of inhibition were measured. A zone greater 
than 16mm indicated sensitivity and is a presumptive positive for S. pneumoniae (Ruoff, 1995). 
2.2.2 Bile solubility 
Results of the optochin sensitivity test were used in conjunction with the bile solubility test, 
performed using the plate method (Ruoff, 1995). A single, well-isolated colony was chosen 
from a 5% TSA plate containing a 18-24 h growth of the suspccted S. pneumoniae. A loopful of 
2% deoxycholate (PH 7.0) was placed directly on the colony, and the plate incubated aerobically 
for 30 min. A positive test was noted if the colony disintegrates under the drop. 
2.3 Antimicrobial Susceptibility Testing 
The majority of the antimicrobial susceptibility testing was performed at Medlab South, 
Christchurch, or the antimicrobial reference laboratory, KSC, Porirua. All pneumococcal 
isolates recovered at Medlab South from clinical specimens were routinely tested against a 
panel of three or four antibiotics depending on the site of infection. Typically isolates would be 
tested for sensitivity to oxacillin (1 ~Lg), erytlu'omycin (15 ~Lg) and chloramphenicol (30 ~g) 
using antibiotic discs (Oxoid, Hampshire, England). Isolates recovered from sputa were tested 
with a different range of antibiotics including oxacillin (1 /-tg), erythromycin (15 /-tg), 
tetracycline (30 ~lg) and co-trimoxazole (25 /-tg). Any isolate that proved to have a decreased 
sensitivity to penicillin was tested further using Etest strips (AB-Biodisk, Solna, Sweden) to 
detennine the isolate's MIC of penicillin and cefotaxime. At this stage disc sensitivities were 
also performed on any antibiotics not covered in the initial screen. Sensitivity to vancomycin 
(30 /-tg) was also tested by disc diffusion. 
Isolates from Medlab South, and other NZ clinical labs, which were shown to have a decreased 
sensitivity to penicillin were submitted to the antimicrobial reference lab, KSC, for confirmation 
(during period 1997 - 2000, selection refmed to cefotaxime-resistant isolates in 2001 due to high 
number of isolates being received). Confirmation included testing susceptibilities to cefotaxime, 
co-trimoxazole, erythromycin and penicillin by Etest, and tetracycline, chloramphenicol, and 
vancomycin by disc diffusion. Where available, sensitivities detennined by the NZ 
antimicrobial reference laboratory were used preferentially over those of the submitting 
laboratory. For some isolates sensitivity data for specific antibiotics was not available, and other 
isolates with unusual phenotypes may have required independent verification. In such cases 
susceptibility testing was performed as stated in section 2.3.1 below. In each instance all tests 
were performed and interpreted according to the NCCLS guidelines (NCCLS, 1999). 
2.3.1 Disc diffusion/Etest 
Bacteria from an overnight culture were suspended in Mueller-Hinton broth to an optical 
density equivalent to a 0.5 McFarland standard. Mueller-Hinton agar plates supplemented with 
5% sheep's blood, were dried for approximately 30 min before inoculation. The cell suspension 
was applied with a sterile cotton swab by streaking across the surface of the agar in threc 
directions. The agar surface was allowed to dry for 10 min before application of discs or Etest 
strips. Typically no more than six discs, or two Etest strips, were applied to any plate. Disc 
zones were measured in millimetres and interpreted according to NCCLS standards (NCCLS, 
1999). Etest results were read and rounded up to the next doubling dilution. 
2.3.2 Agar dilution 
Agar dilutions were performed when determining antibiotic MICs of a large number of strains, 
where testing by Etest would be impractical. The concentration range of eaeh drug tested is 
shown in table 2.2 and followed a standard doubling dilution scheme (I.e. 0.06, 0.12, 0.25 ... 
128, 256 .Ltglrnl). 
2.3.2.1 Preparation of antibiotic stocks 
Antibiotics were weighed on an analytical balance, and a minimum of 20 mg of antibiotic 
powder transferred to a sterile universal tube. The powder was dissolved in an appropriate 
volume of a suitable diluent (Table 2.2) to give a final concentration of 2560 Jlglml (in the case 
of crythromycin a stock concentration of 5120 Jlglml was used), and adjusted to take into 
account the drug potency stated by the manufacturer. Antibiotics used were penicillin (Glaxo), 
piperacillin (Sigma), cephalothin (Lilly Research Laboratories), cefuroxime (Glaxo), cefaclor 
(Lilly Research Laboratories), cefotaxime (Roussel Ltd), meropenem (Astra Zeneca) and 
erythromycin (Sigma). Stocks of ~-lactam antibiotics were not stored after use due to 
degradation. Erythromycin stocks were stored at _20DC 
~ ~,1?"N" -~-~-?~=",",J~f!) 
~ntl6iotic ~ (1ioncentl1ation range l!.+glffil) ~ cc':"~ ~ Diluent ;, e 
c;:' ~ , " ~ , I ") '7 
Cefaclor 
Cefotaxime 
Cefuroxime 
Cephalothin 
Penicillin 
PiperaciIlin 
Meropenem 
Erythromycin 
Oe25 -32.0 
0.12 - 32.0 
0.25 - 32.0 
0.25 - 32.0 
0.12 - 8.0 
0.25 -32.0 
0.06 - 8.0 
1.0 -256.0 
Phosphate buffer, pH 6.0 
Water 
Water 
Phosphate buffer, pH 6.0 
Water 
Water 
Water 
EthanoVWater 
Table 2.2 ArltllJ'lOtlCS and dilutions used for susceptibility testing 
2.3.2.2 Preparation of test media 
A suitable volume (17 ml per plate) of Mueller-Hinton medium was sterilised by autoclaving, 
and maintained at 50°e, The antibiotic stock solution was diluted to an intennediate 
concentration tenfold higher than the final concentration (volume of 2 ml per plate). After 
temperature equilibration of molten agar, the appropriate volume of antibiotic intennediate 
solution was added as well as 5% defibrinated sheep's blood (1 ml per plate). Container 
contents were then gently mixed and poured into petri dishes containing 20 ml of media per 
plate. Plates were stored at 4°C and were used within five days of preparation. Before 
inoculation of the plates, the plates were equilibrated at 37°C to allow the surface of the agar to 
dry. 
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2.3.2.3 Inoculation of test media 
Colonies from an overnight growth (18 h) were suspended in sterile Todd Hewitt broth with a 
sterile cotton swab. The turbidity was adjusted to match that of a 0.5 McFarland standard (ca. 
108 CFU/ml). Suspensions were further diluted 1: lOin sterile broth to give an adjusted 
concentration of 107 CFU/ml. An 100 Jll aliquot of each suspension was transferred into an 
appropriate well of a 32 well seed plate. A replicating device was used to deliver inocula of all 
32 isolates simultaneously. The replicator was calibrated to deliver 1 ~tl (ca. 104 CFU/mI) of 
suspension to the agar surface. Agar plates were inoculated beginning with the lowest dmg 
concentration, and a control plate containing no antibiotic was included at the beginning and 
end of each series of antibiotic plates. Inoculated plates were allowed to stand until all inocula 
had been absorbed by the media, then were incubated overnight at 37°C in 5% CO2• 
2.3.2.4 Interpreting results of agar dilution plates 
Before reading results, dmg free control plates were checked to ensure the viability and purity 
of isolates. Quality control strain ATCC 49619 was also checked to ensure it yielded results 
within the acceptable accuracy ranges, as defined by the NCCLS standards (NCCLS, 1999). 
The MIC was defmed as the lowest antibiotic concentration that inhibited visible growth. 
2.4 Serotyping 
Serotyping was performed by the Streptococcus Reference Laboratory, KSC, using the capsular 
reaction test (Neufeld test) and Danish system ofnomenelature. 
2.5 DNA Manipulations 
Reagents and buffers used for various DNA manipulations are defmed in appendix III. 
2.5.1 DNA extraction 
Unless stated otherwise, all DNA extractions used the rapid guanidine thiocyanate procedure 
described by Pitcher et al (1989). Growth from an 18 h TSA blood plate was collected using a 
sterile cotton swab and suspended in 1.0 ml of 0.9% saline. Cell suspensions were centrifuged 
for 1 min, 4 DC, at 14800 x g and the supernatant discarded. The pellet was resuspended in 100 
JlI of fresh lysozyme (50 rng/ml) in TE buffer and incubated at 37°C for 30 min. Cells were 
lysed with the addition of 500 JlI of GES reagent and incubated at ambient temperature for 5-10 
min. Lysis was assessed by clearing of turbity, after which lysates were cooled on ice, and 250 
~tl of 7.5 M ammonium acetate was added. Samples were kept on ice a further 10 min, before 
addition of 500 ~ll of 24:1 chlorofonnlIAA The phases were mixed by inversion, and separated 
by centrifugation (10 min, 4°C, 14800 x g). The aqueous phase was transferred to a new tube, 
and DNA precipitated by addition of 0.5 volumes of ice-cold 2-propanol with gentle inversion. 
Tubes were incubated at ambient temperature for 10-15 min and DNA harvested by 
centrifugation (10 min, 4°C, 14800 x g). The DNA pellet was washed with 70% ethanol and air-
dried. DNA was re-dissolved in 50 ~l of sterile dH20 supplemented with RNase A (20 ~g/ml). 
2.5.2 Agarose electrophoresis 
DNA (including chromosomal DNA, PCR products and restriction digest products) was 
analysed by electrophoresis through 0.8-3.0% agarose gels. Gels were constructed by heating 
the appropriate amount of agarose (ultraPURE; Life Technologies) in Ix TAE buffer until the 
agarose melted. Gels were cast in perspex gel moulds using plastic combs to form wells. 
Typically, 8 ~l of DNA sample was mixed with 1 ~t1 of 6x bromophenol blue gel dye and loaded 
into each well. To verify fragment size, 3 ~ll of either 100 bp or 1 kb molecular weight marker 
(BioRad) was included in all gels. Electrophoresis was performed in a DNA sub cell apparatus 
(Jordan Scientific Co.) at approximately 6 V/cm. 
Post electrophoresis, were stained in dH20 containing 0.5 ~lg/ml ethidium bromide with 
gentle shaking for 15-20 min. Gels were visualised on a UV transilluminator (254 nm) and 
photographed with a Kodak DC120 electrophoresis documentation and analysis (EDAS) digital 
camera. 
2.5.3 Polymerase chain reaction (peR) 
This section covers generic PCR, and applies to all the work presented in this thesis, with the 
exception of the PCRIDNA nucleotide sequencing performed for muItilocus sequence typing, 
which required substantial "in house" sequencing. For consistency, the primers for the MLST 
scheme are listed below (table 2.3), but the method is outlined separately in section 2.6. 
2.5.3.1 Preparation of peR 
PCR was performed in 0.5 ml thin-walled PCR tubes. Each reaction consisted of the appropriate 
primers at a final concentration of 2 pmol per reaction; each dNTP (dATP, dCTP, dGTP, dTTP) 
at a final concentration of 200 ~lM; 10% of the total reaction was 10x PCR buffer, 2.5 units of 
Taq DNA polymerase and sterile dH20 to bring the reaction volume to 50 ~ll. lOx PCR buffer, 
dNTPs, and Taq polymerase were all obtained from Boehringer MannbeimiRoche. Primers 
(tables 2.3-2.6) were purchased from Gibco/Life Technologies. Reaction mixtures were overlaid 
with 2 drops of mineral oil (Sigma). Primers for MLST (Table 2.3) were as described by 
Enright and colleagues (1998). 
Amplification was carried out in a Corbett Research FTS 320 them1al cycler. Amplification 
consisted of an initial denaturation of 1 min at 94°C, then 35 cycles for the following three step 
cycle; template denaturation for 15 sec at 94°C, primer annealing for 45 sec at 55°C and 
template elongation for 1 min at 72°C. A final extension step of 5 min at 72°C was included, 
followed by an ongoing soak step at 4°C to refrigerate reactions until processing. The presence 
ofPCR amplification products (amplicons) was verified by electrophoresis through 1 % agarose 
gels. 
? '" ~ , ~ "' "''' ~ "~"'0 ,"y, !j ) j.f 
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aroE-up 
aroE-dn 
gdh-up 
gdh-dn 
gki-up 
gki-dn 
recP-up 
recP-dn 
spi-up 
spi-dn 
xpt-up 
ddl-up 
ddl-dn 
5' -gee ttt gag geg aea ge-3' 
5' -tge agt tea (g/a)aa aea t(alt)t tet aa-3' 
5'-atg gae aaa eea ge(g/altle) ag(e!t) tt-3' 
5' -get tga ggt eee at(g/a) et(g/altle) ee-3' 
5' -gge att gga atg gga tea ee-3 ' 
5'-tet eee gea get gae ae-3' 
5'-gee aae tea cat eea gg-3' 
5' - tge aae egt age att gta ae-3' 
5' -tta tte etc etg att etg te-3' 
5' -gtg att gge eag aag egg aa-3' 
5'-tta tta gaa gag ege ate et-3' 
5' -aga tet gee tee tta aat ae-3 ' 
5'-tge (e/t)ea agt tee tta tgt gg-3' 
5' -cae tgg gt(g!a) aaa ee(alt) gge at-3' 
shikimate dehydrogenase 
glueose-6-phosphate dehydrogenase 
glucose kinase 
transketolase 
signal peptidase I 
xanthine phosphoribosyl transferase 
D-alanine-D-alanine ligase 
Table 2.3 PCR primers used for the amplification and sequencing of housekeeping genes for 
multilocus sequence typing. 
pbpJa1827 5'-tgg gat gga tta cae aaa tg-3' pbpJa gene (Asahi and Ubukata, 
pbpJa3098 5' -tgt get tga tga gga tte tg -3 ' 1998) 
pbp2b-seq 5' -gag a(g!e)t tga ege etg aU eet t-3' pbp2b gene This study 
pbp2x958 5'-tat gaa aag gat egt etg gg-3' pbp2x gene (Asahi et aI., 1999) 
pbp2x21 05 5' -aga gag tet tte ata get gaa ge-3' 
Table 2.4 PCR primers used for amplification and sequencing of penicillin binding protein 
genes. 
~0~ j ~ ~ =~ :~ x ~ j:S ~;;( '~ ~ ~~ Tc'" ~\? ~ 
~'lb1jmer name, " ~ud~otide Sequence mal'get gene Refel1enlS,~~r:'T' ~\ ';: 
PnlAup 
PnlAdown 
pbplb-up 
pbplb-dn1a 
pbplb-dn2b 
pbp2a-up 
pbp2a-dn 
Pn2Bup 
Pn2Bdown 
pbp2x-up 
pbp2x-dn 
5 eat teg att tga tte get tet-3' 
5' -etg aga aga tgt ett etc agg -3 ' 
5' -gtg gta taa tag ata aag tga gg-3' 
5' -eee ttg aag aag aag gte g-3' 
5' -eee ttg aea tea aea eee-3 ' 
5' -gtg aae tag agg act etg-3' 
5' -gaa ata gat tga eta teg-3' 
5 eet eta aat gat tet eag gtg 
5' -eaa tta get tag eaa tag gtg ttg 
5' -egt ggg act att tat gae ega aat gg-3' 
5' -aat tee age act gat gga aat aaa eat att a-3' 
Table 2.5 PCR primers for the amplification genes. 
pbpla gene 
pbplb gene 
pbp2a gene 
pbp2b gene 
pbp2x gene 
(Coffey et al., 1991) 
(Hakenbeek et al., 
1998) 
(Hakenbeek et al., 
1998) 
(Dowson et al., 
1989b) 
(Munoz et al., 1991) 
Amplified fragments were subsequently used for RFLP typing (primers Pn2Bup and Pn2Bdown were also used for 
detennination of DNA sequence), (a) designed based on S. pneumoniae R6 DNA sequence, (b) designed based on 
cefotaxime-resistant R6 transfonnant R6TS-CCC (Hakenbeck et al., 1998). 
0:;:0;",0"'2'%;""t;",/)"72'):»/ G~=z;;:;* "",it"" "\Z0::t""0~",-7 '~0"" = ~ ";;,~,, 
~~l1ime!~}lil"i!lI'; "~ueleoti(le seguence "', ' , ' ,,' mal1get gene ,Reference 
Si0" 4:> '\ ~ , '"\ 
ermAM-l 5' -tea aee aaa taa taa aae aa-3' 
ermAM-2 5' -aat eet tet tea aea ate 
mejE-1 5' -agt ate att aat eae tag 
mejE-2 5' -tte tte tgg tae taa agt 
ermB gene 
mejEgene 
(Shortridge et al., 
1996) 
(Sutcliffe et al., 
1996a) 
Table 2,6 PCR primers for amplification and sequencing of macrolide resistance genes. 
2.5.3.2 Restriction digestion ofPCRproducts 
PCR amplicons of the pbp genes (Table 2.5) were typically analysed by restriction 
endonuclease digestion. Restriction endonucleases used in this work were pnrchased from 
Roche, and used as per manufactnrer's instructions. Typically restriction digests were 
performed in 15 f,.tl and incubated at the appropriate temperature for 3 h. The enzymes used for 
this work were DdeI (C'TNAG), Hinfl (G' ANTG) and RsaI (CT' AG), (N represents anyone of 
the fournucleotides; A,T,G or C). 
2.5.3.3 DNA sequencing of peR products 
With the exception of the sequencing performed for MLST (section 2.6), DNA sequencing was 
sent to the University of Waikato DNA sequencing facility. DNA fragments for sequencing 
consisted solely ofPCR products and wcre sequenced using the identical primers for the initial 
PCR amplification. Unincorporated primers and nucleotides were removed from DNA 
templates using the QIAquick spin column PCR purification kit (Qiagen). 
DNA sequencing was performed on an ABI Prism 377 DNA sequencer (Applied Biosystems) 
using BigDye terminators (Applied Biosystems) at the the University of Waikato, Hamilton, 
New Zealand. The nucleotide sequence of both DNA strands was determined and sequence 
alignments were performed using Clustal X (Thompson et al., 1997). 
2.5.4 Pulsed field gel glectrophoresis (PFGE) 
2.5.4.1 Preparation of agarose embedded chromosomal DNA 
Bacterial growth from an 18 h TSA blood plate was collected using a sterile cotton swab and 
suspended in 3 ml ofPETT IV buffer to give a turbidity equivalent to a 3.0 McFarland standard. 
The cells were collected by centrifugation for 3 min, 4°C at 6600 x g. The supernatant was 
discarded and pellet resuspended in 125 ~ll of PETT IV buffer. A 1.6% solution of pulsed field 
certified agarose (Bio-Rad) in dH20 was heated until dissolved and held at 50°C in a water bath. 
Plugs were formed by rapidly mixing 240 ~ll of molten agarose with the cell suspensions and 
injecting into plug moulds (Bio-Rad). Plugs were allowed to solidifY (10-15 min), then placed 
into sterile universal bottles containing 2 ml EC lysis buffer with lysozyme (final concentration 
1 mg/ml) and heat-treated RNase (final concentration 20 Jlglml) and incubated overnight at 
37°C in a shaking water bath. The lysis buffer was subsequently removed after 24 hand 
replaced with 2 ml ESP buffer containing proteinase K (final concentration 0.5 mglml) and 
incubated overnight at 50°C. Following incubation plugs were rinsed by soaking in 20 ml dH20 
at ambient temperature for 30 min. Plugs were transferred to sterile plastic 50 ml tubes and were 
washed twice by incubation inlx TE buffer overnight at 4°C. Plugs were subsequently cut into 
6 even pieces and stored at 4°C in 1 ml of Ix TE until required. 
2.5.4.2 Restriction endonuclease digestion of agarose embedded DNA 
Plug slices were digested using either of the enzymes Sma I or ApaI (Roche). Digestions were 
performed in sterile 1.5 ml Eppendorf tubes and consisted of 20 units of respective enzyme with 
15 JlI of appropriate digestion buffer in 135 Jll of sterile dH20 per reaction. Reactions were 
incubated overnight at 25°C (SmaI) or 30°C (ApaI). 
2.5.4.3 Electrophoresis of agarose embedded DNA 
An 1 % agarose gel was prepared by heating the appropriate amount of pulsed field certified 
agarose (either 1.0 or 1.5 grams) in the corresponding volume ofO.5x TBE buffer (either 100 or 
150 ml respectively). The gel was cast and DNA embedded agarose plugs were loaded into the 
wells. Once loaded the wells were sealed with 1 % agarose to prevent further movement of the 
plugs. Concatamers of lambda DNA (PFG marker, New England Biolabs) was used as a size 
standard. Electrophoresis was performcd on both CHEF mapper and CHEF DRIll (both Bio-
Rad) systems. Both systems required 2 L of 0.5x TBE running buffer. Electrophoretic 
conditions wcre as follows; running temperaturc 14°C, gradient 6.0 V/cm, run time 22 hours, 
initial switch time 5 sec, final switch time 35 see and a linear ramping factor. Following 
electrophoresis, gels were stained in ethidium bromide (05 )1g1ml) for 30 minutcs, and destained 
in dH20 for up to an hour. Gels werc visualised on a UV transilluminator (254 urn) and image 
obtained using a Kodak DC120 digital camera. 
2.5.4,4 Interpretation of banding patterns 
SmaI digests of pneumococcal chromosomal DNA produces approximately 15 fragments, 
ranging in size from 25-500 kbp. Banding patterns were compared visually and were 
interpreted essentially as described by Tenover et al (1995), with some modifications. Tenover 
et al suggest that pattems differing in up to three bands from an index pattern can be considered 
highly related, and those differing in up to six bands considered possibly related. As the cunent 
investigation was spread temporally over five years, it was decided that all "possibly related" 
profiles were to be considered as belonging to the same macro-rcstriction group. Each group 
was numbered arbitrarily as new profiles were observed, e.g., 1, 2, 3 etc. Within each group, 
identical profiles were considered distinct restriction types, and distinguished with a upperease 
letter, e.g. lA, lB, lC etc. Therefore, by definition; all isolates with MRP lA would be 
genetically indistinguishable and considered to belong to the same clonal group; two isolates 
with MRPs lA and IB respectively, would be designated to the same group and considered 
related; and two isolates with MRPs lA and 2A would be designated to different groups and 
considered unrelated. Without the ability (in most instances) to discern an index case, types are 
considered to belong to a givcn group if they differ by no more than six bands from the most 
similar member of the cluster, as suggested by Hall (Hall, 1998). 
Southern hybridisation 
All Southem hybridisations were performed using the non-radioactive digoxygenin-dUTP 
(DIG) DNA labelling and detection kit (Roche). All buffers and solutions used for Southcrn 
hybridisations are described in Appendix III. v. 
2.5.5.1 Probe labelling 
Probes were created using the PCR DIG probe synthesis kit (Roche) as per manufacturer's 
instructions. PCR labelling reactions were performed in 50 )ll volumes. The resultant PCR 
product was purified using the QIAquick spin column PCR purification kit (Qiagen). Prior to 
use, the DIG-labelled DNA probe was denatured by boiling for 5 min, and rapidly cooled on 
ice. 
2.5.5.2 Southern transfer 
DNA separated by PFGE was transferred to a positively charged nylon membrane (Roche) 
using a vacuum transfer unit (Hoefer TransVae TE80). A eonstant suction of 70 mm Hg was 
obtained with an Air Cadet vacuum/pressure station (Cole-Palmer). Transfer was conducted in 
accordance with manufacturer's (Hoefer) protocol. 
Briefly, after assembling the transfer unit and placement of both gel and membrane, the gel was 
treated sequentially with approximately 30 ml of depurination, denaturation and neutralisation 
solutions. Solutions were pipetted onto the gel in sufficient volume to cover the surface and left 
for 20 min under constant vacuum. Liquid was removed by pipette before treatment with 
subsequent solution. Following the neutral~sation solution, 20x SSC buffer was added in 
sufficient volume to cover the entire gel, and transfer was performed for 120 min. Following 
transfer, the agarose gel was re-stained and examined on an UV transilluminator to estimate the 
efficiency oftransfer. The membrane was removed from the TransVac and the transferred single 
strand DNA was fixed to the membrane by exposure to a UV light source for 30 sec, at 1200 kJ 
in an UVC-515 Ultraviolet multilinker (Ultra-lum). 
2.5.5.3 Probe hybridisation 
Hybridisation was condueted as per the manufacturer's instructions (Roche). Briefly, the 
membrane was placed in a Hybaid glass tube, and prewarmed at 42°C with 25 ml (for PFGE gel 
14x15 em membrane) of hybridisation buffer (DIG Easyhyb, Roche). Prehybridisation was 
performed for 30 min in a Micro-4 HB-MCR4 hybridisation oven (Hybaid). Following 
prehybridisation, the buffer was discarded and replaced with 7.3 ml of hybridisation solution 
containing the denatured DIG-labelled probe. Hybridisation was performed at 42°C overnight 
(16 b) with constant rotation. Post-hybridisation, the solution containing the DIG labelled probe 
was decanted and stored at -20°C for future use. The membrane was subject to two 5 min low 
stringency washes (2x SSC, 0.1 % SDS at ambient temperature) and two 15 min high stringency 
washes (0.5% SSC, 0.1 %SDS at 68°C). 
2.5.5.4 Signal detection 
Hybridised DIG labelled DNA probes were detected as per manufacturer's instructions (Roche). 
The membrane was rinsed in approximately 100 ml of washing buffer for 5 min at ambient 
temperature. The membrane was next incubated in blocking solution (30 min), antibody (anti-
digoxigenin-alkaline phosphatase conjugate) solution (30 min), washing buffer (2x 15 min) and 
detection buffer (5 min). The membrane was sealed in plastic with approximately 1 ml of CSPD 
(chemiluminescent substrate for alkaline phosphatase) and incubated at 37°C for 15 min. 
Chemiluminescence from the membrane was detected on hyperfilm (Amersham Pharmacia 
Biotech) after a 5 min exposure. 
2.5.5.5 StrippinglRe-probing membranes 
The DIG-l1-dUTP is alkaline labile, therefore efficient stripping of the blots was easily 
achieved. This was done by first washing the membrane with dH20, before subjecting it to two 
15 min washes at 37°C in 0.2 M NaOH containing 0.1 % SDS. This is followed by a 5 min rinse 
in 2x SSC at which stage the membrane is ready to be re-probed. 
2.6 DNA Sequencing 
Sections 2.6.1 through to 2.6.3 to "in house" sequencing performed at the Kenepuru 
Science Centre. Preparation ofPCR products for sequencing at the University ofWaikato DNA 
sequencing facility was covered in section 2.5.3.3. 
2.6.1 peR amplification of internal gene fragments 
Template DNA for the initial PCR was extracted using the lnstaGene Matrix kit (BioRad) 
according to manufacturer's directions. DNA preps were stored -20°C. PCR was performed in 
0.2 ml thin-walled PCR tubes in a total reaction volume of 50 ml. The PCR reaction mixture 
contained; 6 ~ll template DNA, 1 ~ll of each of the appropriate primers (Table 2.3) at a :final 
concentration of 0.8 pmol and 42 ~ll Platinum PCR supermix (Gibco). 
PCR amplification was performed in a Perkin-Elmer Cctus thermocycler. After an initial 
denaturation step of 5 min at 94°C, amplification consisted of 35 cycles, three steps pcr cycle: 
template denaturation for 30 sec at 94°C, primer annealing for 30 sec at 50°C and elongation for 
30 sec at 70°C. A final extcnsion step of 5 min at 70°C was also included followed by a final 
soak at 4°C. The presence of a reaction product was verified by subjecting 5 ~t1 of the PCR 
reaction mixture to electrophoresis through a 2% agarose gel at 100 V for 1 h. Gels were stained 
with ethidium bromide and visualised on a UV transilluminator. 
PCR products were cleaned using the QIAquick 96-well plate PCR purification kit (Qiagen) as 
per manufacturer's instructions. This procedure also required the QIAvac 96 (Qiagen) and 
vacuum source. Purified DNA was stored at -20°C. 
2.6.2 Sequencing reaction 
To ensure sequence data was as accurate as possible, the nucleotide sequence of both DNA 
strands was determined. This is accomplished by setting up two reactions for each gene, each 
using only one of the two primers. As such, each strain required 14 sequencing reactions. With 
each batch of sequencing reactions performed a control was included to ensure the integrity of 
the sequencing reaction. The control recommended by Perkin Elmer, the plasmid pGEM with 
primer Ml3, was used. Template DNA concentration was determined by comparison with a low 
molecular mass DNA ladder (LifeTechnologies) on a 2% agarose gel as per manufacturer's 
instructions. 
Sequencing reactions were performed in 20 III volumes and contained; 0.5-2.0 III of purified 
template DNA to ensure a final concentration of 5 ng/FI, 1 Fl of each single primer (3.2 pmol), 
4 Fl of BigDye terminator mix (Applied Biosystems) and sufficient dH20 to bring the total 
reaction volume up to 20 Ill. The sequencing reactions were performed in a Perkin-Elmer Cetus 
thermocyc1er. Dye incorporation consisted of 25 cycle reaction, three steps per cycle: template 
denaturation for 10 sec at 94°C, primer annealing for 5 sec at 50°C and elongation for 2.5 min at 
60°C. A fmal soak at 4°C was also included. At the completion of the reaction, products were 
stored at -20°C until ready to purify for sequencing. 
2.6.3 Preparation of product for sequencing 
Prior to sequencing, un-incorporated dye-temrinators were removed by ethanol precipitation. 
This was performed by firstly adding 80 III of dH20 to the 20 III sequencing reaction product. In 
a new 0.5 ml tube, 10 ~tl of 3 M sodium acetate (PH 4.6) and 250 ~tl of 100% ethanol (EtOH) 
was added. The diluted sequencing reaction mixture was pipetted into the EtOH and mixed 
thoroughly. Tubes were incubated at ambient temperature for 15 min to precipitate the extension 
products, before collecting DNA by centrifugation (25 min, 14800 x g). The supernatant was 
carefully discarded and pellet washed with 250 III of 70% EtOH. Again the DNA was collected 
by centrifugation (25 min, 14800 x g) and the supernatant carefully removed. The resulting 
pellet was incubated at 37°C and allowed to air dry. Pellets could be stored at -20°C at this 
stage. 
To complete processing, pellets were resuspended in 15 fll of template suppression reagent 
(TSR, Applied Biosystems) and mixed. The samples were heated in a hot block at 95°C for 2 
min to denature the DNA and immediately placed on ice. At this stage the samples were loaded 
into the ABI Prism 310 automated sequencer (Applied Biosystems) and sequenced using the 
long capillary and a gel temperature of 50°C, in accordance with manufacturer's instructions. 
2.7 Protein Manipulations 
Sections 2.7.1 2.7.3 based on protocol of Zhao, with minor modifications (Zhao et aI., 1999). 
2.7.1 Bacterial membrane preparations 
Pneumococcal cells were grown in 500 ml of brain heart infusion medium to an OD6oo of 0.5 -
0.8. Cells were harvested by centrifugation (4400 x g for 8 min at 4°C) and the pellet washed 
with phosphate extraction buffer. Cells were resuspended in 5 ml extraction buffer and subject 
to mechanical lysis by sonication (Vibra-cell, Sonics). Cell suspensions were pulsed twice with 
a sonicator (each pulse 75% amplitude, one min bursts), with ice bath cooling. 
Crude cell debris was removed by centrifugation at 12000 x g for 10 min at 4°C. Supernatant 
fractions were collected and membrane proteins collected by centrifugation at 
150 000 x g for 35 min (RC-MI50GX ultracentrifuge, Sorvall). Pellets were colleeted, washed 
once, and resuspended in 500 fll of extraction buffer. Protein concentrations were estimated 
using the BioRad protein assay kit as per manufacturer's instructions. Protein extracts were 
stored at -80°C until further use. 
2.7.2 Labelling of penicillin binding proteins with Bocillin FL 
Penicillin binding proteins were detected using Bocillin FL, a commercially prepared 
fluorescent penicillin analogue (Molecular Probes, Inc.). Labelling was performed in 50 ~t1 
volumes containing; 37.5 fll membrane preparation (~150 ~Lg of protein) and 25 fll of Bocillin 
FL solution (final concentration range 0.4-50 ~LM). Reaction mixtures were incubated at 35°C 
for 30 min. After labelling, 50 ~Ll of sample buffer was added, and the reaction mixture 
incubated at 100°C for 3 minutes. Sample volumes of 5-10 fll (7.5-15 flg protein) were 
subjected to SDS-PAGE analysis. 
2.7.3 SDS-PAGE separation oflabeled PBPs 
Separation of protein bands was achieved by electrophoresis through 7.5% polyacrylamide gels 
using a BioRad Mini PROTEAN II electrophoretic unit under a constant current of 40 rnA. 
Polyacrylamide gels prepared as stated in appendix IIliv.ii. Labeled protein bands were 
visualized with the BioRad PluorS Multimager. 
Chapter 3 
Population Dynamics of Antibiotic-
esistant Pneumococci ill Christchurch 
3.1 Introduction 
Christchurch is the largest centre in the South Island of New Zealand, with a population of 
around 340 000. It is situated on the east coast (Figure 4.1), and provides an international entry 
point for the South Island. During the 1990s New Zealand observed an increase in antibiotic 
resistance among S. pneumoniae. Resistance to penicillin increased from 1.8% in 1988-90 to 
19% in 1997-99 among non-invasive pneumococci, and from 1.0% in 1988-90 to 15% in 1997-
99 among invasive isolates (Brett and Ellis-Pegler, 2001). The prevalence of antibiotic 
resistance in Christchurch is among the highest in the country. A study of pneumococci isolated 
from four New Zealand cities during 1997 found the prevalence of high-level penicillin 
resistance (MIC ~ 2 ~lg/ml) to be 10% in Christchurch. By comparison, the incidence in the 
other centres was 6%, 5% and 0% in Auckland, Hamilton and Wellington respectively (Brett et 
aL, 1999). 
Medlab South is a Christchurch community medical laboratory, providing routine diagnostic 
testing for medical practitioners in Christchurch, and the greater South Island area. As part of 
their routine susceptibility testing, increased antibiotic resistance in S. pneumoniae has been 
noted over the past decade (Figure 3.1). In particular, pneumococci with reduced susceptibility 
to penicillin have been recovered with steadily increasing frequency since 1993. In little over 
four years, from late 1994 to early 1999, the incidence of non-susceptible pneumococci rose 
from 3% to 30% of those recovered. This rapid increase in prevalence of resistant pneumococci 
is reminiscent of overseas reports of rapid increases in resistance. The often-cited Icelandic 
experience is perhaps one of the most convincing examples (Soares et aL, 1993). Resistant 
pneumococci had not been observed in Iceland prior to 1988, yet by 1992 prevalence was at 
17% (Kristinsson et aL, 1992). France is another example; resistant pneumococci were rare (s 
1.1 %) until 1987 (Geslin et aL, 1992), but increased steadily thereafter to reach 25% prevalence 
in 1993 (Ferroni et al., 1996). Such observations are not limited to Europe. In Hong Kong, 
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pneumococci with reduced penicillin susceptibility were first reported In 1993; by 1995 their 
prevalence was observed to be 28.9% (Kam et aI., 1995). 
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Figure 3.1. Proportion (%) of all pneumococcal isolates recovered at Medlab South, 
Christchurch, between January 1992 - December 2000, with a reduced susceptibility to 
penicillin (MlC ~ 0.12 ~g/ml) 
In cases of dramatic increases In resistance rates during a short period of time, detailed 
molecular analysis of the pneumococcal isolates often uncovers that a significant proportion of 
the resistant population are c10nally related. In each of the cases previously described (Iceland, 
France and Hong Kong) resistant pneumococcal clonal lineages were found to be largely 
responsible for the increase in prevalence. In France, 65% of resistant isolates were found to 
belong to serotype 23F, and the 23F isolates were genetically related as assessed by macro-
restriction profile (MRP) analysis (Ferroni et aI., 1996). The predominant resistant serotypes in 
Hong Kong were 23F and 19F. Molecular analysis by MRP of 105 resistant isolates detected a 
major clonal group which comprised 74% of the isolates, and which were indistinguishable 
from the globally widespread Spanish23F-l clone. However, in Hong Kong this lineage was 
found to express capsular types 23F, 19F and 14 (Ip et aI., 1999). 
Based on overseas observations such as those described, it was likely that the recent rapid 
increase of pneumococcal resistance in Christchurch is due to the dissemination of a resistant 
clone. To test this hypothesis, resistant pneumococci were collected over a five-year period and 
MRPs of genomic DNA were determined. Profiles were compared visually to cluster closely 
related isolates. 
3.2 Results 
Between 1997 and 2001, 200 pneumococcal isolates with reduced susceptibility to penicillin 
were isolated and included in this study. The majority of these isolates were obtained during 
two sampling periods; August 1997 through to May 1999 (163 isolates), and March 2001 
through to July 2001 (34 isolates). Three random isolates from October 2000 were also 
included. The patients from whom the isolates were recovered ranged in age from one week to 
91 years. Ninety-one isolates (45.5%) were recovered from patients two years or younger, and 
34 (17.0%) recovered from patients 60 years or greater. Isolates were recovered from 104 
(52.5%) females, 94 (47.5%) males, with the sex of two patients unknown. The main body sites 
of isolation are shown in table 3.l. The most prominent sites of isolation were ears, eyes and 
sputa combined accounting for 78.6% of the isolates. As the pneumococcus is commonly 
associated with infections at such sites, it is not unreasonable to assume that the recovered 
isolatcs were significant, and the agent responsible for the consultation. The same eannot 
necessarily be said for the other sites of isolation (e.g., nasal/throat), which may eorrespond to 
asymptomatie earriage of the organism. However, such isolates were included in this study and 
may eonsequently approximate the level of carriage of resistant pneumococci in the community. 
Ear 59 29.5 
56 28.0 
Sputum 42 21.0 
Nasal 19 9.5 
Adenoid tissue 10 5.0 
Throat 4 2.0 
Other 10 5.0 
Table 3.1 Body sites from which penicillin non-suseeptible pneumoeoeci were recovered. 
3.2.1 Antimicrobial susceptibilities 
The eriteria for inclusion in this study was a penicillin MIC of 0.12 Ilg/ml or greater. The 
highest penicillin MIC reeovered was 8.0 Ilg/ml, and the MICso and MIC90 were 2 and 4 ~Lg/m1, 
respectively. Including resistance to penieillin, a further 91 (183) were also resistant to co-
trimoxazole, 79.5% (159) resistant to erythromycin, 75.5% (151) resistant to tetracycline and 
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16.5% (33) resistant to chloramphenicol. No resistance to vancomycin was observed. Multi-
drug resistance, as defined as being resistant to three non-related antimicrobial agents (including 
13-lactams), was observed in 80.5% (161) of the isolates. The most frequently observed multi-
resistant phenotype imparted resistance to co-trimoxazole, erythromycin, tetracycline, as well as 
reduced penicillin susceptibility. This phenotype was noted in 121 (60.5%) of the isolates. 
3.2.2 Typing by DNA macro-restriction analysis 
The 200 pneumococcal isolates could be divided into 26 groups by DNA MRP analysis using 
the enzyme SmaI and pulsed field gel electrophoresis (PFGE). Each of these groups could be 
sub-div,ided into a total of 59 subgroups. The four largest groups (Groups I, 2, 3 and 11) 
accounted for 171 (85.5%) of the isolates (48.5%, 12.5%, 12% and 12.5% for each group 
respectively). Groups 1, 2 and 3 (Figure 3.2 and Table 3.2) are comprised of pneumococcal 
isolates with intennediate to high penicillin resistance (MIC 0.5-8.0 ~g/ml), whereas members 
of group 11 are strictly of intermediate penicillin resistance (MIC 0.12 ~g/ml) although multiply 
resistant to other classes of antibiotics (Table 3.4). 
Figure 3.2 Comparison of the three most predominant DNA MRPs (b>TOUPS 1, 2 and 3) 
belonging to Christchurch isolates of S. pneumoniae with reduced susceptibility to penicil:lin. 
Lanes I) Lambda ladder, 2) isolate SpOl3 (type IA), 3) isolate SpOl9 (type IA), 4) isolate Sp028 (type IC), 5) isolate 
Sp007 (type 2P), 6) isolate Sp020 (type 2A), 7) isolate Sp035 (type 2A), 8) isolate Sp041 (type 3A). 9) isolate Sp009 
(type 3E). 10) isolate Sp211 (type 3C), II) Lambda ladder. 
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The most prominent group containcd 9 7 isolatcs (4S .5°;;), and li ve di rrerent M l~ I's (hg ure 3.3). 
or these, 91 of the SlIIuI proJiks were indis tinguishahk (type 11\) and \VtTe thus considered 
elonul. To further assess the relatedness of this g roup, a subset or 42 isolates were digested with 
the restriction endonuclease 11poI and the resulling DNA rr<l gment s separated by PFG L ble h or 
the isola tes y ielded indi stingui shahle i'vlRPs (Figure 3.4) . l :aeh o f the group I isolates a nalysed 
had the same antimierohial res istance pattern all were res istant to eo-trimo xazole, 
ery thmmyein and tetracycline as well as having reduceu susceptihility to fl-Iactams. Mles to 
penicillin and ed()taximc ranged rrom I-~ p g/ llli a nd 0.5-16 ~lg/ml , respectivel y. 1\11 isolates o r 
thi s gTOUp INeTe susceptible to chloramphe nicol and vancomyc in . Fourteen or the iso lates 
belong ing to this g roup were serog rouped and de tenn ined to bel o ng to scrogroup 19, lour or the 
14 were typed further as 1,)1" . U nfortunately, sero type data 101' all iso lates was llnavailahle. This 
is hecallse only one laboratory in New Zealand (the Streptococcus rcicreneei<lborato ry, KSC, 
FSR) ha s thc Glpacity to scro type pneumococci . Serotyping is res tri c ted to aJl invas ive isolates 
and , I :mhset or penicillin-res istant iso lates. Nevertheless. us ing th e limitcd sero typing 
informatio n <Ivililablc in conjunction with the mo lecular typing data , it is possihle to tenta tiv e ly 
ass ign serot ypcs to major clona l g roups. 
Figure 3.3 <. 'ompari soll of the Sma I I )N A macru-res tri c tion suhtypes or the l1I<lj or group I 
profile pnxlominant amo ng C hri s tc hurch penicillin non-susceptible isolates or .'i'. pJlC'WI1Unill L' . 
t.anes I ) L nllbcl a ladder, 2) i ,o lal ~ . 'p003 (Type 1.\1. .') l,ol~le Sp2(j l) (Type 1 Il). 4) i ., ()I ~ I \c Sp02X (fype I C ), :,) 
i.'o late ::; p22 1 (fypc 1 D) . (,) j, oi;lte Sp4 72 (Type 1 F), 7) Lll11htl~ll;ldd er . 
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2 
1 
0.5 
1 
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I 
1-2 
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SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, CHLd 
SXT, ERY, CHL 
SXT, ERY, CHL 
SXT, ERY, CHL 
SXT, ERY, CHLd 
SXT, ERY, TET, CHL 
SXT, ERY, CHLd 
SXT, ERY, TET, CHL 
SXT, ERY, TET, CHL 
SXT, TET, CHL 
SXT, ERY, TET, CHL 
SXT, ERY, TET, CHL 
SXT, TET, CHL 
SXTe 
SXTe f 
SXT 
SXT 
SXTf 
Table 3.2 Distribution ofMRP subtypes, and their associated serotypes and antibiotic resistance 
profiles, among the three major groupings of penicillin-resistant pneumococci in Christchurch. 
(a) Number of isolates serotyped represented in parentheses, (b) 14 isolates confirmed as serogroup 19, 4 typed 
further as serotype 19F, (c) Only serogroup determined, (d) Some isolates also resistant to tetracycline, (type 2A - 2 
resistant, type 2E I resistant, type 2G 2 resistant), (e) not all isolates resistant to co-trimoxazole (type 3A 4 
resistant, type 38 3 resistant), (fJ one isolate resistant to erythromycin and tetracycline but sensitive to co-
trimoxazole. nd not determined, SXT co-trimoxazole, ERY erythromycin, TET tetracycline, CHL chloramphenicol. 
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Figure 3.4 / 117([1 genomic diges ts of isolates belonging to MRP 1 A 
Lanes I) Lambda ladder, .2) iso late Sp43'J, .\) isolak Sp440, 4) i,o lale Sp4-U, 5) i s ol ~lle Sp447, (,) i,ol ' lll' Sp45.l , 
7) i, olate .sp45o, K) isol 8le ~p45:-:. lJ) isolale Sp4S'), 10) iso!/<Jle Sp46 I, I I) i,o l'llc Sp4(,.2 , 12) iso la le Sr467. 
1.\ ) i,ol'lle Sp47.\ 14) iSll lale Sp474 , 15) i,ol~llc !)lJ-:'iYJ, I (,) L. ~ II11hda j~ldder. 
Figure 3.5 Compari 'on of'thc ,\'1//(/1 DNA macro-restriction subtypes ol'thc major MRI' group 2 
predominant amon~ Christchurch p~nicillin nOll-susceptible isolales of 5; /JIl t' litnoniac. 
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2 B). 5) iso jate SpOOK (Ty pe 2(').6) i,o l<ltc SpOl4 (Type 2['.),7 ) i.sol ate SpOO-l (Type 2/-). K) isolale Sp045 (Type 2(1). 
I)) i s() I ~ 11C , ·pO .\O (Tyl'c 21 1), 10) La mhd 'i ladder. 
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Macro-restriction group 2 (Figure 3.2) was the second largest group containing 25 (12.5%) of 
the isolates. The group was genetically heterogeneous, which is evident by the many subtypes 
observed associated with this group. These subtypes arose due to slight, but distinct, changes in 
mobility of individual bands around 200-250 kb (Figure 3.5), presumably the result of insertions 
or deletions. A total of 13 different subtypes were identified, each containing from one to nine 
isolates (Table 3.2). Isolates within group 2 had a range of penicillin MICs from 0.5-4.0 jlg/mL 
All isolates were multi-resistant, typically exhibiting resistance to co-trimoxazole, erythromycin 
and chloramphenicol, with some isolates also resistant to tetracycline (Table 3.2). Ten 
representative isolates from this group were serotyped, and expressed capsular type 23F. 
Macro-restriction group 3 (Figure 3.2) consisted of 24 isolates in five types. Each subtype 
contained between four and six isolates (Table 3.2). Penicillin MICs for this group ranged from 
0.5-4 ~tg/ml. This group was typically not multi-drug resistant, although several isolates were 
resistant to co-trimoxazole as well as penicillin. Only two members of this group were 
serotyped, and were found to be serotype 9 and 14 (Table 3.2). 
Macro-restriction group 11 contained 25 isolates distributed among ten subtypes. Each subtype 
contained between one and eight isolates. Quite a degree of heterogeneity was exhibited 
between MRPs. However, most of the diversity observed could be attributed to a single SmaI 
fragment, which varied in size between 100~150 kb (Figure 3.6). Group 11 isolates were all 
intermediately resistant to penicillin (MICs 0.12-0.25 jlg/ml), but all were multi-drug resistant. 
All group 11 isolates were resistant to co-trimoxazole and erythromycin. Most (96%) were also 
resistant to tetracycline. Only two group 11 isolates were serotyped, and both of these were 
found to be untypable (lUlencapsulated or an unrecognised serotype). The MRP 11 was 
associated predominantly with eye swabs Table 3.3. 
Type 1 (n=97) 18 22 38 12 10 
Type 2 (n=25) 16 36 24 8 16 
Type 3 (n=24) 12.5 12.5 335 12.5 29 
Type 11 (n=25) 92 4 0 0 4 
Table 3.3 Proportion (%) of MRP types and their association with main body sites. 
Macro-restriction profiles 4-10 and 12-25 represented unique profiles that differed significantly 
from each of the major groups, and from each other. Of these 21 groups, most (81 %) contained 
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SB 1 nd L 0 O.S nd SXT 
6 1 nd M E 1 nd 
7 1 nt B B 2 O.S SXT, TET, CHL 
8 1 6 B B 2 1 SXT, ERY, TET, CHL 
9 9A 3 19 (2) G G 1-2 1 ERY, TET 
9B 1 nd G G 2 1 SXT, ERY, TET 
10 lOA 2 19F B B 2-4 2-4 SXT, ERY, TET, CHL 
lOB 1 19F B B 2 2 SXT, ERY, TET, CHL 
lOC 1 19F B B 2 1 SXT, ERY, TET, CHL 
12 12A 1 nd H J 0.12 0.06 SXT 
12B 1 nd I L 0.12 0.06 SXT 
13 1 nd E B 0.12 0.5 ERY, TET 
14 1 nd E L 0.12 0.12 
15 1 nt A B 2 1 ERY 
16 1 nd E L 0.12 0.06 SXT 
17 1 nd I L 0.12 0.06 SXT 
18 1 nd A B 1 1 SXT, ERY, TET 
19 1 nd A A 2 O.S SXT, ERY, TET 
20 1 nd B B 1 nd SXT 
21 1 nd B D 0.12 0.12 ERY 
22 1 nd N B 1 O.S SXT, TET, CHL 
23 1 nd A L 1 nd SXT, TET 
24 1 nd I L 0.12 nd SXT 
25 1 nd C B 0.12 0.12 SXT, ERY, TET 
Table 3.5 Distribution of SmaI MRP subtypes, and their associated serotypes and antibiotic 
resistance profiles, among the minor groups of penicillin-resistant pneumococci in Christchurch. 
nd not determined, nt non-typable, SXT co-trimoxazole, ERY erythromycin, TET tetracycline, CHL 
chloramphenicol. 
3.2.3 Analysis of pbp genes 
Gene fragments encompassing the transpeptidase (penicillin binding region) coding region of 
pbp2b and 2x were amplified using the primers described in Table 2.4. Amplicons were 1.5 kb 
and 2.0 kb for the pbp2b and 2x genes respectively and subsequent digestions were performed 
with the enzymes DdeI (Pbp2b) and HinfI (Pbp2x) (Figure 3.7 and Figure 3.9 respectively). 
RFLP analysis was performed on both genes for all 200 isolates, and comparison of resulting 
profiles was performed visually. The association of pbp RFLP types with MRPs and their 
associated 0-lactam MICs is shown in Table 3.2 through to 3.4. Graphical interpretations of the 
RFLP profiles for both pbp2b and 2x are shown in Figure 3.8 and Figure 3.10 respectively. 
These figures document all diversity observed in the pbp RFLP patterns, including that 
observed in Chapter four. 
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3.3 Discussion 
The isolation frequency of penicillin non-susceptible pneumococci has increased significantly in 
many parts of the world during the 1990s. Examination of resistant isolates by conventional 
phenotypic techniques may reveal a common serotype or antibiotic resistance profile among the 
isolates, suggesting the clonal spread of an organism with these traits. The application of 
molecular techniques adds further resolution to such analysis and can effectively provide 
discrimination between clonally related isolates, and genetically unrelated isolates sharing a 
common phenotype. When applied to rapidly emerging resistant pneumococcal populations, 
clonal lineages are often found to eomprise a large proportion of the population. Macro-
restriction profiling by PFGE is a powerful tool in such analysis. 
In the current study, PFGE discriminated 59 distinct MRPs from a total sample of 200 
pneumococcal isolates. From this data it was shown that 86.5% of the isolates could be assigned 
to one of four macro-restriction groups, the largest of which contained 97 (48.5%) of the 
isolates. Two of the four major PFGE groups·(MRPs 2 and 3), eould tentatively be described as 
belonging to globaily widespread epidemic clones; the Spain23F_l clone and the France9V-3 
clone respectively. Isolates belonging to the PFGE group 2 were phenotypically (as assessed by 
serotyping and antibiotic susceptibility - Table 3.2) and genotypically (as assessed by PFGE -
Figure 3.5) similar to the Spain23F_l clone. This clonal group comprised 12.5% of the 
Christchurch sample of resistant isolates. It is not surprising to find this isolate in New Zealand 
given its broad international spread. 
Besides the two international clones, another two MRP groups contained significant proportions 
of resistant isolates. PFGE groups 1 and 11 each contained 97 (48.5%) and 25 (12.5%) isolates, 
respectively. Each of these two groups has similar antibiotic susceptibility profiles; they are 
both resistant to erythromycin, co-trimoxazole and tetracycline, but sensitive to 
chloramphenicol. The main distinguishing feature between the two clonal groups is their 
respective penicillin MICs. Isolates from PFGE group 1 typically have penicillin MICs ranging 
from 1-8 ~Lglml while group 11 tend to be of intermediate penicillin resistance (MIC 0.12 
~lg/ml). 
The PFGE group 1 comprised nearly half the penicillin-resistant isolates from Christchurch 
included in this study. At the time this work was performed, this represented a hitherto 
undescribed multi-resistant pneumococcal clone. This observation provided the stimulus for 
much of the work described in this study, as this clone was characterised in more detail. As will 
be shown in following chapters, the predominant New Zealand clone was shown quite 
convincingly to be a variant of a recently described clone from Taiwan (Shi et aI., 1998). 
The fourth major MRP group is interesting in that it is multi-drug resistant (erythromycin, co-
trimoxazole and tetracycline), yet it has only intermediate resistance to penicillin (MIC 0.12 
~lg/ml). Unfortunately this clone had few other distinguishing features the two isolates 
submitted for serotyping were non-typable. Due to the low level of penicillin resistance in this 
clone, it was not investigated any further, other than this initial observation. However, the 
relative abundance of this clone as well as its multi-drug resistant phenotype, make it a good 
candidate for future investigation. 
3.3.1 Intercontinental spread of resistant pneumococci 
3.3.1.1 Spread a/the Spain23F_1 clone 
As discussed in Chapter one, the best-described multi-resistant pneumococcal clone is the 
Spain23F_l clone. The intercontinental spre~d of this clone was fIrst demonstrated in 1991 
(Munoz et aI., 1991), and has subsequently been reported worldwide. The origin of penicillin 
resistance in Spain is attributed to the high use of antibiotics in this country; in 1983 Spain 
prescribed 1.5 times more penicillin than the France, 1.7 times that ofItaly, and 5.4 times more 
than the UK (Baquero et aI., 1991). Furthermore, a clear linear relationship was shown to exist 
in Spain between the amount of penicillin used in a year, and the prevalence of resistance 
(Baquero et al., 1991). 
Given the prolific nature of this pneumococcal clone, it is not possible to speculate on a 
potential source of introduction into New Zealand. It is quite feasible that this clone has been 
introduced multiple times, from many locations. 
3.3.1.2 Spread a/the France9V-3 clone 
The France9v-3 clone, like the Spanish 23F clone, has a global distribution and for this reason it 
is not possible to speculate an immediate source of this clone in New Zealand. Studies on 
members of this clone have demonstrated its capacity to disseminate globally, and establish 
itself in regions geographically widespread (assuming France to be the origin of this clone). For 
example, a study in Uruguay documented the spread of an increase penicillin and co-
trimoxazole resistance within its paediatric population (Camou et al., 1998). The use of PFGE 
identified a common MRP among 77% of the isolates, which was found to be indistinguishable 
from that of the France9v-3 clone. The predominant serotype associated with this clone in 
Uruguay was 14, suggesting that serotype switching had occurred in this clone, this was later 
confirmed by Coffey and colleagues (1999). The serotype 14 France9V-3 clone was first detected 
in 1992, and rapidly became the dominant resistant clone (Camou et a1., 1998). 
Like the Spain23F_l clone, an origin of importation cannot be determined for the France9V-3 
clone. Both clones are well-established throughout the globe and could have effectively been 
introduced from anywhere. This study shows they are also present and established in New 
Zealand and contribute significantly to the resistance burden. 
3.3.1.3 Origin of the major New Zealand clone 
In 1997, 228 pneumococcal isolates with high level penicillin resistance (MIC 2 2 ~lg/ml) were 
submitted to ESR, Kenepuru. Of these, 114 (50%) belonged to serogroup 19 (46 of which were 
further serotyped as 19F) (Brett, 1997). Significantly, 1997 marked a large increase in 
prevalence of pneumococcal resistance to cefotaxime (MIC 2 2 ~g/ml), which increased from 
5.4% in 1996 to 36.6% in 1997. Notably, the cefotaxime-resistant isolates included 30 with very 
high resistance (MIC 8-32 ~g/ml). These isolates were all serogroup 19 and referred mainly 
from Christchurch and Palmerston North (Brett, 1997). DNA MRP analysis ofthesc strains also 
suggested that these isolates were clonal (Brett, 1997, Brett, 2001). This was the first report of 
the epidemic multi-resistant 19F clone that is now prolific in New Zealand; in the following 
chapter it will be shown that this clone was prevalent in New Zealand as early as 1995. 
At the time, no descriptions of a multi-resistant 19F pneumococcal clone which matched the 
New Zealand clone existed in the literature. This suggested that the cefotaxime-resistant 
pneumococcal clone might have been an indigenous clone; however, the literature suggested 
that the rapid establishment and spread of a resistant clone is generally due to the importation of 
a pre-existing clone. This observation was a major impetus for this study. 
This study shows that the New Zealand 19F clone is genetically very homogenous as assessed 
by MRP analysis. This suggests that this novel clone may have only recently begun to 
disseminate. Other globally widespread pneumococcal clones have small, but significant 
changes in their MRP profiles from evolutionary divergence of individual lineages. It was 
realised that this homogeneity also provided a unique opportunity to study the cefotaxime-
resistance mechanism in these isolates. Although there was some variation observed in the 
cefotaxime MICs, the MRP profiles suggested the genetic backgrounds were comparable 
between isolates. 
Reference : Portions of this chapter have been published in Streptococci and Streptococcal 
Diseases Entering the new Millennium, Proceedings of the XN Lancefield Symposium on 
Streptococci and Streptococcal Disease, 2000. pp 229-234. Edited by Martin, D. R. and Tagg, J. 
R. Securacopy. New Zealand. 
hapter 
Global Epidemiology 
4.1 Introduction 
Microorganisms do not respect the artificial constraints of national borders. As illustrated in 
previous chapters, many clonal strains of S. pneumoniae have been shown to have successfully 
spread throughout the world (Munoz et al., 1991, McGee et al., 1997). In such instances, 
molecular mcthods such as macro-restriction profiling (MRP) have been used to show that 
isolates from one country were indistinguishable, or closely related to, those from another 
country. Analyses such as these are useful, particularly when a geographical or temporal 
epidemiological link: may provide insight as to the origin of a given bacterial isolate. However, 
these links are not necessarily immediately obvious. In the previous chapter, an undescribed, 
multi-resistant pneumococcal clone was shown to be the predominant clone among New 
Zealand isolates. Two options exist with regard to the origin of this clone; 
1) this clone arose in New Zealand, or 2) this clone evolved elsewhere in the world and was 
subsequently imported into New Zealand. Numerous reports have been published in the last 20 
years documenting movement of resistant pneumococcal clones between different countries, 
and it was, therefore, hypothesized that this would be the case in New Zealand. However, New 
Zealand's geographic isolation coupled with high levels of tourism and migration into the 
country, mean the potential source of the resistant pneumococcal clonc is ambiguous; the clone 
could literally have arisen anywhere in the world. In order to investigate the origin of this clone, 
a methodology for global epidemiology is necessary. 
To track the movement of microorganisms on a global scale requires a change in strategy from 
that oflocal epidemiology. The molecular methods described in previous chapters (e.g.,PFGE 
and PCR based idcntification) are based on genomic variations between isolates of a given 
species. These methods are designed to exploit variation between genomes in such a way that 
maximal discrimination between unrelated isolates will be observed. This is achieved by using 
multiple target sequences throughout the genome, whether they are restriction sites, or repetitive 
PCR primer binding sites. Any significant variation that occurs within the genome is likely to 
affect the relative distribution of such targets, witnessed by an effect on the profile obtained. By 
way of example, should a transposon containing one new restriction site integrate into the 
genome of a given isolate, it will result in a difference of up to three bands when compared by 
MRP to the original organism (Tenover et a1., 1995, ThaI et a1., 1997). In such an instance the 
two isolates would still have homogenous genetic backgrounds (with the exception of the 
transposon), yet their respective MRP patterns would be dissimilar (ThaI et a1., 1997). In such a 
way, relationships between isolates can become rapidly blurred. In short, such methods are 
designed to target DNA sequence variation that tends to accumulate relatively rapidly to 
maximise the possibility that any significant changes in genotype of isolates will be detected. 
The rapid acquisition and ease of detection of this variation provides these methods with a high 
level of discriminatory power. Consequently they are very useful for short-term epidemiological 
studies or outbreak investigation (Tenover et aI., 1995). 
However, for longer-term epidemiological investigations, methodologies which index rapidly 
acquired genetic variation can be less than satisfactory (Enright and Spratt, 1999b). For 
example, when comparing isolates from distant geographic locations, strains may have arisen 
from a common ancestor but rapid acquisition of genetic variation could well mask this 
relationship. To embark on long-term epidemiological studies, markers that provide a high 
degree of discrimination between isolates are still required, however the variation between these 
markers must accumulate at a rate slow enough not to provide a long-term elonal stability. This 
can be achieved by using selectively neutral targets, such as housekeeping genes. This works on 
the assumption that housekeeping genes are not under the influence of external selective 
pressures and consequently any variation observed between isolates is likely to be the cause of 
random rearrangements (whether these arise through point mutations, insertions, or 
recombination is academic). 
A method exploiting the slow accumulation of variation in housekeeping genes, is multilocus 
enzyme electrophoresis (MLEE). MLEE is a technique that compares the relative 
electrophoretic mobilites of housekeeping enzymes on starch gels (Selander et aI., 1986). 
Variation in the primary DNA sequence of genes may lead to the incorporation of different 
amino acids into enzymes. This in tum may alter the overall eharge on an enzyme, which can be 
observed as an altered mobility when the enzyme is subjected to electrophoresis. To overcome 
the limited variability that might be expected at anyone loci, MLEE utilizes multiple enzymes 
as targets to maximise variation. Up to twenty-five different loci may be examined for 
maximum resolving power (Selander et a1., 1986). Although MLEE has many attractive features 
as a system for strain differentiation, it suffers from being laborious, somewhat subjective and 
thc results generated arc difficult to compare betwcen laboratories (Enright and Spratt, 1999b). 
A technique that builds on the principles of MLEE - multilocus sequence typing (MLST) - has 
recently been described (Maiden et a1., 1998, Enright and Spratt, 1999b, Spratt, 1999). 
Multilocus sequence typing also documents slowly acquired variation in the housekeeping 
enzymes, but is based on the partial DNA sequence (-500 bp) of the genes encoding these 
enzymes rather than the electrophoretic mobilities of the enzymes themselves. As such each 
individual nucleotide may be interpreted as a unique character in a comparison between isolates. 
This gives the MLST system sevcral benefits ovcr MLEE; (1) fewcr loci need be examined as 
MLST documents all nucleotide changes, including silent mutations which may not alter the 
amino acid composition of any given enzymc; (2) sequence data is unambiguous, whereas 
banding patterns on electrophoretic gels are subject to user interpretation, and; (3) sequence data 
is electronically pOliable allowing rapid comparison and sharing bctwcen laboratories via the 
internet. 
MLST was initially validated on a set of 107 isolates of N. meningitidis isolated from invasive 
disease that had previously been studied by MLEE (Maiden et a1., 1998). Eleven housekeeping 
genes were selected initially and their partial nucleotide sequence (~450bp) were determined. 
The allelic profiles of the eleven loci resolved 74 sequence types among the 107 strains. The 
results obtained from MLST were highly congruent with those obtained by MLEE, with a few 
exceptions (Maiden et a1., 1998). As the congruence between sequence data and MLEE was 
better for some gene fragments than others, a subset of six loci was chosen that produced a 
dendrogram which correlated almost perfectly with that expected from the MLEE data (Maiden 
et a1., 1998). The first application of MLST to clinical isolates of N. meningitidis included the 
addition of a seventh locus (Feavers et a1., 1999) to provide greater resolution between lineages. 
MLST schemes have been subsequently extended to cover several other bacterial species 
including Streptococcus pneumoniae (Enright and Spratt, 1998), Campylobacter jejuni (Dingle 
et a1., 2001), Staphylococcus aureus (Enright et a1., 2000), and Streptococcus pyogenes (Enright 
et a1., 2001). At the time of this writing, MLST databases were also being compiled for 
Streptococcus agalactiae, Haemophilus injluenzae and Burkholderia pseuodomallei. 
ill practice, application of MLST to a pneumococcal population first requires isolation of 
chromosomal DNA from the isolate of interest; peR amplification of internal gene fragments of 
several housekeeping genes; and determination of the nucleotide sequence of the gene 
fragments on both strands, using the same primers as the initial PCR (Spratt, 1999). Once 
obtained the forward and reverse sequences are aligned for comparison, ambiguities resolved 
and trimmed to the length specified for the given gene fragment To determine if a gene 
sequence has been observed before, the MLST database may be queried via the illternet 
(http;//www.mlst.net). Every allele of each loci within the database has been assigned an 
arbitrary number. The sequence determination at all seven loci (aroEJ gdhJ gkiJ reePJ spiJ xpt 
and ddl; see Table 2.3 for complete descriptions) provides an allelic profile (e.g., the allelic 
profile of the major Spain23F -1 multi-resistant clone is 4, 4, 2, 4, 4, 1, 1). The allelic profile of an 
isolate defines the given isolate's sequence type (ST). Designation of a ST may be perfoffiled 
via an interrogative interface on the MLST website. 
Typically pneumococcal isolates are considered to be members of the same clonal complex if 
they have the same allelic profile or differ at one loci. Phylogenetic relationships between 
isolates that differ at more than three of the seven loci are likely to be unreliable (Enright and 
Spratt, 1999b). For the purpose of this work, 'pneumococcal isolates are organised into clusters 
according to major clones defined by the pneumococcal molecular epidemiology network 
(PMEN) when possible (see Table 1.4 for descriptions). 
4.2 Results 
A total of 76 isolates of S. pneumoniae were chosen for MLST (Appendix A.lii and A.Liii). Of 
these, 74 isolates were obtained from throughout New Zealand between 1992 and 2000, and two 
representative PMEN clones were included as internal controls. The control strains used were 
ATCC 700671, (Spain9v-3) and ATCC 700669 (Spain23F_l). Pneumococcal isolates were 
selected for characterisation by MLST to fulfil three criteria. Firstly, typical isolates of each of 
the major clones in New Zealand (as determined by PFGE and serotyping) were characterised; 
secondly, isolates were selected retrospectively to establish when major clones were first 
recovered in New Zealand; thirdly, isolates with novel phenotypes (e.g., antibiotic resistance 
uncharacteristic of a given clone) or genotypes (e.g., members of a clonal group with an 
uncharacteristic PFGE profile) were. 
Isolates were selected from hospitals and laboratories throughout New Zealand (Figure 4.1) 
with 47 (63.5%) included from the North Island and 27 (36.5%) from the South Island. The two 
major contributing centres were Auckland and Christchurch, with 25 (33.8%) and 22 (29.7%) 
isolates from each, respectively. 
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Of the 74 NZ strains 50 (67.6%) were strains from invasive disease. The remaining 24 (32.4%) 
strains were isolated from non-invasive sites and were included due to their decreased 
susceptibility to penicillin. There was an uneven distribution of the strains by serotype; 2 
serotype 6B (2.7%), 2 serotype 9N (2.7%), 9 serotype 9V (12.2%), II serotype 14 (14.9%), 4 
serotype 19A (5.4%), 33 serotype 19F (44.6%) and 13 serotype 23F (17.5%) were selected. The 
disproportionately high number of serotype 19F isolates was due to the high recovery of 19F 
isolates expressing decreased antibiotic susceptibility and their clonal spread as shown by MRP 
(Chapter 3). 
Auckland (25) ~~:.c, 
Christchurch (22) 
AlIII--::r'--lnvercargill (1) 
Figure 4.1 Geographic distribution throughout New Zealand of cIties from which 
pneumococcal isolates characterised by MLST were isolated. Number of isolates included from 
each centre shown in parenthesis. 
Fifty-two of the isolates were resistant to penicillin (MlC ~ 2.0 ~glml ), and seven were of 
intermediate resistance (MIC 0.12-1.0 ~glmI) . The remaining 15 isolates were susceptible to 
penicillin, and were included due to their involvement in invasive disease. Erythromycin- and 
chloramphenicol-resistance was encountered in 42 (56.8%) and 19 (25.7%) isolates 
respectively. Testing for susceptibility to co-trimoxazole and tetracycline was not routinely 
perfonned on invasive isolates from 1997, consequently susceptibility data is available for only 
63 and 56 isolates respectively. The observed rate of resistance among isolates included in this 
study was 60.3% for co-trimoxazole, and 53.6% for tetracycline. 
Of the 74 pneumococcal isolates analysed by MLST, 58 (78%) isolates matched previously 
described pneumococcal STs in the MLST database. The frequency of known STs identified 
amongst the New Zealand isolates is shown in Table 4.1. The remaining 14 isolates were 
comprised of allelic profiles for which no ST had been designated. This includes variants of 
existing STs and completely unique allelic profiles. 
~ 
" sm 11 Serotype PMEN Ren €Jef AIlelil,l profiles 
~"' designation aroB gdh gki l'ecB spi xpt ddl 
9' 1 14 EngiandJ4-9 S S 1 5 4 5 5 1 8 
36 2 23F SIR S/I 1 8 4 1 1 4 6 
66 2 9N S S 2 8 2 4 6 1 
81 * 13 14/19F/23F Spain23F~1 R I/R 4 4 2 4 4 1 
83* 1 23F Spain23F_l R I 4 4 2 4 6 1 
90' 2 6B Spain6B-2 R I 5 6 1 2 6 3 4 
124 2 14 S S 7 5 1 8 14 11 14 
129 14 S S 7 5 1 8 14 11 5 
146 19F S S 7 6 2 6 15 14 
156' 8 9V/14 France9V-3 R S/I 7 11 10 6 8 1 
162' 3 9V France9V-3 S S 7 11 10 6 8 14 
199 2 19A I S 8 13 14 4 17 4 14 
236' 5 19F Taiwan19F-14 R S/I 15 16 19 15 6 20 26 
237' 1 19F Taiwan 191'_14 I R 15 16 19 15 6 20 1 
271' 13 14/19F Taiwan19F -14 R IIR 4 16 19 15 6 20 26 
346 1 14 I S 10 41 47 16 6 14 2 
Table 4.1 Distribution of MLST sequence types for 58 New pre-
existing allelic profiles in the database. 
STs marked with asterisks are those representing PMEN clones or their derivatives. Pen, penicillin; Cef, cefotaxime; 
Susceptibilities inferred from MICs; S, susceptible « 0.1 [.tg/ml); I, intennediate resistance (0.1-1 [.tglml); R, resistant 
(2. 2.0 [.tglml) 
4.2.1. MLST data by PMEN clonal group 
To facilitate analysis of the data obtained from MLST, it is convenient to focus on the major 
international clones that have been identified in this study. ill particular, the clones, as defined 
by PMEN Crable 1.4), serve as useful standards against which to compare other isolates. The 
clones of particular interest are Spain23F_l, Spain6B-2, France9V-3 and Taiwan19F-l4. Isolates that 
do not belong to the PMEN clones will be considered based on their closest match in the MLST 
database (Section 4.2.2). Isolates that did not closely match (>3 alleles mismatched) any of the 
entries in the database will be considered separately in section 4.2.3. 
4.2.1.1 Spain23F_1 clonal group 
Fourteen Spain23F_l clones were identified (Table 4.2); all but one of these had the allelic profile 
4, 4, 2, 4, 4, 1, 1 (ST 81). Strain 97-350 had an altered spi allele giving it the profile 4, 4, 2, 4, 6, 
1, 1 (ST 83). Ten of the 14 isolates expressed the serotype 23F, an additional three were 
serotype 19F and one was serotype 14. The first member of the Spain23F_1 clonal group 
identified in this study was isolated in Auckland during early 1994. Serotype 2311' isolates 
recovered previous to this yielded unrelated allelic profiles suggesting that the Spain23F -1 clone 
may have arrived in New Zealand around 1993-94. 
~ Strain" ~lelic profile - sm MIrnb Se~~ Mmc RR" - ; - l1bil -
"'. --~ ~ C «ro :gila g1ii rec spi-: xpt 'ii/II , P (Sl ~b ~x 
l§;", ~' '" \ » >Yo: ;1''' z ~~ G 
SP264 4 4 2 4 4 1 81 2 23F 2 0.5 S,T,C B B 
94-008' 4 4 2 4 4 1 81 2 23F 2 T,C B B 
94-099' 4 4 2 4 4 1 81 2 23F 2 S,T,C B B 
94-212' 4 4 2 4 4 1 81 2 23F 2 1 E,S,C B B 
96-165' 4 4 2 4 4 81 2 19F 2 E,S, C B B 
97-036' 4 4 2 4 4 81 2 14 2 E,S, C B B 
97-350' 4 4 2 4 6 83 2 23F 2 E, S,C! B B 
97-550 4 4 2 4 4 1 81 2 23F 2 E,S,C B B 
98-122' 4 4 2 4 4 1 81 2 23F 2 C B B 
98-136' 4 4 2 4 4 1 81 2 23F 2 cg B B 
98-283' 4 4 2 4 4 81 2 19F 4 2 cg B B 
98-299' 4 4 2 4 4 1 1 81 2 23F 2 1 cg B B 
98-475' 4 4 2 4 4 1 81 2 23F 2 cg B B 
99-074' 4 4 2 4 4 1 81 2 23F 2 4 C g B B 
00-058 4 4 2 4 4 81 2 19F 4 8 S,T,C B B 
Table 4.2 Allelic profiles, serotype and antibiotic resistance profiles of 14 clinical isolates and 
control (SP264/ATCC700669) related to the Spain23F-l clone (ST 81). 
Bold indicates variant allele, (a) Isolates marked with asterisk from invasive disease, (b) MRP based on profiles 
desclibed in chapter 3, in not all instances could isolates be assigned to specific groups (c) Penicillin, and cefotaxime 
(respectively) MICs in ~lgJml, (d) Resistance profile, all isolates tested against erythromycin (E), co-trimoxazole (S), 
tetracycline (T) and chloramphenicol (C) unless stated othenvise, (e) RFLP pattem ofPCR amplified pbp gene, based 
on profiles described in chapter 3, (I) Resistance to tetracycline not detennined, (g) Resistance to co-h;moxazole and 
tetracycline not detennined. 
Within the Spain23F_1 clonal lineage, pbp2b and 2x RFLP profiles were conserved, as were the 
corresponding MICs to both penicillin and cefotaxime. A notable exception can be seen, 
however, in the members of the Spain23F -1 clonal group expressing the 19F capsular type. In 
two of the three 19F isolates, the MIC is at least one doubling dilution higher for both f3-lactams 
than those isolates expressing the 23F capsule. This suggests that determinants for f3-lactam 
resistance may have been transferred in addition to the genes for synthesis of the type 19F 
capsule. 
4.2.1.2 Spain6B-2 clonal group 
Two serotype 6B isolates were included (P93-241 and P96-466), isolated in 1993 and 1996 
respectively (Table 4.3). Both isolates were penicillin-resistant (MIC 2.0 ~Lglml) and of 
intermediate cefotaxime-resistance (MIC 1.0 ~Lg/ml). Although sharing similar susceptibilities to 
f3-lactams, they have quite different RFLP patterns for both pbp2b and 2x genes. The two 
isolates had similar, although not identical PFGE profiles (Figure 4.3). Both were ST 90, the ST 
associated with the globally widespread multi-resistant Spanish serotype 6B clone (Spain6B-2). 
These two members of the Spain6B-2 clonal group were also resistant to every other class of 
antibiotic tested, with the exception of vancomycin. This is entirely consistent with the PMEN 
description of this multi-resistant clone. Isolate 93-241 was the first reported penicillin-resistant 
pneumococcus recovered from invasive disease in New Zealand (1993). 
~iir~in/'~~~~ ~;~, ~ i\Uelicprofile"' " ,~£, sm ,Sei1,;:v~~"Ml(!il!:' Ruf%":: pJjPcd 
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93-241 * 
96-466* 
5 
5 
6 
6 
1 
1 
2 
2 
6 
6 
3 
3 
4 
4 
90 
90 
6B 
6B 
2 1 
2 
S, T, e B G 
B,S, T,e G B 
Table 4.3 Allelic profiles, serotype and antibiotic resistance profiles of two clinical isolates 
related to the Spain6B_2 clone. 
(a) Isolates marked with asterisk from invasive disease, (b) Penicillin, and cefotaxime (respectively) MICs in ~lg/ml, 
(c) Resistance profile, all isolates tested against erythromycin (E), co-ttimoxazole (8), tetracycline (T) and 
chloramphenicol (C) unless stated othelwise, (d) RFLP pattern of PCR amplified pbp gene, based on profiles 
described in chapter 3. 
4.2.1.3 France9V-3 clonal group 
Eleven pneumococcal isolates were found to belong to the France9V-3 clonal group (Table 4.4). 
Of these the most common allelic profile was 7, 11, 10, 1, 6, 8, 1 being observed in eight 
isolates. All isolates with this profile were isolated during 1995 or thereafter, and exhibited 
reduced susceptibility to p-Iactams. Three isolates were included that were susceptible to 
penicillin, and were all isolated during, or prior to, 1995. Each of these three sensitive strains 
had alternative ddl alleles, giving an overall allelic profile 7, 11, 10, 1, 6, 8, 14. The acquisition 
of fl-Iactam resistance is also coupled with a change in the pbp RFLP pattems. Furthermore it 
should be noted that the pbp RFLP profiles are conserved between members of the France9v-3 
clonal group and the Spain23F -1 clonal group. In both groups of isolates, these profiles appear to 
be associated with penicillin resistance, and intermediate cefotaxime-resistance. None of the 
New Zealand examples of the France9v-3 were found to be multi-drug resistant, although isolate 
93-347 did express resistance to co-trimoxazole as well as penicillin. This phenotype is 
consistent with the PMEN description of tllls clone. The relatedness of this group is further 
demonstrated by the sinlilarities between MRPs of members of this clonal group (Figure 4.2). 
Straing Allelic profile C sm MRPb Sem MICBc RPd pbpe 
----------------------------- -----------
UtlU' gil" gki rec spi XBI 1m p ~ ~ ~ 2b 2x 
'" ~"""'~ ~ w !" j 
TL7/1993 7 11 10 6 8 156 3B 9V 2 B B 
94-015' 7 11 10 6 8 14 162 3B 9V 0.03 0.016 D D 
94-115' 7 11 10 6 8 1~ 162 3B 9V 0.016 0.Q3 D D 
95-213' 7 11 10 6 8 14 162 3B 9V 0.016 0.016 D D 
95-347' 7 11 10 6 8 156 3 9V 2 1 S B B 
97-377' 7 11 10 6 8 156 3 9V 2 f B B 
97-552' 7 11 10 6 8 156 3B 9V 2 f B B 
98-206' 7 11 10 1 6 8 156 3B 9V 2 g B B 
98-263' 7 11 10 6 8 156 3 9V 2 0.5 g B B 
98-286* 7 11 10 6 8 156 3B 14 2 1 g B B 
98-356' 7 11 10 6 8 156 3 9V 2 g B B 
98-555' 7 11 10 6 8 156 3 14 2 g B B 
Table 4.4 serotype antibiotic resistance isolates 
and control (700671/ATCC70067) related to the France9v-3 clone. 
Bold indicates variant allele, (a) Isolates marked with asterisk from invasive disease, (b) MRP based on profiles 
described in chapter 3, in not all instances could isolates be assigned to specific groups, (c) Penicillin, and cefotaxime 
(respectively) MICs in Ilg/ml, (d) Resistance profile, all isolates tested against erythromycin (E), co-trimoxazole (8), 
tetracycline (T) and chloramphenicol (C) unless stated otherwise (dashes indicate sensitivity to all four agents), (e) 
RFLP pattern ofPCR amplified pbp gene, based on profiles described in chapter 3, if) Resistance to tetracycline not 
delennined, (g) Resistance to co-trimoxazole and teh'acycline not determined. 
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Figm'c 4.2 DNA macro-restriction prolilcs of' representative isolates cxpressing serotypes 9V 
and 9N (including control strain ATCC 70(671). 
Llne.s I) I.amhda kidder .. 2) ,; train AT 'C 7()06 7 1 (. T 15(), ,;erotype ')\1) . :\ ) P04·11 5 (ST l(l2, ,;crotype ')V ). 4) P1)5-
21 .1 (ST Ih2 , '; l'rotype !)\'), 5) 1'1)7-552 (ST 156. serotype ,>V), (l) P<)5-.14 7 (ST 156, serol ype I)V). 7) !,In-377 (ST 
15(), sLTot)PL' fJV) , X) 1'1)4-01 5 (ST Ih2 , S(;rotypc ')V), 9) PI)5 -21)X (S I" 66, ,erutype ') ~) . Ill) jll).1-1l 75 (ST hh, 
serot ype IJ N). 
4.2. !.4 L'ng:!ilIu{I_f) ciUlla! gJ'()IIP 
One out or the cl even serotype 14 isolates belonged to the PM EN clomil group 1 ': llgl andl~-9 
('['able 4.5), 'Ibis clonal grnup, as described by PMEN , is sensitive to penicillin, but exhibits 
resistance to erytnromycin. [solate 92-095 corresponds to these phenotypes. )ut the Live 
penicillin-susceptible serotype 14 isolates included in thi s study, 92-(9) was the lirst isolate (in 
19(2), and the only example or the England 1,1_9 clone . T hi s suggcsts th,lt although the 
r ': ngland l.I -9 clone is encountered frequcntly in Europe, it does not <Ippear to he ,t problem in 
New l.eal 'll1d. 
Strain" Allelic profile ST Sero j\UCb RY pbpd 
-------------------------------- ------------
a,.o gdh g/(; ,.ec spi xpt lldl P C 2b 2x 
92-09S' 5 4 5 9 14 not() OOI(i [ nd C 
Table 4.5 Allelic prolilc, serolype ami anlibiotic resistance profile of' clinical isolate 92-095 -
rclalcd to the England I4 -l) clone. 
(u) Isolales lll ~ rked with astcrisk I"mlll in,a,;j\e di,cilse, (h) I'cllic'illill , und cct( lt,IXil11e (respecti , cl y) MI( 's in)1" ml. 
(e ) Rl'S,isl,lnce prolik, iii I i,;ol,lte,; le, t,~d il,l!aill:;t <.: rylhrol11yeill (I ' ). co-tril11ox,lzok (S) , letracyc line (J') and 
chlor,ll11pilL'niCll\ « ') lInk"s st;lkd otiler\vi.,e, ( Ii) IU"L!' p,lttern Ill" Pl'R illnplili ed I,h/ , gen e. hased Illl prnlik,; 
descI'ibcd ill <.:il ilptcr .t 
Global Epidemiology 72 
1 2 3 4 ~. 6 7 8 
~ ..... =-:c. 
-
---~ ~ 
~ 
... 
- ... 
- -- -
- - -
-- ---.- -
,,'.-
.. 
-- • -.. -
--- -
- - -
.. 
- - - -
'" 
-
~iiI III ... --
-
... ~ :; - "4'~ - '"*i ... 
-
... 
Figure 4.3 DNA macro-restriction profiles of representative isolates expressing serotypes 68 
and 14 
Lanes I) Lambda ladder, 2) 1'93-241 (ST 90, snolype 613), 3) P96-466 (ST 90, serotype (3), 4) 1'95-194 (ST 11 24, 
slOrotype 14), 5) ]'94-055 (ST 124, ~erotyplO 14). 6) P94-001 (ST 129, serotype 14), 7) 1'92-0')5 (ST l) , serotype 14), X) 
1'94-271 (ST undesignated. serotype 14). 
Although a RFLP pattem for the jJhp2h gene of isolate 92-095 was not detennined, the php2x 
pattern observed is consistent with penicillin susceptibility. The serotype 14 isolates included in 
this study appear to have considerable genetic heterogeneity as assessed by DNA macro-
restriction profiles (Figure 4 .3) . To this end it is not surprising that ST 9 was observed only once 
among the New Zcaland serotype 14 isolates characterised by MLST. 
4 7 1 - 1" 19/' 14 I I ,_, .) W \1 '(/1/ - C 011(1 gr(}up 
Of the 74 isolates that wcrc characteriscd by MLST, 26 (35 %) bdonged to the Taiwan"!'-14 
donal group (T,tble 4.6). All 26 isolatcs were serotype 191" with thc exception of one (99-909) 
that was type 14. The majority of the New Zealand isolates belonging to this group were 
actually single locus variants of the Taiwan
"
JI- 14 clone, and rather are members of major 
Korean IlJF clone. Of the 26 isol,ltcs in this group 14 (54'Yo) had the allelic protile 4 , 16, 1'1 , 15, 
6, 20, 26 (ST 236) characteristic or the major Korean IlJl' clone, Five of the 26 (I ()%) had thc 
allelic profi Ie characteristic or the Taiwanl YI-14 clone; 15, 16, 19, 15 , 0 , 20, 26 (ST 271 ), 
For convenience and case of explanation, ,I ch'lllge in nomenclature is walT,1I1ted, In breaking 
from the guidelines established by PMEN (Mctiee et aI. , 200Ib), the major clone in New 
Zealand shall be referred to as the Korea l9F_14 clone, rather than the cumbersome "Korean 
variant of the Taiwan19F_14 clone". This new suggested nomenclature allows the population 
structure of resistant pneumococci in New Zealand to be described more readily. This is because 
the Korea19F_14 clone is not recognised as a PMEN clone, but rather a single locus variant of the 
Taiwan19F -14 clone. Most of the variants of this clone in New Zealand are single locus variants 
of the Korea l9F-14 clone, which in tum makes them double locus variants of the Taiwanl9F_14 
clone. It should be noted however, that apart from a single allele difference at the aroE loci, the 
Taiwanl9F-14 clone and Korea l9F-14 clone are indistinguishable. The Korea19F_14 clone has the 
most dominant ST identified in the current study; use of this ternl better facilitates its 
description when discussing data obtained from MLST. 
The New Zealand isolates contained five examples ofthe Taiwanl9F-14 clone (ST 236), as well 
as one single locus (ddl) variant (ST 237, isolate 98-537), two double locus (gki and ddl) 
variants (isolates 93-380 and 94-993) and one triple (gki, xpt and ddl) locus variant (isolate 93-
612). These three isolates were recovered dpring 1993-94 and their PFGE type has not been 
observed since. Thirteen examples of the Korea19F-14 clone (ST 271) were identified, as well as 
four unique single allele variants. Isolates 95-176, 98-370, 98-441 98-619 each differed from 
the Korea l9F-14 clone at the xpt (allele 20-+1), ddl (allele 26-+8), ddT (allele 26-+85) and spi 
(allele 6-+5), loci respectively (Table 4.6). 
It should be noted that the Taiwanl9F-14 clone has a characteristic PFGE profile (Figure 4.4), 
which is identical to that described in the previous chapter as belonging to the major resistant 
pneumococcal clone in New Zealand. The major Taiwan19F-14 strain and it variants appear to 
have become established in New Zealand in 1995 as no corresponding PFGE type has been 
noted before. The New Zealand Taiwanl9F-14 clonal group is resistant to erythromycin, co-
trimoxazole, and tetracycline (with the exception of strains 93-380, 93-612 and 94-993 which 
are susceptible to co-trimoxazole) and uniformly susceptible to chloramphenicol and 
vancomycin (with the exception of 99-104, 00-499 and 00-716 which appear to have recently 
acquired resistance to chloramphenicol). 
Levels of p-Iactam resistance are quite variable among this group. In the case of the five 
members of the Taiwan19F-14 clone, the penicillin and cefotaxime MICs are consistently 2 and 1 
J-lg/ml (one instance of a cefotaxime MIC of 0.5 ~lg/ml) respectively. However, in the 14 
Korea19F_14 variants MICs vary from 1 to 8 ~lg/ml and 0.5 to 32 J-lg/ml for penicillin and 
cefotaxime respectively. This variability in the p-lactam MICs is not mirrored in the respective 
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IJhr RJ'LP profiles. In all instances (with the exclusion of isolate 98-441) all the New Zealand 
members have identical pbp RFLP prolilcs. Isolate 9R-44 I however, has pbp RHY profiles 
identical to those associated with the Spain231 -1 and FranccYV -3 clonal groups. Interestingly, this 
iso late is also unusual in that it s celotaxime M IC is quite low (0.5 )lg/ml ) as compared to its 
high penicillin MI (4 pg/ml). As was seen with the France'l\-:~ clonal group, a ch'lIlge in the 
1)/)1' RH .J> patterns was also associated with the <lcquisition of a ncw ddl allclc (allele 26 - ) KS). 
Figure 4.4 DNA macro-restriction proliles of selected scrogroup I C) isolatcs analysed by 
MLST. 
Lanes I ) Lllnbda laddl'!", 2) Pl)S-O(,(, (S I unde_,i"n ~lled, serolype I')A), 3) N)4-')I) .3 (S I uIHJc,ign~]lell , ,ewlype I l)I-), 
4) P<)7-076 (ST LI(" sewlype I I)!,), S) PI>7 -21) I (ST 27 1, ,erolype I ()F), 6) NIK-.170 (ST 1IlHbig naled , serulype I ()[-), 
7) A<)X-61<) (ST ul1cil;siglla tl'd, serolype IIJ F), S) PC)7-(,26 (ST 27 1, sel'nlypc II)F), (.» N)6-7SS (ST 271 , serotype 
1<)['), 10) A'J7-()()6 (ST 236, serolype Il)[). II) N>7-724 (ST 271 . serulype I')F). 12) ,'\<)8-44 1 (S-I undesignaled. 
semlype 1<)1), 1.1) ;\l)l)-SJ9 (''I' 27 1, ,t:rolype Il)I), 14) .'-\<)<)-1014 (ST 27 1, serolype 19F), 15) <)1) _l)09 (ST 271. 
,el'lllypc 14) 
~ Strain,i ~ ~'~, 'Allelic profile ~ sm MRlif ~Sero !j\ti~!l RP'/ pop/!; 
--------------------------- -------~ , ettO gJlll ,gkl ree 5pi, :PI, «ill ~~ lP ~!0l 2b '2J: 
Taiwan19F_14 clone 
97-006 15 16 19 15 6 20 26 236 lA 
97-503 15 16 19 15 6 20 26 236 lA 
97-066 15 16 19 15 6 20 26 236 lA 
97-076* 15 16 19 15 6 20 26 236 lA 
98-120' 15 16 19 15 6 20 26 236 nd 
98-537 15 16 19 15 6 20 1 237 nd 
Taiwan19F-14 variants 
93-380 15 16 2 15 6 20 new NA nd 
94-993 15 16 2 15 6 20 new NA nd 
93-612 15 16 2 15 6 5 new NA 
Korea l9F-14 clone 
95-061 
95-235 
4 
4 
16 19 15 6 20 26 271 
16 19 15 6 20 26 271 
96-755 4 16 19 15 6 20 26 271 
97-359* 4 16 19 15 6 20 26 271 
97-635 4 16 19 15 6 20 26 271 
97-291* 4 16 19 15 6 20 26 271 
97-626* 4 16 19 15 6 20 26 271 
4 16 19 15 6 20 26 271 97-724 
99-539 
99-909 
4 16 19 15 6 20 26 271 
4 
99-1014 4 
00-499 
00-716 
4 
4 
16 19 15 6 20 26 271 
16 19 15 6 20 26 271 
16 19 15 6 20 26 271 
16 19 15 6 20 26 271 
Koreal9F_14 variants 
nd 
lA 
lA 
lA 
lA 
lA 
lA 
lA 
lA 
lA 
lA 
IE 
lA 
lA 
95-176 
98-370 
98-441 
98-619 
4 
4 
4 
4 
16 19 15 6 1 26 NA nd 
16 19 15 6 20 8 NA lA 
16 19 15 6 20 85 NA lA 
16 19 15 5 20 26 NA 1B 
Table 4.6 serotype and =U'V"J"'-' 
related to the Taiwan19F-14 clone. 
19F 2 E,S,1' 
19F 2 S, T 
19F 2 S, T 
19F 2 1 Ef 
19F 2 0.5 Eg 
19F 0.5 16 E, S, l' 
19F 2 
19F 2 
19F 4 
19F 2 
E,S,T 
E, T 
E,S, T 
S, T 
19F 2 1 E, S, T 
19F 2 E,S, T 
19F 4 E,S, T 
19F 4 2 S, T 
19F 4 2 E, Sf 
19F 4 8 E,Sf 
19F 8 32 E, S, T 
19F 4 8 
14 4 8 
S,T 
S, T 
A A 
A A 
A A 
A A 
A A 
A A 
G G 
G G 
nd G 
A A 
nd A 
A A 
A A 
A A 
A A 
A A 
A A 
A A 
A A 
19F 4 4 E, S, T, C A A 
19F 4 8 E, S, T, 
19F 8 16 S, C 
19F 4 2 E, S, T 
19F 4 E, S, T 
19F 4 0.5 S, T 
19F 4 E, S, T 
A A 
A A 
A A 
A A 
B B 
A A 
Bold indicates valiant alleles, (a) Isolates marked \-'lith asterisk from invasive disease, (b) MRP based on profiles 
described in chapter 3, (c) Penicillin, and cefotaxime (respectively) MICs in ~lg/ml, (d) Resistance profile, all isolates 
tested against erythromycin (E), co-trimoxazole (S), teh'acycline (T) and chlommphenicol (C) unless stated 
otherwise, (e) RFLP pattern of PCR amplified pbp gene fragment, based on profiles described in chapter 3, (f) 
Resistance to tetracycline not cietel1nined, (g) Resistance to co-trimoxazole and tetracycline not detennined. 
4.2.2 Non PMEN groups identified by MLST 
Fourteen isolates yielded allelic profiles that matched, or were single allele variants of those 
already in the ML8T database (Table 4.7). These 14 isolates could be described as members of 
(or variants of) one of seven previously defined groups, serotype 9N, 14 (2), 19A (2), 19F or 
23F respectively. 
'~tr3ill" i\llelic profile Sill Sero ,~ Miel,' '~RPc ,pbi 
,~ ------
~,}(" aro gill, glfi ref! spi xpt ldl p e 2b 2x 
93-075' 2 8 2 4 6 1 66 9N 0.016 0.016 D E 
95-298' 2 8 2 4 6 1 66 9N 0.03 0.016 G E 
94-055' 7 5 1 8 14 11 14 124 14 0.016 0.016 E E 
95-194 • 7 5 1 8 14 11 14 124 14 0.016 0.016 E E 
94-001 * 7 5 1 8 14 11 5 129 14 0.016 0.016 S E E 
93-116' 7 5 1 4 14 11 14 NN 14 0.016 0.016 E E E 
95-255' 10 41 47 16 6 14 2 346 14 0.5 0.12 J N 
92-247' 8 13 14 4 17 4 14 199 19A 0.25 0.06 S L 
93-345' 8 13 14 4 17 4 14 199 19A 0.12 0.06 S B L 
95-066' 8 13 14 4 6 4 14 NAg 19A 0.12 0.06 S I L 
93-216' 7 13 14 28 31 NA" 19A 0.016 0.016 E E 
94-054' 7 6 2 6 15 14 146 19F 0.016 0.016 E E 
93-316' 1 8 4 4 6 36 23F 0.016 0.016 D D 
97-083' 1 8 4 1 4 6 36 23F 2 1 Ce nd D 
Table 4.7 profiles, serotype antibiotic resistance of strains for which there 
was an exact or near match in the MLST database, but were not related to PMEN designated 
clones. 
Ordered by serotype. Bold indicates variant alleles, (a) Isolates marked with asterisk ii-om invasive disease, (b) 
Penicillin, and cefotaxime (respectively) MICs in ~lg/ml, (c) Resistanee profile, all isolates tested against 
erythromycin (E), eo-trimoxazole (8), tetracycline (T) and chloramphenicol (C) unless stated othelwise (dashes 
indicate sensitivity to all four agents), (d) RFLP pattern of PCR amplified pbp gene fragment, based on profiles 
described in chapter 3, (e) Resistance to ten'acycline not detennined (j) single locus variant (rec) of ST 124, (g) single 
locus variant (spi) of ST 199, (Ii) single locus variant (gdh) of ST 186. 
4.2.2.1 Serotype 9N: ST 66 
Two serotype 9N isolates gave identical allelic profiles that corresponded with sequence type 
66, which has been identified previously in Sweden and the UK from cases of pneumonia and 
bacteraemia. Both isolates were penicillin-sensitive, as were the other 81' 66 isolates described. 
Isolates reeovered in 1993 and 1995, have similar although not identical PFGE patterns. A 
change in the RFLP profile of the pbp2b also occurred within the 1995 isolate, which may 
account for the doubling in penicillin MIC. 
4.2.2.2 Two serotype 14 groups: ST 124 and 346 
Two groups of sequence types both expressing serotype 14 were identified. The first group 
contained four isolates from invasive disease. Two of the isolates belonged to sequence type 
124, and two were single allele variants; one had an altered ddt gene (ST 129) and the other an 
altered reeP gene (undesignated ST). Sequence type 124 (and its derivatives) is the major 
serotype 14 clone associated with invasive disease. Isolates belonging to this type have been 
recovered throughout Europe, including Sweden, Denmark, Norway, Finland and the UK. 
Members of this clone have also been isolated outside Europe, in Australia and Canada, 
suggesting that it is globally distributed. This group is susceptible to all antibiotics tested, 
including f3-lactams, and had conserved pbp RFLP profiles. All four strains had similar (not 
identical) PFGE patterns; 
The second serotype 14 group identified by MLST contained one isolate and belonged to 
sequence type 346. Only one example of a sequcnce type 346 is listed in the MLST database, 
this belongs to a serotype 15C isolate from Norway. Furthermore, the isolate had a penicillin 
MIC of 0.25 Ilg/ml (intermediate) and was susceptible to erythromycin. In contrast, the ST 346 
isolate (95-255) in the current study was serotype 14, suggesting transfer of capsular genes. 
Isolate 95-255 also had intermediate susceptibility to penicillin and was susceptible to 
erythromycin. The pbp RFLP and MRPs of this isolate were unique when compared to other 
New Zealand isolates. 
4.2.2.3 Two serotype 19A groups: ST 199 and 186 
Two groups both expressing serotype 19A were identified. The first group contained three 
isolates; two belonging to ST 199, and one single locus (spi) variant (undesignated sequence 
type). Sequence type 199 isolates have been recovered previously from invasive disease in the 
UK, although one ST 199 isolate expressing serotype 15B has been isolated from the 
Netherlands. All three New Zealand isolates belonging to this group have intermediate 
penicillin resistance and are susceptible to cefotaxime. These isolates were also resistant to co-
trimoxazole, but susceptible to other non-f3-lactam antibiotic groups tested. All three isolates 
had identical RFLP profiles for pbp2x, but some variability was observed in pbp2b, although 
this did not result in a change in MIC. 
Isolate 93-216 is a single locus variant (gdh) of ST 186. A single example of this sequence type 
exists in the MLST database, an invasive serotype 19A isolate from Australia. Both New 
Zealand and Australian isolates had identical antibiotic resistance profiles; fully susceptible to 
penicillin and erythromycin. Isolate 93-216 displayed pbp RFLP profiles common with other 
penicillin-susceptible sequence types such as ST 124. This sequence type, having to date only 
been reported in Australia, could represent an invasive strain endemic to this region of the 
Pacific. 
4.2.2.4 Serotype 19F: S1'146 
One example of a ST 146 was identified. This isolate (94-054) expressed serotype 19F, yet the 
other two ST 146 isolates described in the MLST database are serotype 6B. Sequence type 146 
has been identified previously in the UK and US. The UK isolate was susceptible to both 
penicillin and erythromycin, but the isolate from the US had intennediate resistance to 
penicillin. The New Zealand ST 146 isolate was sensitive to penicillin and all other antibiotics 
that it was tested against It also shares the PQP RFLP patterns of the other pencillin-susceptible 
isolates. 
4.2.2.5 Serotype 23F: S1' 36 
Two serotype 23F isolates representative of ST 36 were identified. ST 36 has been isolated 
previously in Canada and the UK. In each case these isolates were acquired from invasive 
disease. One of the New Zealand ST 36 isolates was susceptible to penicillin, as were all the ST 
36 isolates in the MLST database. However the other of the two ST 36 isolates was resistant to 
penicillin (MIC 2 ).lg/rnl) and had intermediate cefotaxime-resistance (MIC I ).lg/rnl). 
Furthennore, this isolate also expressed resistance to chloramphenicol. The two New Zealand 
isolates were recovered in 1993 and 1997 respectively, suggesting that these resistance 
mechanisms were acquired by a ST 36 isolate relatively recently. 
4.2.3 Pneumococcal isolates without significant MLST matches 
Six undesignated allelic profiles, which do not have a strong resemblance to any ST, are shown 
in Table 4.8. This group of six isolates was recovered between 1993-95 and are predominantly 
serotype 19F. 
Of particular interest are two isolates, 93-431 and 95-109, which have little resemblance to any 
entry in the MLST database, but appear to be members of the same clonal group. These two 
isolates are both serotype 19F, have similar MICs, identical resistance profiles, common MRPs 
andpbp RFLP patterns. This clonal group was isolated prior to 1995, but subsequent to that date 
it was observed less frequently and the Taiwan19F_14 clone became more prominent. Both these 
isolates are phenotypically identical to the Taiwanl9F-14 clone, but are quite distinct 
genotypically. 
None of the isolates shown in Table 4.8 currently has a matching ST in the MLST database. 
These sequences have bccn submitted for inclusion in the database, but due to the stringcnt 
standards maintained by the curator of the database, several loci have had to be re-sequenced. 
Owing to the high cost involved with automated DNA sequencing, this has not been performed 
to date. Furthermore, for the completion of this study it is not necessary for the isolates to be 
included in the MLST database. However for the benefit of pneumococcal researchers 
worldwide it would be beneficial to have MLST data from New Zealand included. It is 
anticipated that the necessary repeat sequencing will be performed, and the results made 
available to the research community through the MLST database. 
;Itrain'/ c ~~sru'~" Ser:~  RR~ /3' phjl' 
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94-271' 18 3 4 18 15 1 14 NA 1ge 0.016 0.016 nd E 
93-431 7 6 9 2 1 4 67 NA 19F 2 1 S, T F F 
95-109 7 6 9 2 1 4 67 NA 19F 4 1 E, S, T F F 
93-060' 7 5 19 16 14 14 28 NA 19F 1.0 0.12 nd M 
93-308' 10 13 34 16 15 1 4 NA 19F 0.016 0.016 TEE 
93-295* 2 2 9 2 6 4 14 NA 23F 0.12 0.12 K K 
Table 4.8 Allelie profiles, serotype and antibiotie resistance profiles of isolates for there 
was no near match in the MLST database. These isolates represent newly identified sequence 
types. 
Ordered by serotype, (a) Isolates marked with asterisk from invasive disease, (b) Penicillin, and cefotaxime 
(respectively) MICs in Ilg/ml, (c) Resistance profile, all isolates tested against erythromycin (E), co-tlimoxazole (S), 
tetracycline (T) and chloramphenicol (C) unless stated otherwise (dashes indicate sensitivity to all four agents), (d) 
RFLP pattern of PCR amplified pbp gene fragment, based on profiles described in chapter 3, (e) Not serotyped, only 
determined to group. 
4.3 Discussion 
In the short time since it has been described MLST has proved itself to be a useful tool in the 
global tracking and epidemiology of various baeterial pathogens. MLST was initially validated 
with the pneumococcus using 20 well-defined isolates including one Streptococcus mitis strain 
(Enright and Spratt, 1998). Four isolates of the Spain23F -1 clone, two of which were capsular 
variants (19A and 19F respectively), were shown to be identical by MLST, as were three 
reference isolates of the Spain6B-2 clone. The remaining twelve isolates have been previously 
characterised by MLEE and PFGE analysis (Hall et a1., 1996). The groupings obtained by 
MLST proved to be highly congruent with the results obtained by MLEE and PFGE, with the 
exception of two isolates. A serotype 9N and 9V isolate were not related by MLST (different at 
617 loci), yet they differed at only 211 0 loci by MLEE. The two isolates were not however, 
considered related by PFGE (Hall et aI., 1996). 
MLST is well-suited to tracking the occurrence of clonal strains worldwide. This is of particular 
importance in the identification of emerging antibiotic-resistant, or hyper-virulent clones. 
Application ofMLST to 274 pneumococci isolated globally from invasive disease with no pre-
selection for serotype or antibiotic resistance, identified 143 isolates, 34 of which were 
represented more than once (Enright and Spratt, 1998). Of these, twelve groups, which were 
represented with five or more isolates, were defmed as virulent clones. Of the twelve virulent 
clones, seven were found in at least two continents, and four clones were found on three 
continents (Enright and Spratt, 1998). 
Seventy-four multi-drug resistant pneumococcal isolates from Taiwan were analysed by MLST 
(Shi et al., 1998). Of the 74 isolates, 86% could be grouped into one of three penicillin-resistant 
clones. Of these three groups, 29 isolates belonged to the Taiwanl9F-14 clone, 21 isolates 
belonged to the Spain23F_1 clone, and 15 isolates belonged to the Taiwan23F-15 clone. Two of 
these clones were unique to Taiwan, but nevertheless, the Spain23F -1 clone was still fairly 
dominant. This demonstrates yet again the capacity of the Spain23F -1 clone to travel between 
countries, and the utility with which MLST was used to differentiate it from endogenous 
resistant clones. The utility of MLST to detect pneumococcal clones was further demonstrated 
by Zhou and colleagues (Zhou et a1., 2000). These investigators showed that predominant 
clones (Spain23F_l, Spain6B-2, France9V-3 and Spain14_5) eould be identified throughout the 
world. Although in some instances phenotypically different (e.g., the Spain23F_l clone may 
express serotype 19F or 19A; the France9V-3 clone may be penieillin-susceptible or resistant) 
the allelic profiles are well conserved among the clonal groups. 
The use ofMLST in conjunction with other molecular methods of bacterial strain identification 
allows the molecular epidemiological data presented in the previous chapter to interpreted with 
more clarity. The designation of pneumococcal isolates into groups based on their MRPs is 
useful for local molecular epidemiological analysis. Indeed it identified groups of isolates that 
appeared clonal in nature, and allowed temporal changes in the population structure to be 
monitored. Major clonal groups identified by MRP analysis could be tentatively identified as 
belonging to certain worldwide clones, but such designations are haphazard, being based largely 
on phenotypic characteristics. Using this data in conjunction with MLST allows information 
gcnerated through conventional molecular epidemiological methods to be interpreted globally. 
4.3.1 Origin of penicillin-resistant pneumococci in New Zealand 
Fifty-eight (78%) of the 74 New Zealand pneumococcal isolates in this study were able to be 
assigned to one of 15 STs. Fmihermore, ten of the remaining 16 isolates were either single (7), 
double (2) or triple (1) allele variants of previously described STs. The remaining six isolates 
differed from all isolates previously described by MLST in >3 alleles. Of the 68 isolates that did 
have close or exact matches in the MLST database, 48 (71 %) could be designated into one of 
three clonal groups. 
Not surprisingly, two of the major drug resistant pneumococcal clones identified in New 
Zealand were determined to be members of the Spait13F_l clone and the France9v-3 clone. 
Theses two clones accounted for 19% and 15% of the isolates characterised by MLST, 
respectively. Previous MLST studies have shown the widespread global distribution of these 
clones (Shi et aI., 1998, Zhou et a1., 2000). Due to worldwide prevalence of these clones, it is 
not possible to determine an origin from where these isolates may have been imported. 
The same cannot be said for the 23 isolates belonging to the Korea19F-14 clonal group. Having 
been described only recently, members of this group have only started to disseminate globally 
over the last few years. The first isolate of this clone identified in New Zealand was recovered 
in 1995, yet the members of the clone had been recovered in Asia as early as 1993. This 
suggests this clone may have originated in Asia, and subsequently been imported into New 
Zealand. 
Until relatively recently, the issue of antibiotic resistance has not received a great deal of 
attention in Asia. The formation of Asian Network for Surveillance of Resistant Pathogens 
(ANSORP) in 1996 has revealed that levels of antibiotic-resistance in Asian countries are 
among the highest in the world (Song et al. , 1999). Consequently, the emergence of highly 
rcsistant strains of S. pneumoniae in Asia is not unexpected, given recent reports of resistance in 
this part of the world. A multi-centre study conducted in 1996-1997 found the prevalence of 
penicillin resistance in the pneumococcus to be as high as 79.9% in Korea (Song et a1., 1999). 
Other countries with notably high resistance include Japan (65.3%), Vietnam (60.8%) and 
Thailand (57.9%). Taiwan was reported to have a prevalence rate of 38.7%. These resistance 
rates are extremely high and arc quite in excess of rates being reported in other parts of the 
world, including the well-identified centres of pneumococcal resistance such as Hungary, Spain 
and France (see Figure 1 J for comparison). The main serotypes of resistant pneumococci 
isolated throughout Asia are 23F and 19F (Song et al., 1999). 
The level of penicillin non-susceptible S. pneumoniae carriage seen in a Taiwanese paediatric 
population has been shown to be 71 % (Chiou et al., 1998). The same study reports 
comparatively high rates of resistance to other antibiotics as well, most notably the macrolide 
antibiotic clarithromycin, to which 95% of the isolatcs showed resistance. A similar report 
observed resistance rates of 82% and 90% to erythromycin and clarithromycin respectively 
(Hsueh et al., 1999). This high level of macrolide-resistance is attributed to the availability of 
this class of antibiotic that can readily be acquired without prescription (Chiou et al., 1998, 
Hsueh et al., 1999). 
The Taiwan19F -14 clone is the major multiply antibiotic-resistant strain of S. pneumoniae in 
New Zealand. The earliest confirmed identification of this clone in New Zealand is 1995, which 
coincides with a period of increased prevalence of penicillin-resistant S. pneumoniae. It seems 
likely, therefore, that the increase is due to the importation and subsequent dissemination of the 
Taiwan19F -14 clone. This follows what has been observed elsewhere the most notable example 
being Iceland (Soares et al., 1993). Iceland is similar to New Zealand in that both countries are 
geographically isolated and resistant strains had to literally be imported. Yet once established 
the resistant strains are quite effective at displacing the natural population and spreading 
clonally. 
When the serotype 6B multi-resistant clone spread from Spain into Iceland, several factors were 
suggested that might have facilitated its spread. The large proportion (57%) of the country's 
population living in the city of Reykjavik; the high proportion (77%) of children in Reykjavik 
attending day care centres; and the popularity of Spain as a holiday destination may have 
contributed to the importation and spread of the Spain6B_2 clone in Iceland (Soares et al., 1993). 
Some parallels can be drawn between the situations in Iceland and New Zealand. New Zealand 
has been actively promoting its tourist industry during the last decade, which has led to an 
increase in intemational visitors to New Zealand. Furthermore, New Zealand has one of the 
highest per capita intemational travel rates in the world, with Oceania and Asia representing the 
two most popular short-term travel destinations (Crump et a1., 2001). New Zealand also accepts 
more than 50 000 immigrants annually, predominantly from the same regions (Crump et a1., 
2001). Between 1991 and 1996 New Zealand's overseas-bom population increased by almost 
78,000 people, with 72% bom in Asia (Statistics New Zealand, 2000). hlterestingly, when the 
data from the 1991 and 1996 New Zealand census are compared, the two biggest increases were 
in people bom in Korea and Taiwan (Table 4.9). 
t' (2lountr~ of 1991 ~~nsus 1996 Census ~ °10 ~" 
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New Zealand 2812035 84.2 2848209 82.5 1.3 
Australia 48636 1.5 54575 1.6 12.2 
UK!Ireland 239157 7.2 230052 6.7 -3.8 
South Korea B01 <0.1 12 183 0.4 1 421.0 
Taiwan 3411 0.1 10932 0.3 220.5 
Malaysia 8820 0.3 11 889 0.3 34.8 
China 9225 0.3 19518 0.6 111.6 
Hong Kong 4929 0.1 11760 0.3 13B.6 
India 9456 0.3 12807 0.4 35.4 
Other Asia 25473 O.B 38706 1.1 51.9 
Total 3373923 100 3618306 100 7.2 
Table 4.9 Country of birth ofNZ population (adapted from (Statistics New 2000)). 
This increase in population of persons born overseas coincides with the time the Taiwan19F-14 
clone is thought to have arrived in New Zealand. Although the absolute numbers of people born 
either Korea or Taiwan is not as high as those of Australia and United Kingdom (two highest) 
the percentage increase in a short period of time is quite dramatic. This rapid increase could 
have allowed a theoretical threshold at which an exogenous microorganism could become 
integrated into the community, to be exceeded. 
The Taiwan19F-14 clone is apparently a fairly recent clone to emerge; the first formal 
identification made when multiply antibiotic-resistant S. pneumoniae from Taiwanese hospitals 
were examined by MLST (Shi et aL, 1998). This major 19F clone was present in Taiwan as 
early as 1993. In 1995, two serotype 19F isolates were recovered from blood cultures in a 
London hospital that had the same allelic profile. This is the same year that the Taiwanl9F_14 
clone was observed in New Zealand. Therefore it seems likely the Taiwan19F-14 strain did in 
fact originate in Taiwan, or elsewhere in Asia, and began to disseminate globally as early as 
1995. 
4.3.2 Penicillin resistance and sequence type 
In several strains analysed by MLST, most notably the serotype 9V strains, a change from 
penicillin-sensitivity to resistance was accompanied by a change in ST from 162 ( sensitive) to 
156 (rcsistant). This change in ST was associated with a single allele change of the ddl gene, 
encoding D-alanyl-D-alanine ligase. This is a cytoplasmic enzyme involved in the biosynthesis 
of a peptidoglycan precursor. The ddl gene itself is located 783 bp downstream of another gene 
whose product is involved in peptidoglycan biosynthesis, pbp2b. The possibility that the ddl 
gene "hitchhikes" with the pbp2b gene under f3-lactam selection was explored by Enright and 
Spratt, 1999 (Enright and Spratt, 1999a). They found 52 different ddl alleles in the entire 
pneumococcal MLST database of 566 submissions (as of 1999). Analysis of the sequence 
showed that these alleles could be divided into two groups. The first group was uniform and was 
found in both sensitive and resistant isolates .. The second group showed sequence diversity and 
were only present in penicillin-resistant isolates. Hitchhiking of the dd! gene was shown to 
occur in three New Zealand isolates (94-015, 94-115 and 95-213). This was further confmned 
by the pbp2b RFLP analysis of these strains - ST 162 has a RFLP pattern (type D) quite 
different :fl:om the ST 156 (type B). 
4.3.3 Serotype switching in the pneumococcus 
Changes in capsular types are a phenomenon MLST is well-suited to detecting. Switching of 
serotype in the pneumococcus is a well-documented occurrence. The Spain23F -1 clone has, for 
example, been found to express serotypes 3, 9N, 14 and 19F (Coffey et aI., 1991, Nesin et aI., 
1998). Serotype switching seems to be due to movement of "cassettes" containing capsular 
genes between organisms. The required genes to synthesize a given serotype may be uptaken 
(presumably via natural transformation) and recombine in the region of the original capsular 
genes. This may result in the loss of the original capsular genes as demonstrated on a group of 
isolates belonging to the Spain23F_l clone, but expressing serotypes 19, 14, or 3. These isolates 
were tested using DNA probes for each of the 18 open reading frames (ORFs) of the 23F 
capsular locus. ill no case were there any 23F-spccific genes retained, with the possible 
exception of genes already known to be common to the capsular loci involved (Ramirez and 
Tomasz, 1999). 
Five isolates among those analysed by MLST showed evidence of having switched their 
capsular type. One Spain23F -1 clone (ST 81) was found to express serotype 14 (isolate 97-036) 
and two were of serotype 19F (isolates 98-283 and 00-058). hl each case these three isolates 
resembled the Spain23F -1, but for the change in serotype. As stated previously, members of the 
Spain23F_1 clone have been found to express multiple capsular types, including 14 and 19F 
(Coffey et al., 1991, Nesin et aI., 1998), so this observation is not necessarily surprising. Two 
members (isolates 98-286 and 98-555) of the France9V-3 clone (ST 156) were found to belong to 
serotype 14. This transfer has also been doeumented previously (Coffey et al., 1999). One 
member (99-909) of the Koreal9F-14 (ST 271) was found to express serotype 14, rather than 
19F. This is of particular concern, as this serotype is one more frequently associated with 
invasive disease (Shapiro and Austrian, 1994). The predominant Koreal9F-14 clone in New 
Zealand is highly antibiotic-resistant, consequently increased invasive disease due to this clone 
could pose an important public health problem. A fmal example of serotype switching was 
noted in isolate 94-054, belonging to ST 146. This sequence type is associated with an invasivc, 
serotype 6B clone, recovered from patients in the UK and US. The implieations of this 
particular transfer are not immediately obvious. However, given the rapid spread of the 
Korea l9F-14 clonc in New Zealand, perhaps this eapsular type lends itself more readily to 
colonisation of new hosts. 
It should be noted that in each of the seven isolates in which serotype switching was observed, 
all other genotypic and phenotypic traits (e.g., antimicrobial resistance, PFGE profiles etc) were 
consistent with the parental strain. This is of particular concern if capsular types associated with 
invasive disease are transferred to highly antibiotic-resistant isolates. Such transfer has been 
observed betwcen New Zealand isolates, and could potentially mark the beginning of very 
difficult to treat, serious pneumococcal infections. 
Chapter 5 Pneumococcal B-Lactam Resistance 86 
Chapter 5 
Pneumococcal ~-Lactam Resistance 
5.1 Introduction 
A notable feature of the penicillin-resistant pneumococci isolated in New Zealand is their 
association with high-level resistance to cephalosporins. TypicaUy, a penicillin-resistant isolate 
will have a cefotaxirne MIC lower than its respective penicillin MIe. However, in New 
Zealand, a large proportion of the penicillin-resistant isolates that have been recovered have 
cefotaxirne MICs which exceed their penicillin MICs (Brett, 2001). Highly cefotaxirne-resistant 
(for the purposes of this study a cefotaxirne MlC ~ 4 ~g/ml will be referred to as highly 
resistant) isolates were first detected in New Zealand in 1997 (Brett, 1997). In the current study, 
30 of the 200 Christchurch isolates exhibited high-level resistance to cefotaxirne. When the 
MRPs of the 30 highly cefotaxirne-resistant isolates were examined, it was noted that resistance 
was associated with the MRP of the Korea 19F_14 clone (Figure 5.1). 
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Figure 5.1 Proportion of Christchurch isolates exhibiting high-level cefotaxime-resistance 
(MIC ~ 4.0 ~g/ml) associated with MRP group 1 and non group 1. 
The major 19F clone in New Zealand has been shown to be geneticaUy homogenous (Chapter 
3). Characterisation of isolates by MLST (Chapter 4) enabled variants from Korea and Taiwan 
to be distinguished from one another. The largest degree of variability observed in this group, 
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however, is in a specific phenotype; resistance to 13-lactams. A wide range of MICs of penicillin 
and cefotaxime were observed in New Zealand members of this clone. Penicillin MlCs ranged 
between 0.5 and 8.0 lJ.g/ml and cefotaxime-resistance was more variable still, with MICs 
between 0.5 and 16 lJ.g/ml observed. Furthermore, the distribution of MICs was unexpected. 
While the range of penicillin MICs formed a normal distribution with a median MIC of 2 lJ.g/ml, 
the range of cefotaxime MICs formed a bimodal distribution, with one resistance peak at 1-2 
J.lg/ml, and a second peak at 8 J.lg/ml (Figure 5.2). This chapter describes the analysis of the 13-
lactam resistance mechanism in the New Zealand variant of the Taiwan l9F-14 clone in more 
detail. 
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Figure 5.2 Frequency of the penicillin and cefotaxime MICs among the 97 Christchurch 
isolates of the New Zealand L 9F clone. 
5.1.1 Mechanism of 13-lactam resistance 
As discussed in Chapter 1, the development of (3-lactam resistance in the pneumococcus is 
attributed mainly to alteration of the target enzymes, the penicillin binding proteins (PBPs) 
(Coffey et aI., 1995b). Resistant PBPs have alterations that reduce their affmity toward 
penicillin, as shown initially by Tomasz and co-workers (Hakenbeck et aI., 1980, Zighelboim 
and Tomasz, 1980). These investigators incubated pneumococcal protein extracts with 
radioactively labelled penicillin, then performed SDS-PAGE and autoradiography. This 
demonstrated that the PBPs of resistant pneumococci bound less eH]-peniciliin than PBPs of 
susceptible pneumococci (Hakenbeck et aI., 1980). It was noted that there were at least five such 
proteins that bound penicillin in the sensitive pneumococcus, and in some cases a sixth 
(Hakenbeck et aI., 1980). Subsequently the PBPs were named PBPla, lb, 2a, 2b, 2x and 3, in 
order of descending molecular weight. By using a range of concentrations of radiolabelled 
penicillin, it was possible to determine which of the PBPs was most susceptible, and what 
concentration of the antibiotic was required to fully saturate any given PBP target (Hakenbeck 
et a1., 1980). It was also soon established that different PBPs had differing affinities for 
antibiotics (Williamson et a1., 1980). Furthermore, the low affinity PBPs could be introduced 
into susceptible pneumococci by successive transformation experiments with DNA of a resistant 
isolate (Zighelboim and Tomasz, 1980). 
The cloning of pbp genes allows the contribution of individual PBPs in penicillin resistance to 
be examined. A cloned pbp gene (or gene fragments amplified by peR) from a resistant isolate 
was introduced into a sensitive strain (typically strain R6) and the resistance phenotype (MIC) 
imparted by the introduced genes was measured. Using this methodology it was shown that 
certain pbp genes were more inlportant in imparting resistance than others. Alterations in the 
gene encoding PBP2B were shown to mediate low-level resistance to penicillin (Grebe and 
Hakenbeck, 1996, Krauss et a1., 1996), while changes to PBP2x mediated low-level resistance 
to cephalosporins (Munoz et aI., 1992, Grebe and Hakenbeck, 1996, Krauss et aI., 1996). High-
level resistance to either class of drug was imparted by subsequent alterations of PBPIA 
(Reichmann et aI., 1996). 
The application of DNA sequencing tcchnology showed that the alterations in the PBPs could 
be directly attributed to changes in the nucleotide sequence of the genes encoding them 
(Dowson et aI., 1989b). Examination of the nucleic acid sequence of pbp genes from resistant 
isolates revealed replacement of segments of these genes with corresponding regions from those 
of closely related bacteria (Dow son et aI., 1994). These resistant genes are referred to as 
"mosaic" genes, and their formation believed to be facilitated by thc natural competence of S. 
pneumoniae. The mosaic pbpJa, pbp2b and pbp2x genes of penicillin-resistant pneumococci 
contain regions from the corresponding genes of at least three different streptococcal species 
(Dowson et a1., 1989a, Laible et aI., 1991, Martin et aI., 1992b). 
5.1.2 Methods of investigating ~-lactam resistance 
The "classical" methods used to determine the mechanism of resistance, as described in the 
previous section, remain the most effective for investigation of p-Iactam resistance. 
5.1.2.1 Transformation 
S. pneumoniae is a naturally competent bacterium. Non-encapsulated strains will readily take up 
DNA from their environment, and depending on its similarity to host pneumococcal DNA, it 
may be recombined and expressed. Transformation of susceptible strains with mosaic pbp genes 
has previously been shown to provide a system by which the role that individual pbp genes play 
in p-Iactam resistance may be elucidated (Munoz et a1., 1992, Coffey et al., 1995a, Grebe and 
Hakenbeck, 1996). Recipient strains are unencapsulated to help facilitate the transformation 
process. Encapsulated strains have been transformed by addition of exogenous CSP (Yother et 
al., 1986). 
5.1.2.2 PBP fJ-lactam affinity 
Affinity of individual PBPs toward penicillin can be determined by preparation of crude 
pneumococcal cell wall extracts and incubation in the presence of labelled penicillin. Penicillin 
forms a stable covalent linkage to the active site serine residue, allowing PBPs to be separated 
and identified by conventional SDS-PAGE. Previous studies have employed 3H _, 14C_, or 125I_ 
labelled penicillin to detect PBPs. To avoid the need to use radioactivity, and the problems 
associated with working with radioactive materials, a recently described, commercially 
available fluorescent penicillin; Bocillin FL (Zhao et al., 1999) was used. Bocillin FL is a 
fluorescent derivative of penicillin V, which fluoresces at 511 nm upon excitation at 504 nm. 
The chemical structure of this compound is given in Figure 5.3. 
Figure 5.3 Chemical structure of BOCILLIN FL 
The utility of this compound to detect penicillin-binding proteins was assessed by incubating 
pneumococcal protein extracts with increasing concentrations of the labelled penicillin to 
determine the MIC of each individual PBP (estimated as the minimum concentration of drug 
needed to bind and label each PBP). Based on the effectiveness of the fluorescent penicillin, 
competition experiments were also to be performed. These involve first incubating protein 
extracts with defined concentrations ofp-Iactam drugs (e.g., cefotaxime) and then labelling with 
an excess of Bocillin FL. This enabled the primary targets of various ~-lactam drugs to be 
elucidated. 
5.1.2.3 Analysis ofpbp gene DNA sequence 
The formation of mosaic pbp genes necessarily involves alteration of their nucleotide 
sequences. This mosaicism can be exploited to document the differences in these genes. This 
can be done in one of two ways; directly, by determining the nucleotide sequence to the genes 
of interest; or, indirectly by exploiting the altered distribution of restriction endonuclease 
cleavage sites in these mosaic genes encoding PBP. The latter method (pbp RFLP) was used 
previously in chapter 2 and 3. The current chapter builds on the pbp RFLP data, and includes 
nucleotide sequence data to support observations. 
5.2 Results 
5.2.1 ~-lactam agar dilutions 
To further examine the variability of ~-lactarri resistance in the Taiwanl9F_14 clone, the MICs of 
seven ~-lactam antibiotics was determined for 43 clinical isolates. Isolates were taken from 
throughout the country, including several of those included in chapter 3. All isolates included 
belonged to MRP group 1. The seven different ~-lactams and their molecular structures are 
shown in Figure 5.4. 
First Generation Cephalosporins 
Q--CH2 CONH-:J=(S, 
o TCH20COCI-Il 
COOH 
Cephalothin 
Second Generation Cephalosporin 
O--CCONH----r-(~" {\ .)-N~ 
I 0 Ci-l:<0CONH2 
OCI-Il eOOH 
Cefuroxirne 
Penicillins 
o-CI-bCONH---r-r--«S Clio 
)-N_ CH" 
o 
COOH 
Benzy~penicillin 
o-1HCONH~Sl 
NH, O}-NyAcl 
COOH 
Cefaclor 
Third Generation Cephalosporin 
i-I:<NM 
8~CONHnS, 
~ 0'" N~Ci-I:<OCOCI-ll 
, OCH, COOH 
Cefotaxime 
Piperacillin 
Figure 5.4 Chemical structure of the seven ~-lactam antibiotics used m agar dilution 
determination ofMIC. 
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Raw data for the p-Iactam MIC determination are given in Appendix IV, a summary is shown in 
Table 5.1. All of the isolates tested were of either intermediate (7%) or fully (93%) penicillin 
resistance. The MIC range ofpiperacillin was to be narrower than that of penicillin, although for 
both compounds the MICso was 4 Ilg/m1. The MICs of the cephalosporin antibiotics ranged 
considerably between the 1st, 2nd and 3rd generation agents. All 43 isolates were resistant to 
cefac10r (MIC ;;::: 64 ~lg/ml). The MICs of cephalothin followed a normal distribution centered 
around a MIC50 of 16 Ilg/ml. Cefuroxime and cefotaxime both had bimodal distributions. In 
each case a peak of 16 isolates had MICs of 4-8 Ilg/ml and 1 Ilg/ml respectively for cefuroxime 
and cefotaxime. In each case a second peak was observed at 32 Ilg/ml and 8 ~Lg/ml respectively. 
All isolates had a reduced susceptible to meropenem compared to control strain ATCC 49619. 
Meropenem MlCs ranged between 0.5 and 1.0 Ilg/ml, which exceed than the suggested 
meropenem breakpoints (PilGS et aI., 1997, Fitoussi et aI., 1998). 
It is interesting to note differences between the MICs determined by agar dilution and Etest. 
Although results were comparable (both give MlCso of 4 ~lg/ml and 8 Ilg/ml for penicillin and 
cefotaxime, respectively), some variation was observed at the resistant end of the spectrum. 
Etests tend to approximate higher MlCs, the MlC90 for penicillin is 4 Ilg/ml and 8 Ilg/ml when 
measured by agar dilution and Etest respectively. A similar result is observed for cefotaxime, 
the MlC90s are 8 Ilg/ml and 16 ~lg/ml when measured by agar dilution and Etest respectively. 
The MlC data was used to select isolates for further analysis. 
g~vl J- ~ Tti"';,"'" t " }'sY N ,; ~, & y '" , " ,,;'" "" ;.,," '" \" 't \ 2 ,,,,,, " \;"''0 -
,~et1io!l' Antibiotic~c:';' ~ " ':: '" 1VIl~ (u~ffill 
~ - ~O.06 0.12 0.25, n,a, ~,~ i~~ ~ 2 'I 8 Iii ~l ~ ~64 
~ s'0:fS '" " ",,, '" '" 
Agar Penicillin ND ] * 2 13 27 ND ND ND 
Dilution Piperacillin ND * 4 29 10 ND 
Cefaclor ND ND * 43 
Cephalothin ND ND 
-- * 6 19 17 
Cefuroxime ND ND -- * 9 7 1 25 1 
Cefotaxime ND * 16 1 25 1 
Meropenem * 18 25 ND ND ND 
Etest** Penicillin 1 * 10 25 5 
Cefotaxime 
-- * 4 9 3 3 10 11 1 
Table 5.1 Distribution of MlCs of seven p-Iactam antibiotics of 43 S. pneumoniae isolates 
belonging to MRP group 1. 
ND not detennined, * ATCC 49619 MIC to respective agent **two strains did not have Etests performed 
,;"C-,-!h '-'.j'II",>(-".!CI,--,· )"-..- __________ -"'--"'I.....,lC"'·U ..... Ill"'U""CI""ll:""·C"'-'--" " i? -I.actarn Rcs i s ta ncc 02 
5.2.2 pbp RFLP analysis 
It wa !'> observeu in Chapter twu that the Ta iwan l Y1-14 clone was not always m;sociated with the 
same /!hp2x RFLP type. Although the profiles were typ ically Rfl ,P type A, occasional ly all 
isol<i te would pruduce type 13 profiles. To investigate this heterogeneit y further, 55 i.'mbtes of' 
thi s clolle lwu /!hp2x RrLP ,malysis perlt>rllled us ing an audiLiollal two enzymes. For each or 
the three enzymes (IJdd, [lin/l and Hwl) two ditTerent res triction protiles were gcner<lted 
(l :jgure 5.5). 
Figure 5.5 RepreSenl<ltive /!h/!2x RFLP prolllcs of MRP group I isolates generateu with three 
restricti on endunucleases. 
The distribution or uiJTerent RFLP pallcrns is presented in Table 5.2. The 1I10st commonly 
observed combination or profiles (A, A, A) occurred in 83.6% or the MRP group 1 iso lates. 
However, the MI(' range il.lr both penicillin allo eclotaxime was variable in isolates ex hihiting 
these profiles. For the rel11<1illing 16.4% o f the isolates, va rioLls combinations of profiles were 
observed Crable 5 .2). Although no obviolls eurrc1ation between RI-'LP proJilcs Clnd either 
penicillin of ccfotaxime MIC was noted, this dill serve to show the vari,lbility that exists within 
this gene. Thi s suggested thai by using a method tbat would provide greater resolution (e.g., 
dctenni'nation of DNA sequence), such a eorre\,ltion might be observed. To test this the genes 
/!h/ ) /a , 2h and 2x had their p<lrtial nucleotide sequence determined. 
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, 'liblt2x REItiD ~tofile .Frequency t%1 ' ' 'm(b (~~mI1 ' 
, 11ileI ,Pllin.1i!- llstil ' - ,Den (be{: 'J 
Y» '" -- "'''I ,{ -" " ,,~'" ~ ~ ~ ~ 
A A A 46 (83.6) 2-8 0.5 -16 
A A B 1 (1.8) 4 2 
A B A 1 (1.8) 2 2 
A B B 1 (1.8) 4 8 
B A A 1 (1.8) 4 2 
B B A 3 (5.6) 1 - 2 1 - 2 
B B B 2 (3.6) 4 0.5 1 
Table 5.2 Distribution of pbp2x RFLP 
endonucleases, and their associated p-lactam MICs. 
5.2.3 Nucleotide sequence ofpbp genes 
The nucleotide sequence of three pbp genes, la, 2b, and 2x, was determined in four, six and 
eleven isolates, respectively. All DNA sequencing was performed on New Zealand isolates of 
the Taiwan19F-14 clone, as shown in Table 5.3. See Table 2.4 for descriptions of the primers 
used for DNA sequencing. Isolates were chosen to give the greatest range of p-Iactam resistance 
as deseribed in section 5.2.1. 
~ ;q '" , "Si/«! 'I'AC'< »0"""01' ~ ~/"""g::~JJ'; \; ~~ \ ~ ~ 
Isolate _ c,:'ltIJRge~~s :~~:hf'''[Q1:~~9,li~~(I«- ~', ' (be!,oIafX;;~ie,,~(I '-: 
-,". -'. "' ' 'x" '_ sequencf,lj}- ~:, ~ s,'~ gIJPll:- -$ _<-~ ,': - (m,~mll 
98-537 2b,2x 0.5 16 
98-120 2x 2 0.5 
98-491 (Sp202) la, 2b, 2x 2 0.5 
98-441 (Sp194) 2b,2x 4 0.5 
97-816 (Sp038) 2x 4 1 
98-618 (Sp272) la, 2b, 2x 4 1 
95-176 (Sp042) 2x 4 2 
98-560 (Sp262) 2x 4 8 
99-539 la, 2b, 2x 4 8 
99-205 (Sp419) 2x 4 16 
99-206 (Sp421) la, 2b, 2x 8 16 
Table 5.3 Isolates of the Taiwanl9F-14 that had the nucleotide sequence of their pbp genes 
determined, and their respective penicillin and cefotaxime MICs. 
5.2.3.1 Partial pbpla gene sequence 
The nucleotide sequence of the pbp1a gene from five pneumococcal isolates was determined. 
One of the five isolates was sensitive to penicillin (96-079), and the remaining four were 
resistant. DNA sequenee was detenmned for an 1105 bp region of the four resistant isolates, and 
an 1012 bp region for isolate 96-079. These regions covered nucleotides 1880-2985 and 1959-
2971 of the transpeptidase respectively. The predicted amino acid sequences derived 
from these regions of DNA are shown in Figure 5.6. Within the 1.1 kb region of the four 
resistant isolates, 200 (18.1 %) nucleotide substitutions, resulting in 42 amino acid changes, 
were noted when compared to sensitive strain R6. Nucleotide substitutions were noted in all 
three of the conserved motifs (shaded), but only one resulted in an amino acid change; Thr-
371-+Ser By comparison, there were only eleven nucleotide substitutions noted in the pbpJa 
gene of isolate 96-079, resulting in seven amino acid changes. 
R6 
pbpla.* 
96-079 
R6 
pbpla.* 
96-079 
R6 
pbpla.* 
96-079 
R6 
pbpla.* 
96-079 
R6 
pbpla.* 
96-079 
R6 
pbpla.* 
96-079 
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96-079 
YNTDEYVAYPDDELQVASTIVDVSNGKVIAQLGARHQSSNVSFGINQAVE 
-*S*Q-*S**--O---*-*V*--**---*******-*A-----*T-*---***--
PIT DYAPALEYGVYESTATIVHDEPYNYPG'IN'IPVYNWDRGYFGN 
373 
433 
VETLNKVGLNRAKTFLNGLGIOYPSIHYSNAISSNTTESDKKYGASSEKMAAAYAAFANG 493 
**-**--**D****-*--**--*-*M**A*------*-*N---*----*---*--*-*--
GTYYKPMYIHKVVFSDGSEKEFSNVG'rRAtvJKETTAYMMTDMMKTVLSYGTGRNAYLAWLP 553 
*I*H-----N-I----**--**-O~****--***----*E---***T*-*-*G-***-** 
----------------------~-------*-------------A------P--------
SNy'roEETENHIKTSQFVAPDELFAGYTRKYSMAVWTGYSNRLTPLVGNGLTV 613 
---*-*---KY--NTGY-**--M-V*-*---*-----*-**-***I**D*FL* 
--N-G--T-------------------------------------------
AAKVYRSMMTYLSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWSSPAPQQPPSTESSSSS 673 
**--*-------------------------------------------------------
--------1---------------------------------------------------
SOS 676 
Figure 5.6 The predicted amino acid sequence pbpJa gene. pbpJa* represents amino acid 
sequence of all four resistant isolates. 
Shaded regions represent conserved motif.~, dashes (-) indicate the amino acid sequence is identical to R6, asterisks 
(*) indicate a silent substitution in the codon. R6 pbpJa sequence taken from (Martin et aI., 1992a), accession number 
M90527. 
5.2.3.2 Partial pbp2b gene sequence 
Initially a 1.3 kb region of the pbp2b transpepddase domain was sequenced from two isolates 
(98-537 and 99.539) using primersPn2Bup and Pn2Bdown (Table 2.4). 
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EMPG1S1STSWDRKVLETSLSS1VGSVSSEKAGLPAEEAEAYLKKGYSLNDRVGTSYLEK '16 
-----------------------*----------------------------** ****-* 
--------*---*-1---*----*--------------------------***-------
QYEETLQGKRSVKE1HLDKYGNMESVDT1EEGSKGNN1KLT1DLAFQDSVDALLKSYFNS 136 
-***----------------------------------------*-------*------* 
-***-*-*------------------------------------*-------*------* 
ELENGGAKYSEGVYAVALNPKTGAVLSMSG1KHDLKTGELTPDS 
--G-------*-*------*---*-----*L---*---D-------------*-* 
AT1SSGWENGVLSGNQTLTDQS1VFQGSAPINSWYTQAYGSFP1TA 
*--------***---*-*-*-P-
*--------***---*-*-*-P-*-----**Y---KL*****-*-**E**-
---***---*-*-*-P-*-----**Y---KL*****-*-**E** 
---***---*-*-*-P-*-----**Y---KL*****-*-**E** 
---***---*-*-*-P-*-----**Y---KL*****-*-**E* 
**---*-*-*-P-*-----**YP--KL*****-*-**E** 
-* 
-*-
-*-
-*-
-*-
196 
256 
TALGLMGQTYQPNMFVGTSNLESAMEKLRSTFGEYGLG'l'ATG1DLPDESTGFVPKEYSFA 316 
****1-**---*---**----**T--G-*-A-------*A-*-------------------
****1-**---* *---**T--G-*-A-------*A-*-------------------
****1-**---*---**---**T--G-*-A-------*A-*-------------------
****1-**---*---**---**T--G-*-A-------*A-*-------------------
****1-**---*---**---**T--G-*-A-------*A-*-------------------
****1-**---*---**---**T--G-*-A-------*A-*-------------------
NY1TNAFGQFDNYTPMQLAQYVAT1ANNGVRVAPR1VEG1YGNNDKGGLGDL1QQLQPTE 376 
---------------------------D--------------------------------
--**----------*------------D----------*--*----****E***A1DTK* 
--**----------*------------D----------*--*----****E***A1DTK* 
--**----------*-------------D--------------------------------
--* *------------0--------------------------------
--**-S--------*------------D--------------------------------
MNKVN1SDSDNSILHQGFYQVAHGTSGLTTGRAFSNGALVS1 
------------------------------------*-----
I*---**E*--A----*-***S-*--P***-**--D*-T**** 
1*---**E*--A----*-***s-*--P***-**--D*-T**** 
*----*-***s-*--P***-**--D*-T**** 
-----------*----*-***S-*--P***-**--O*-T**** 
-----------*----*-***S-*--P***-**--D*-T**** 
NTNAVAYAPSDNPQ1AVAVVFPH 459 
----------------*------
---*---*-TE-*-***-*----
---*---*-TE-*-***-* 
---*---*-TE-*-***-*----
---*---*-TE-*-***-*----
SYVAOGQQAT 436 
--k*G-*E*N 
--**G-*E*N 
--**G-*E*N 
--**G-*E*N 
--**G-*E*N 
98-441 ---*---*-TE-*-***-*----
'Figure 5.7 The predicted amino acid sequence pbp2b gene. 
Shaded regions represent conserved motifs, dashes (-) indicate the amino acid sequence is identical to R6, asterisks 
(*) indicate a silent substitution in the codon. R6 pbp2b sequence taken from (Dowson et a!., 1989b), accession 
number X13136. 
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The majority of the significant nucleotide substitutions occurred in a region between nucleotides 
654 and 1341. This region began 66 nucleotides downstream of the sequence encoding the SER-
V AL-V AL-L YS conserved motif. The area around this motif seems well conserved in several 
isolates examined (Smith and Klugman, 1995) and may not in itself playa large role in reducing 
the penicillin affmity of PBP2b. Subsequent DNA sequence was obtained from another four 
isolates targetting the region of maximum variability, nucleotides 609 - 1377, using primer 
pbp2b-seq and Pn2Bdown (primer sequences given in Table 2.4 and Table 2.5). Figure 5.7 
shows the predicted amino acid, including codons with synonymous nucleotide substitutions. 
The pbp2b genes of the six isolates contained between 58 (7.5%) and 134 (17.3%) nucleotide 
substitutions within the 773 bp region when compared to the pbp2b sequence of sensitive strain 
R6. The predicted amino acid sequence contained between 11 (4.3%) and 31 (12.1%) residues 
which differed from R6 (Figure 5.7). Within the 773 bp examined, three major regions of 
variability were evident (Figure 5.8). The first spanned nucleotides 616-858, and contained 54 
(22.3%) nucleotide substitutions common to all six isolates. Thirty-six of the 54 substitutions 
were silent; the remaining 18 resulted in ten changes within the amino acid sequence. The 
second major region of divergence spanned nucleotides 1177-1365 and was common to all but 
one (98-537) isolate. This 188 bp region contained 48 (25.5%) nucleotide substitutions, of these 
30 were silent, while the remaining 18 were responsible for ten changes in the predicted amino 
acid sequence. Isolate 98-537 did not contain this region of altered sequence and maintained 
98.9% sequence identity with R6 over this region. A third region of variability was noted in the 
two most resistant strains (99-539 and 99-206). This is a 100 bp region spanning nucleotides 
1064-1164. This region contained 31 (31 %) nucleotide substitutions, of these 13 were silent and 
16 were associated with nine amino acid substitutions. 
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Figure 5.8 Mosaicism observed in the pbp2b nucleotide sequence. Shaded regions represent 
sequence divergent from that of sensitive strain R6, 
a) strain 98-537, b) strains 98-491 , 98-618 and 98-441 , c) strains 99-539 and 99-206. 
5.2.3.3 Partial pbp2x gene sequence 
The nucleotide sequence of pbp2x was detennined for eleven isolates of S. pneumoniae using 
primers listed in Table A 1020 bp region was sequenced between nucleotides 1021 and 
2040 (numbering based on (Laible et al., 1989)). Predicted amino acid sequences, including 
codons with synonymous nucleotide substitutions, are shown in Figure 5.9. The eleven isolates 
could be placed into one of three groups based on their pbp2x sequence. Group 1 contained five 
isolates (95-176, 99-539, 99-206, 99-205, and 98-560), each had 183 (17.9%) nucleotide 
substitutions resulting in 40 amino acid changes when compared to sensitive strain R6. 
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Figure 5.9 The predicted amino acid sequence pbp2x gene. 
Shaded regions represent conserved motifs, dashes (-) indicate the amino acid sequence is identical to R6, asterisks 
(*) indicate a silent substitution in the codon. Group 1 consists of 6 isolates; 95-176, 99-539,99-206, 99-205 and 
98-560, Group 2 contains isolates 98-491, 98-120 and 97-816, Group 3 consists of isolates 98-618 and 98-441. R6 
pbp2x sequence taken ti'om (Laible et aI., 1989), accession number X 16367. 
Group 2 contained three isolates (98-491, 98-120 and 97-816) that differ in their sequence of 
pbp2x by 180 (17.6%) nucleotides when compared to strain R6. Of the 180 nucleotide 
substitutions 129 (72%) were silent. The remaining 51 were associated with 38 amino acid 
substitutions. Isolate 98-537 was most similar in sequence to group 2, but had a single 
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A( 1900)~G which resulted in an ammo acid change of threonine to alanine immediately 
following the KSG conserved motif. For this reason this isolate is considered separately, 
although it is otherwise indistinguishable from group 2. 
Group 3 contains two isolates (98-618 and 98-441). Both isolates differ from strain R6 at 181 
(17.7%) nucleotides, of which 128 (70.7%) were silent. Group 3 isolates had 40 amino acid 
substitutions when compared to R6. Substitutions unique to group 3 include Lys(259) ~ Gin, 
Glu(282) ~ Gin and Ser(504) ~ Pro. 
5.2.4 Protein labelling 
Labeling of PBPs using Bocillin FL was performed as previously described (Zhao et aI., 1999). 
Figure 5.10 shows Bocillin FL-Iabeled cell wall extracts from a penicillin-susceptible clinical 
strain. The sizes of the proteins binding the Boci'l'1in FL are in congruence with the size which 
have been cited for high weight PBPS (between 92-78 kDa). Furthermore the resulting banding 
pattern resembles closely profiles documented for other sensitive pneumococcal isolates 
(Hakenbeck et aI., 1980, Percheson and Bryan, 1980). 
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Figure 5.10 SDS-PAGE gel of Bocillin-FL labeled PBPs from isolate 96-079. 
7 
Lane I Mol.ecular size marker. lanes 2-6 decreasing Bocillin-FL concentTations 10 flM. 5 flM. I flM. 0.5 flM. 0.25 
lAM respectively, lane 7 control containing no Bocillin-FL. 
As was to be expected of PBPs from a sensitive isolate, they bind Bocillin FL at a low 
concentration. Furthermore, with decreasing concentration of Bocillin FL, less of the drug is 
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available to be bound by the proteins, and subsequently those with lower affinities are not 
labelled. In this instance the PBPs lA, IB and 3 appear to have the greatest affinity for Bocillin 
FL, while the affinities of PBP2A and 2B are less. 
5.3 Discussion 
5.3.1 Application of Bocillin FL 
Bocillin FL holds great potential as a reagent to study the activities of penicillin-binding 
proteins without the need to employ radioactivity. Initial trials with this agent on penicillin-
susceptible clinical isolates (such as 97-069 shown in Figure 5.1 0) showed great promise. The 
PBPs bound the reagent at the concentration suggested (Zhao et aI., 1999), and produced 
interpretable profiles of PBPs. Unfortunately, these results could not be reproduced with 
penicillin-resistant isolates. Even at excessive drug concentrations, which should theoretically 
saturate all PBPs, the proteins could not be detected. Subsequent work with Bocillin FL was 
halted. It is possible the bulky attachment of the fluorescent component of Bocillin FL interferes 
with its interaction with resistant PBPs. If -this is the case, radioactively labelled penicillin 
would be superior reagent for the analysis of resistant PBPs. 
5.3.2 Interpretation of the nucleotide sequence of pbp genes 
5.3.2.1 Interpretation ojpbpl a nucleotide sequence 
The pbp1a nucleotide sequences were essentially identical for all four isolates sequenced. This 
is a notable finding as PBPIA is one of the PBPs most implicated in resistance to 
cephalosporins (Munoz et aI., 1992), and isolates with maximum variation in cefotaxirne MIC 
were selected for DNA sequence analysis (range 0.5 - 16 flg/ml). 
Blocks of mosaic sequence were not observed in the partial nucleotide sequence of pbp1a, 
rather the first 970 bp of sequence contained multiple substitutions, resulting in 42 changes in 
the predicted amino acid sequence. The remaining 150 bps sequenced did not differ in sequence 
from the corresponding sequence of pneumococcal isolate R6. This structure is not dissimilar to 
that which has been described for mosaic pbpJa genes previously (Coffey et aI., 1995a). The 
amino acid sequence of pbpJa of the New Zealand 19F clone resembles that of two classes of 
PBP described previously (Asahi and Ubukata, 1998). Residues 320 - 505 match exactly with 
isolate 14/Z42 (group IV), and residues 506 - 675 match with isolate 2/H26 (group lll) in all 
but two residues (Ala550 and Ser657) (Asahi and Ubukata, 1998). The two isolates are quite 
different, suggesting that at least two insertions from different donors may have occurred in the 
New Zealand clone. Isolate 14/Z42 is a serotype 14 with penicillin and cefotaxime MICs of 
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0.125 and 0.25 ~lg!ml respectively; and isolate 21H26 is a serogroup 19 isolate with penicillin 
and cefotaxime MICs of 2 and 0.5 ~tg/ml respectively. 
All four isolates sequenced have the Thr-371-tSer substitution within the Ser-X-X-Lys 
conserved motif of PBP lAo This change is synonymous with the Thr-338-tAla change within 
the Ser-X-X-Lys motif of resistant PBP2x. It does not seem unreasonable that the structural 
implications of this substitution in PBP2x also hold true in PBPla (see section 5.3.2.3). This 
alteration was noted within two isolates previously described, and thought to contribute to 
penicillin resistance (Asahi and Ubukata, 1998), as well as in a highly resistant S. mitis isolate 
(Hakenbeck et al., 1998). 
5.3.2.2 Interpretation ofpbp2b nucleotide sequence 
Analysis of the partial pbp2b gene sequence revealed three regions of divergence from the 
sensitive strain R6 (Figure 5.8). The first rcgion of divergence resulted in 11 amino acid 
substitutions, and was associated with a minimum penicillin MIC of 0.5 ~Lg/m1. This region of 
~250bp falls in the centre of the transpeptidase encoding region of pbp2b and is flanked by two 
of the three conserved amino acid motifs common to all penicilloyl transferases (Ghuysen, 
1991); the Ser-X-X-Lys tetrad (residues 192-195) and the Ser-X-Asn triad (residues 249 - 251). 
The amino acid substitutions observed within this block also coincide with what has been 
previously described as a "class B" pbp2b gene (Dowson et aI., 1989a). The resistant class B 
pbp2b genes differed from their homolog in the sensitive strain R6 by 75 nucleotide 
substitutions. All but one of these substitutions occurs within the first 331 codons, resulting in 
14 amino acid changes. This is very similar to what was observed within the pbp2b gene of 
isolate 98-537. Dowson and colleagues described isolates recovered as early as 1984 (penicillin 
MICs 2 ~Lg!ml) that were found to contain the class B pbp2b gene. This suggests that the 
original transfonnation event that led to this particular mosaic pbp2b gene may have occurred 
up to two decades ago. 
The observations noted in class B resistant pbp2b genes, were identical to those described as 
'profile 4' by Smith and IGugman (1995). The four 'profile 4' isolates were serotype 6 (1) and 
19 (3), and had penicillin MICs of 4 (2) and 0.25 (2) ~g!ml. This profile was one of five 
described by Smith and Klugman, yet it was common to all six isolates examined in the current 
study. It is suggested that these changes resulted in, at least, an increase to an intermediate level 
of penicillin resistance (Smith and Klugman, 1995). The current study supports this observation, 
as one isolate (98-537) where only the first region diverged from R6 (Figure 5.8), had an 
intennediate penicillin resistance (0.5 )lg/ml). The other five isolates had additional regions of 
divergence (block 2 and 3) and correspondingly greater penicillin MICs. It has been suggested 
that this area of pbp2b forms part of the penicillin-binding site that interacts with the Rl side 
group of penicillin. In particular, the importance of the alanine for threonine-252 has been noted 
(Dowson et al., 1989b). This substitution occurs adjacent to the Ser-X-Asn motif. Based on 
comparison with class A p-Iactamases, it is proposed the threonine residue fonns a hydrogen 
bond with the carbonyl group of the Rl side chain of penicillin. The substitution of threonine 
with alanine, removes the hydroxyl group previously available to form the hydrogen bond. 
'" '" \~ "y " \ ~ ~ ;;, T 
~liirlmtt' ~mino acid substitutiqnl! ISolates' iR~n MII(fl (fleft m~ 
<" ,'" ~ _ ~ ~_ " Yi 
Group A S218P, N228Y, T232K, Q233L, Q244E, T252A, 
(12 subs.) L26II, S279T, E282G, S286A, T295A, N334D 
Group B A398S, G403P, N412D, L41 A425G, D431G, 
(10 subs.) Q434E,T436N,S446T,D447E 
Groupe D367E, Q371A, L372I, Q373D, P374T, T375K, 
(9 subs.) M377I, D384E, S388A 
Table 5.4 substitutions ... ""'vv,, ..... , ... with major 
group 1 isolates. 
98-537 0.5 
98-441 4 
98-491 2 
98-618 2 
99-206 4 
99-539 4 
16 
1 
8 
8 
MRP 
The Thr-252--)Ala substitution is one of only three from this block that are consistently 
associated with reduced penicillin-susceptibility. Glu-282--)Gly is also a common substitution, 
the significance of which has not yet been elucidated. A third substitution Asn334-~Asp, 
although lying outside the region of divergence, may be significant as it is found associated with 
many resistance pneumococcal isolates (Smith and Klugman, 1995). 
The second block of amino acid substitutions (Figure 5.8) occurred between residues 398 and 
447. This region also contains a conserved amino acid motif; the Lys-Thr-Gly triad (residues 
421-423). This block of altered amino acid sequence was found in five of the six isolates 
sequenced, and was associated with increased penicillin MICs (2-4 )lg/ml). The second block 
contained ten amino acid substitutions (Table 5.4). Nine of the ten substitutions had been 
observed previously by Smith & Klugman (1995) in a "profIle 4" isolate. Of the four "profile 4" 
isolates described by Smith & Klugman, three displayed high amino acid sequence identity to 
the originally described resistant "class B" pbp2b sequence (Dowson et aI., 1989a). 
5.3.2.3 Interpretation ofpbp2x nucleotide sequence 
The gene encoding PBP2x of S. pneumoniae R6 had its DNA sequence determined in 1989 
(Laible et al., 1989). Also sequenced was a laboratory mutant C506, in which three amino acid 
susbstitutions were observed; Met-289----?Thr, Gly-597----?Asp, and Gly-60l----?Val. These three 
alterations occurred at either end of the transpeptidase region of PBP2x, and their contributions 
to resistance could not be fully elucidated (Laible et al., 1989). The latter two substitutions lie 
outside the region sequenced in this study. Analysis of crystal structure data has revealed these 
residues compromise part of an a-helix and are quite distal to the active site (Gordon et aI., 
2000). Consequently they may not interact directly with p-lactam antibiotics. Sequence analysis 
of laboratory mutants created by PCR-derived mutagenesis identified the substitution of Thr-
550----?A1a that imparted a fourfold increase in resistance to cefotaxime (Grebe and Hakenbeck, 
1996). This alteration was observed in only one of the eleven isolates sequenced in this study; 
isolate 98-537. Interestingly isolate 98-537, while having a high resistance to cefotaxime, has an 
uncharacteristically low penicillin MIC of 0.5 ~tg/ml. The Thr-550----?A1a mutant described 
although having an increased cefotaxime MIC, also had a decreased oxacillin MIC (Grebe and 
Hakenbeck, 1996). This suggests a possible mechanism of increased cefotaxime-resistance at 
the expense of increased sensitivity to penicillin. This is demonstrated further by Sifaoui and 
colleagues (Sifaoui et ai., 1996), who showed that the single amino acid substitution Thr-
550----?Ala was responsible for an increase in cefpodoxime resistance while becoming more 
sensitive to amoxicillin. 
Thr-550 lies within a p-sheet (P3) within 6.5A of the active site serine residue (Gordon et aI., 
2000). Thr-550 binds the carboxylate group of the cephalosporin ring via the hydroxyl side 
chain Ox. The a-amide group also H-bonds with the cephalosporins. The mutation Thr-
550----?A1a reduces enzyme efficiency for 2nd and 3rd generation cephalosporins. Site directed 
mutagenesis of Thr-550----?Ala in strain R6 showed a 90% reduction of acetylation efficiency by 
cefotaxime, while penicillin G was unaffected (Mouz et al., 1999). This change was 
accompanied by a 46% decrease in hydrolytic activity of the mutant on substrate analogue of 
cell wall peptides (Mouz et ai., 1999). 
In the current study, the predicted amino acid sequence of PBP2X was organised into three 
main groups on the basis of sequence identity. Group I contained highly resistant isolates with 
penicillin and cefotaxime MICs in the range of 4-8 and 2-16 ~lg/ml, respectively. The predicted 
amino acid sequences of group I isolates have sequence similarities with previously described 
group V isolates of a study performed by Asahi and colleagues (Asahi et aI., 1999). This is 
particularly evident around the conserved amino acid motifs, including two substitutions within 
the STMK motif; a Thr-338~Ala, and a Met-339~Phe; and a Lys-546~Val substitution just 
prior to the KSG motif. The isolates with all three of these substitutions tended to have high 
eefotaxime MICs (2-8 /lg/ml), whieh is in agreement with the eurrent study. Isolates whieh 
lacked the Met-339~Phe substitution (Group N) tended to have lower cefotaxime MICs (0.5-1 
~lg/ml) (Asahi et aL, 1999), which again is in agreement with isolates of groups II and III of the 
current study. 
Recently the erystal structure of a resistant PBP2X enzyme was described (Dessen et aI., 2001). 
The enzyme was derived from a clinieal isolate, Sp328, which eontains 92 mutations when 
eompared to the sensitive forru derived from R6. It was shown that the Thr-338~Ala 
substitution within the STMK conserved motif weakens the loeal hydrogen bonding network 
within the active site. Other substitutions of interest include the Ser-389~Leu and Asn-
514~His, (both observed in all eleven isolates of the current study) which open the active site. 
This may not be involved in the resistance mechanism proper, but alters the catalytic funetion of 
the enzymes allowing abnormal branched peptides to be used as substrates. 
5.3.2.4 Overall interpretation ofpbp gene nucleotide sequences 
Much inforruation can be derived from examination of DNA sequence, and the predicted amino 
acid sequence derived from it. Such examinations are enhanced if other inforruation, such as 
crystallographic structure data is available. In the current study, it was shown that although a 
seemingly homogenous clone, the Taiwanl9F-14 clone has a lot of variability in its p-Iactam 
MICs, which at the molecular level is imparted by several different mosaie pbp genes. It seems 
also that the pbp genes of the Taiwan!9F-14 clone have been acquired by horizontal gene transfer 
from other resistant S. pneumoniae isolates. This is supported by the observation that all mosaic 
pbp genes described were very close, often identical, to those described in the literature. 
Chapter 6 
Macrolide Resistance Mechanisms 
6.1 Introduction 
The macrolide group of antibiotics are useful broad-spectrum agents that have proved effective 
in the treatment of upper and lower respiratory tract infections, being particularly effective 
against streptococcal and mycoplasmal infections. This class of antibiotic, typified by 
erythromycin, is especially useful in the trcatment of persons allergic to penicillin. Maerolides 
were originally isolated from Streptomyces species, and acquired their name from their chemical 
structure, a macrocyclie lactone ring to which various amino sugars are attached. The most 
clinically important macrolides are the 14-; 15- and 16-membered ring compounds, which 
consist of natural products and semisynthetic derivatives. Maerolides owe their activity to their 
capacity to inhibit protein synthesis. Macrolides reversibly bind the 50S ribosomal subunit, 
inhibiting the ribosomal transpeptidation/translocation process, causing premature detachment 
of incomplete peptide chains (Retsema and Fu, 2001). 
There are currently three recognised mechanisms of resistance to macrolide antibiotics; target 
modification, inactivation, and efflux (Pechere, 2001). A large number of resistance 
determinants that confer these macrolide resistance mechanisms have been identified (Roberts 
et al., 1999). The two most common mechanisms of macrolide resistance reported in S. 
pneumoniae are target modification and drug efflux, mediated by the erm and mef genes 
respectively (Peehere, 2001). 
The erm(B) gene (previously ermAM) product methylates a specific adenine residue (A2058) 
within the 23 S rRNA (Weisblum, 1995). This modification conveys cross-resistance to 
macrolides, lincosamides and §treptogramin B. compounds (MLSB phenotype) and is also 
associated with high-level resistance (:2:64 flg/ml). 
The mej(A) gene (previously mejE, but reclassified due to high sequence identity with S. 
pyogenes mefA (Roberts et al., 1999)) encodes an efflux pump, which is specific only for 14-
and 15- membered macrolides (M phenotype) Crait-Kamradt et aI., 1997). The macrolide efflux 
system was first reported in S. pneumoniae and S. pyogenes in 1996 (Sutcliffe et aI., 1996b). 
The prevalence of either mechanism tends to be specific to certain geographic locations. hI the 
United States, the M phenotype is more prevalent (Shortridge et aI., 1999), while in Europe the 
MLSB phenotype dominates (Schmitz et aI., 2001). Although pneumococcal resistance to 
erythromycin has been documented in New Zealand (Brett et aI., 1999), no studies on the 
mechanisms of resistance have been performed. The current chapter describes the prevalence of 
two macrolide resistance determinants (erm(A) and mefiB» in New Zealand, as assessed by 
PCR analysis. 
6.2 Results 
6.2.1 Erythromycin MIC determination 
Of the 200 clinical isolates collected from Christchurch during 1997-2001, 150 isolates 
exhibiting resistance to erythromycin were randomly selected. These isolates had been 
previously screened for erythromycin resistance using a disc diffusion assay. Erythromycin 
MICs were determined by agar dilution testing. Of the 150 erythromycin-resistant isolates, 141 
(94.0%) had high-level erythromycin resistance (MIC > 256 ~lglml). The remaining 9 (6.0%) 
isolates had MICs between 2-8 ~g1ml. Erythromycin resistance was typically associated with 
resistance to other antimicrobial agents; one hundred and forty-two (94.7%) isolates were also 
resistant to co-trimoxazole, 137 (91.3%) were resistant to tetracycline and 26 (17.3%) were 
resistant to chloramphenicol. 
6.2.2 PCR detections of macrolide resistance genes 
PCR detection of the macrolide resistance determinants was performed on a11150 isolates ( 
Figure 6.1). The mef(A) gene was detected in 105 (70.0%) isolates and the erm(B) gene in 142 
(94.7%) isolates (Table 6.1). Surprisingly, both the mef(A) and erm(B) genes were detected in 
97 (64.7%) isolates. In all but one instance, when both genes were detected in the same isolate, 
its corresponding erythromycin MIC was >256 ~g1ml. The high-level erythromycin resistance 
observed was presumably imparted by a functional erm(B) gene. 
The erm(B) PCR primers also generated a "ghost" band, approximately 550 bp in size ( 
Figure 6.1). This band was consistently associated with erm(B) positive PCR product, and 
absent when the PCR was negative. Given the consistent association with the presence of the 
erm(B) PCR product proper, it seems likely this secondary product may be due binding of one 
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l' _ ~"'- J ,,~ ~" " 0-
; Macro- Nurftbel1 "Positive for 'RQsitive for "Positive for 
~restriction group analysea ermm) gene milfl/A.) gene both ermm) 
, only (%) only (°10) ana nut1J.,A.) 
:" , " ~ '" _ , ~ " _ ~ene (0)h) 
1 95 0 2 (2) 93 (98) 
2 24 17 (71) 4 (17) 3 (12) 
9 4 4 (100) 0 0 
10 4 1 (25) 3 (75) 0 
11 18 18 (100) 0 0 
Table 6.2 m~f(A) genes macro restriction groups. 
6.2.3 DNA sequence analysis of macroliae resistance genes 
To verify the identity of the amplicons generated from the Koreal9F-14 clone the nucleotide 
sequence of PCR amplicons was determined. PCR amplicons from isolate 99-539 were used as 
templates for DNA sequencing. The resulting nucleotide sequences of the erm(B) and mej{A) 
genes had 98% and 100% sequence identity respectively, to the synonymous genes in the 
Genbank database. . 
6.2.4 Southern blot aetection of macroliae resistance genes 
To verify the presence of these genes in the genome, Southern hybridisation experiments were 
performed on SmaI-digested genomic DNA separated by PFGE (Figure 6.2). Probes were 
synthesized using PCR. The same primers used for identification of the erm and mef genes were 
used to generate the probes. In each case, probes for both genes hybridised with the same 120 
kb DNA fragment of the Taiwanl9F-14 genomic digest (isolate 99-539). Isolates in which only 
the erm gene had been detected by PCR hybridised only with the erm probe. The erm probe 
bound to the same 388 kb DNA fragment in the three isolates ofMRP 2. This is consistent with 
Spain23F -1 isolates from Italy (Marchese et al., 1998). Isolate SpO 17 with low level macrolide 
resistance (MIC 4 Ilg/ml) hybridised only with the mefprobe, consistent with the results ofPCR 
detection. The size of the restriction fragment to which respective probes hybridised is given in 
Table 6.3. Three isolates were included in the Southern hybridisation analysis serving as 
negative controls, isolates Sp046, Sp081 and strain RXI. 
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Spratt, 1998), and the current study has shown the Taiwan19F_14 to be the dominant resistant 
done in New Zealand. However, both the South African and New Zealand variants of this clone 
differ from the Taiwan19F_14 clone in that they have high level (MIC >256 )lg/ml) erythromycin 
resistance, while the Taiwan19F-14 clone is reported as containing only the mej(A) gene and 
having low level resistance (MIC 1.5-8.0 jlg/ml) (Shi et aI., 1998, McGee et aI., 200 1 b). Only 
two ofthe Taiwan19F_14 isolates in this study have this genotype (Table 6.2) 
Isolate Sp413 had a low-level of erythromycin resistance although both resistance genes were 
detected; it was also susceptible to clindamycin when tested by disc diffusion. Low-level 
erythromycin resistance, and susceptibility to clindamycin, are characteristics of the M 
phenotype (Sutcliffe et aL, 1996b, Tait-Kamradt et aI., 1997). Presumably, therefore, isolate 
Sp413 contained a defective erm(B) gene, which still permitted its detection by PCR, and a low 
level of resistance mediated by products of a functional mej(A) gene. 
The presence of both macrolide resistance genes mapping to the same ~5% of the pneumococcal 
genome raises the possibility the two genes may be linked. This could potentially be explained 
by an apparent pre-selection of pneumococcal transposons to interrupt other transposons and 
form composites. For example, conjugative transposon Tn525l (of the Tn9l6 family) was 
found integrated into Tn5252 to form the composite element Tn5253 (Provvedi et aI., 1996). 
Transposon Tn917 was found integrated in Tn38?2 (McDougal et aL, 1998). Furthermore, in 
the recently sequenced pneumococcal genome (Dopazo et aI., 2001), a locus was identified 
which appeared to have been the result of three separate transposition events. Both erm(B) and 
mej(A) have been identified on transposons in S. pneumoniae. The erm(B) gene is typically 
carried on a conjugative transposon Tn1545; a 25.3 kb element that imparts resistance 
kanamycin and related aminoglycosides, tetracycline, and the MLSB antibiotics (Courvalin and 
Carlier, 1986). The mej(A) gene has recently been identified on a transposon, Tn120?1 
(Santagati et aL, 2000); a 7244 bp mobile element. Therefore, a potential explanation for the 
relatively close proximity of erm(B) and mej(A) may be that they have formed a composite 
transposon. 
This study focused on the two most common erythromycin resistance determinants, as described 
in the literature. That does not preclude the existence of other resistance mechanisms in this 
population that may have been overlooked. Several other resistance determinants have recently 
been described in S. pneumoniae. An unusual derivative of the M phenotype, imparted by a 
mutation in the 23S rRNA, provides resistance to 16-membered macrolides (Depardieu and 
Courvalin, 200 I). The A2062C mutation was present in all four copies of the 23S rRNA of isolate 
BM4455, and was associated high MICs (512 flg/ml) for 16-membered macrolides, such as 
spiramycin, but was sensitive to 14-membered (e.g., erythromycin) and I5-membered (e.g., 
azithromycin) macrolides. This isolate was also scnsitive to lincosamidc and streptogramin 
antibiotics. Other mechanisms of resistance have been observed imparting ML and MSB 
phenotypes (Tait-Kamradt et aI., 2000a). The former phenotype is associated with an A2059G 
mutation in the 23S rRNA, and the latter with a three amino acid substitution (69GTG7I to TPS) 
in the ribosomal protein L4. Serial passage of S. pneumoniae in the presence of azithromycin 
has produced similar mutations in the 23S rRNA in vitro (Tait-Kamradt et aI., 2000b). An 
erm(A) methylase (previously erm(TR) of S. pyogenes) gene has been identified in S. 
pneumoniae (Syrogiannopoulos et aI., 2001). The erm(A) determinant imparts low-level 
resistance to 1 and 15-membered rnacrolidcs, is inducibly resistant to clindamycin, and 
susceptible to streptogramin B. 
The results from this study show that the most predominant erythromycin resistance genotype in 
New Zealand is erm(B) mef(A). This combination of genes imparts a phenotype essentially 
identical to that of erm(B) alone. The majority of erm(B) mef(A) strains in New Zealand appear 
to belong to a multi-resistant serotype 19F clone, which has much in common with a recently 
multi-resistant 19F clone recently described in South Africa (McGee et at, 2001a). Assuming 
these strains are identical, this would support the global spread of this clone. 
Reference : This chapter has been accepted for publication 111 Journal of Antimicrobial 
Chemotherapy, October 2002 (Vo150, No 4, pg 597-599). 
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7 
Discussion 
7.1 Summary of Results 
The current study was under taken with the premise of investigating the population structure of 
antibiotic-resistant S. pneumoniae in New Zealand. The prevalence of penicillin resistance in 
New Zealand has been increasing steadily every year over the past decade, in both invasive and 
non-invasive isolates. Despite this increase, investigation into the population structure of the 
organisms responsible for such a dramatic increase has been at best superficial. The lack of 
enquiry into the nature of the spread of resistant pneumococci limits any possibility of 
controlling the further spread, and understanding how it originated. To this end, a detailed 
molecular study of resistant isolates from a defined region (Christchurch) was performed. Two 
hundred isolates were recovered over a five-year period, from 1997-2001 and subjected to 
genotypic methods of strain identification. Christchurch served as a good population base for 
acquisition and testing of resistant pneumococci, having rates of resistance comparable, if not 
higher, than other centres in the country. 
Of the 200, 97 (48.5%) were found to have related SmaI DNA macro restriction profiles. This 
observation supported the first of our hypotheses, that a penicillin-resistant pneumococcal was 
responsible for the increased prevalence in resistance observed in Christchurch. Further 
investigation of this group of isolates revealed many insights. The clone appeared to be 
genetically homogenous as assessed by SmaI digestion and separation of genomic DNA by 
PFGE. To investigate the homogeneity of the strain further, a second enzyme was employed, 
ApaI. Genomic digests with ApaI proved to be just as stable as those performed with SmaI. 
Analysis of the genes encoding penicillin-binding proteins (pbp2b and pbp2x) in this clone also 
showed they were conserved among isolates, although a slight degree of variation was noted. 
Phenotypically, members of the predominant New Zealand clone were also homogenous. All 
isolates belonging to this clonal group for which serotype data was available indicated the clone 
expressed capsular type 19F. Furthermore all members of the clone also displayed identical 
antibiotic resistance phenotypes; resistance to co-trimoxazole, erythromycin and tetracycline, 
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and susceptibility to chloramphenicol and vancomycin. Interestingly, phenotypic variability was 
observed among the members of the predominant New Zealand 19F clone as variations in 
susceptibility to J3-1actam antibiotics. The range of MlC for penicillin and cefotaxime was 1-8 
~lg/ml and 0.5-16 ~lg/ml respectively. This observation prompted interest in this clone not only 
from a epidemiological view, but also with regard to the clones variable J3-lactam resistance. 
The major New Zealand clone looked unlike any other international clone described at the time. 
However, the rapid increased in prevalence of such a genetically homogenous clone suggested 
that it may have, in fact, been imported into New Zealand and successfully disseminated. To 
test the hypothesis that the prominent New Zealand resistant pneumococcal clone had been 
imported into the country from an exogenous source, we applied the recently described 
technique, multilocus sequence typing. Furthermore, to verify that the clone was not limited to 
Christchurch, MLST was applied to a group of isolates recovered throughout New Zealand. 
Analysis by MLST identified the major multi-drug resistant 19F clone to be indistinguishable 
from a 19F clone first identified in Taiwan. The PMEN designation for this clone is Taiwan19F_ 
14. Most of the New Zealand examples of the Taiwan19F -14 clone differed from the Taiwan19F_ 
14 proper, in that they had an altered aroE allele. This alteration gave a sequence type that 
belonged to the Korean variant of the Taiwanl9F-14 clone. 
7.2 Future researeh 
The current study has provided evidence that supports the hypothesis that penicillin-resistant 
pneumococci were imported into New Zealand. Furthermore, Asia was identified as a likely 
source of incoming resistant organisms. Many of the newly emerging resistant isolates have 
been identified as having novel resistance phenotypes and genotypes. Consequently the current 
thesis immediately suggests two main avenues for further research: 
a) The continued molecular surveillance of antibiotic-resistant bacteria in the 
AsialPacific region to identify and monitor emerging resistance trends. 
b) The further molecular characterisation of antibiotic resistance phenotypes. 
The fust of these two points has obvious public health benefits. Although the WHO currently 
monitors levels of antibiotic resistance in the Asia/Pacific region, it does not provide any 
information with regard to population structure. Concerted collaborations between laboratories 
from this part of the world could strengthen these reports. Of particular importance is molecular 
data for strain identification to monitor epidemic clones, and the significance they have on 
resistance rates. The second point, molecular characterisation of antibiotic resistance 
phenotypes, is important in the identification of new resistance determinants. Understanding of 
resistance mechanisms is important for the design of new antibiotics, and to make better use of 
existing agents. 
7.2.1 On-going molecular epidemiology 
This work highlights the need for greater surveillance of movement of pathogens and 
antimicrobial resistance in the Pacific region. Parts of Asia have reported extremely high rates 
of pneumococcal resistance. With New Zealand's status as a "nation of travellers" there is 
ample opportunity for persons entering the country to unwittingly bring in new pathogens, or 
antibiotic-resistant variants of existing pathogens. This study illustrates the use of molecular 
methods of strain identification to characterise a resistant population, and the use of that 
knowledge to trace the resistant organisms back to their probable origin. Further work in this 
field is certainly warranted to monitor movel1).ent of new and existing pathogens throughout the 
AsialPacific region. 
This study has highlighted the usefulness of the MLST technique for monitoring the global 
spread of microorganisms. Undoubtably, this technique is currently the most satisfactory for 
such analysis, and is likely to grow in popularity as an epidemiological tool. The major 
limitation of this methodology, however, is its expense. A recent report by Sa-Leao and 
colleagues estimated the cost of typing one isolate by MLST as US$120 as opposed to US$2.50 
by PFGE (Sa-Leao et al., 2001). The approach adopted in this study, typing isolate collections 
by PFGE or similar method, and selecting representative isolates for MLST analysis, seems an 
effective compromise. 
7.2.2 Antibiotic resistance mechanisms 
7.2.2.1 j3-1actam resistance mechanism 
The variable resistance to p-Iactams by the Korea19F_14 clone, and the reasonably homogenous 
genetic background (as assessed by PFGE) provided an opportunity to examine the relative 
contribution of individual pbp genes in resistance. Although, significant information was gained 
through examination of the nucleotide sequence of these genes, the data would have been more 
conclusive if interpreted with the penicillin binding affinities of individual PBPs. The data 
obtained from labelling with Bocillin-FL was limited, and of little use. Had time permitted, 
repeating the experiment with radioactively labelled penicillin would have been desirable. 
Transformation of sensitive strain Rx1, with individual pbp genes of a resistant pneumococcal 
isolate would also have been desirable, and is an experiment that remains to be performed. 
No attempt was made to identify non-pbp genes involved in 13-lactam resistance of the Korea19F_ 
14 clone. As recently several genes have been identified which may also contribute to 13-lactam 
resistance in the pneumococcus, this also warrants further exploration. In particular, the MurM 
enzyme involved in the biosynthesis of branched-stem cell wall muropeptides (Filipe et al., 
2000a) could potentially be important in resistance (Filipe et al., 2000b, Smith and Klugman, 
2001). Investigation of the murMN operon in the Korea19F_14 clone may provide an explanation 
for the bimodal distribution of cephalosporin resistance observed in New Zealand. 
7.2.2.2 Macrolide resistance mechanism 
The Korea l9F-14 clone in New Zealand was found to contain two macrolide resistance genes. 
This was a novel fInding, the only comparable report coming from South Africa (McGee et al., 
2001a). Southern hybridisation of probes .specific for the erythromycin resistance genes 
indicated they were located in the same ~5 % of the genome. Further investigation is required to 
ascertain what elements (e.g., transposons) these genes are associated with, and if the two genes 
are linked via a composite genetic element. Furthermore, investigation into the macrolide 
resistance phenotype could be further investigated; are the resistance genes induced or 
constitutively expressed? is the Korea 19F -14 strain resistant to streptogramin B compounds, as is 
expected of the MLSB phenotype? 
7.2.2.3 Resistance determinants of other antibiotics 
Study of macrolide resistance in the New Zealand major multi-resistant clone facilitated the 
finding that it harbours two different genes encoding macrolide resistance. This clone is also 
resistant to tetracycline and co-trimoxazole; however, the mechanisms of resistance have not 
been explored in tlns clone. Molecular studies of the mechanisms of resistance to these drugs, 
and others (e.g., chloramphenicol and fluoroquinolones), may reveal other novel genotypes. 
7.2.2.4 Mechanisms of emerging resistance phenotypes 
The rapid emergence of multi-drug resistant pneumococci during the 1980s is a stem reminder 
that one cannot be complacent about antibiotic resistance. Currently there are pneumococcal 
strains in the community resistant to all available antibiotics, save vancomycin; it would be 
naIve to presume that resistance could not develop to the glycopeptides and other modem 
antilnicrobial agents. The vanB gene, conferring resistance to vancomycin, has been identified 
in the genus Streptococcus, and was transferable, in vitro, to other species (Poyart et aL, 1997). 
Although resistance has not yet been described in the pneumococcus, vancomycin tolerance has 
been observed (Gilmore and Hoch, 1999, Novak et al., 1999). This suggests that the "last line of 
defence" may soon have lost much of its effectiveness. Consequently it is important that 
pneumococci are screened for resistance to glycopeptides, and other new antimicrobials 
(described in Chapter 1), and that potential resistance mechanisms are investigated. 
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Appendix I 
Bacterial Isolate Descriptions 
Table A.I. i Descriptions of Christchurch isolates of S. pneumoniae included in the 
current study. 
Pen, penieillin; Ctx, cefotaxime (both detennined by Etest); ERY, erythromycin, SXT, co-ttimoxazole, TET, 
tetraeycline, CHL, chloramphenicol 
SpOOl 25-Aug-97 1 F Ear B B 23F 2B 2 SXT, ERY, CHL 
SpOO2 26-Aug-97 83 M Nose A A 19F 1A 4 1 SXT, ERY, TET 
SpOO3 02-Sep-97 M Adenoid A A 19F 1A 2 8 SXT, ERY, TET 
Sp004 03-Sep-97 69 F Sputum B B 23F 2F 2 1 SXT,ERY, CHL 
Sp005 04-Sep-97 23 M Sputum G G 9A 1 ERY, TET 
Sp006 08-Sep-97 3 M Ear B B 3A 1 SXT 
Sp007 09-Sep-97 48 M Sputum B B 19F lOB 4 2 SXT,ERY, CH 
Sp008 11-Sep-97 1 F Ear B B 23F 2C 2 1 SXT,ERY,CHL 
Sp009 12-Sep-97 2mth M Eye B B 9 3E 2 1 SXT 
Sp010 15-Sep-97 4 F Nose B B 23F 2K 2 SXT,ERY, CHL 
SpOll 16-Sep-97 4 M Throat 0 I 4 1 1 ERY,TET 
Sp012 24-Sep-97 1 M Eye B B 19F lOB 2 1 SXT, ERY, TET, CHL 
Sp013 30-Sep-97 4 Adenoid A A 19 1A 4 8 SXT, ERY, TET 
Sp014 30-Sep-97 7 F Pus B B 23F 2E 4 2 SXT,ERY, CH 
Sp015 01-Oct-97 60 M Sputum B B 6 8 2 SXT, ERY, TET, CHL 
Sp016 01-Oct-97 11 mth M Ear A A 19 lA 2 SXT, ERY, TET 
Sp017 01-0ct-97 68 M Sputum B B 19 lOA 2 2 ERY, TEl', CHL 
Sp018 03-0ct-97 73 F Eye D I l1F 0.12 0.12 SXT,ERY 
Sp019 06-0ct-97 1 F A B 19 1A 4 4 SXT,ERY,TET 
Sp020 06-0ct-97 M Ear B A 23F 2A 2 1 SXT, ERY, CHL 
Sp021 13-0ct-97 1 M Ear A A 1A 4 8 SXT, TET 
Sp022 14-0ct-97 41 F R.Antmm A A 19 1A 4 2 SXT, ERY, TET 
Sp023 21-0ct-97 3 M Adenoid D I llA 0.12 0.12 ERY,TET 
Sp024 21-0ct-97 5 F D I lIB 0.12 0.12 SXT, TEl' 
Sp025 30-0ct-97 1 F Throat A A 19 1A 4 2 SXT, ERY, TET 
Sp026 30-0ct-97 1 F Throat A A 1A 2 1 SXT, ERY, TET 
Sp027 31-0ct-97 65 F Sputum G G 19 9A 2 1 ERY,TET 
Sp028 04-Nov-97 F Pus A B 19 lC 4 8 SXT, ERY, TET 
Sp029 07-Nov-97 1 F Sputum G G 19 9A 2 1 ERY, TET 
Sp030 10-Nov-97 4 F Skin B A 23F 2H 2 2 SXT, ERY, TET, CHL 
Sp031 Il-Nov-97 5 M Adenoid A A 19 1A 4 2 SXT, ERY, TET 
~I'~~~ .. _ 12-Nov-97 69 M B B 19 lOA 4 4 CHL 
-
Sp033 
Sp035 
Sp036 
Sp038 
Sp039 
Sp040 
Sp041 
Sp042 
Sp043 
Sp044 
Sp045 
Sp046 
Sp047 
Sp051 
Sp055 
Sp056 
Sp057 
Sp058 
Sp059 
Sp061 
Sp062 
Sp069 
Sp076 
spon 
Sp078 
Sp079 
Sp081 
Sp082 
Sp089 
Sp091 
Sp096 
SplO1 
Spl05 
Spll0 
Spl15 
Sp1l9 
Sp120 
Sp122 
Sp133 
Sp138 
Sp145 
Sp147 
Sp150 
Sp160 
Sp161 
Sp162 
Sp168 
171 
13-Nov-97 
19-Nov-97 
19-Nov-97 
21-Nov-97 
M Adenoid 
1 M Eye 
3 M Ear 
F Ear 
24-Nov-97 16 days M 
25-Nov-97 27 F Eye 
6mth F 
69 M 
3 mth F 
2 M 
3 M 
6 M 
9mth F 
4 M 
5 F 
3 F 
Ear 
Sputum 
Eye 
Eye 
Adenoid 
Throat 
Eye 
Eye 
Eye 
28-Nov-97 
02-Dec-97 
05-Nov-97 
08-Dec-97 
09-Dec-97 
09-Dec-97 
12-Dec-97 
08-Jan-98 
14-Jan-98 
14-Jan-98 
16-Jan-98 
19-Jan-98 
20-Jan-98 
21-Jan-98 
21-Jan-98 
04-Feb-98 
18-Feb-98 
23-Feb-98 
24-Feb-98 
24-Feb-98 
25-Feb-98 
25-Feb-98 
ll-Mar-98 
16-Mar-98 
76 M Sputum 
2 M Eye 
70 M Sputum 
2 M Adenoid 
1 F 
4 F 
2 F 
7 F 
8 F 
12 M 
4 F 
Ear 
Eye 
Nose 
Eye 
Eye 
Ear 
15 F Eye 
70 M Sputum 
? M Eye 
19-Mar-98 10 mth F 
24-Mar-98 18 F 
26-Mar-98 90 M 
02-Apr-98 84 M 
08-Apr-98 70 M 
16-Apr-98 70 M 
17 -Apr-98 70 F 
l1-Apr-98 1 F 
01-May-98 33 F 
07-May-98 8 mth M 
18-May-98 1 F 
16-May-98 1 F 
20-May-98 M 
Eye 
Eye 
Sputum 
Sputum 
Sputum 
Sputum 
Ear 
Ear 
Nose 
Ear 
Ear 
Ear 
Eye 
02-Jun-98 
02-Jun-98 
02-Jun-98 
04-Jun-98 
08-Jun-98 
M Ear 
2 
67 
25 
37 
F Adenoid 
M Sputum 
F Sputum 
L, .•• · •• ".·· .. ·.·· •••••• " ••••• M SPlltll~ 
B B 2J 0.5 SXT, TET, CHL 
B B 23F 2A 4 2 SXT, ERY, TET, CHL 
E L 14 0.12 0.12 
A A 19 1A 4 1 SXT, ERY, TET 
A A lA 4 SXT, ERY, TET 
A B nt 15 2 ERY 
B B 3A 1 ND SXT 
A A 19 lA 4 8 SXT, ERY, TET 
F I 5A I SXT 
DInt 111 0.12 0.12 SXT, ERY, TET 
B B 23F 2G 2 SXT, ERY, CHL 
B B 
E L 
A A 
D I 
D I 
A A 
D I 
A' A 
A A 
H J 
D G 
G G 
D I 
D I 
G H 
M E 
D I 
A A 
D I 
B B 
14 3B 1 1 
16 0.12 0.06 SXT 
lA 4 1 
11 C 0.12 0.12 
lIC 0.12 0.12 
1A 2 
nt lID 0.12 0.12 
19 1A 4 16 
19 lA 2 2 
12A 0.12 0.06 
llA 0.12 0.12 
9B 2 1 
lID 0.12 0.12 
lID 0.12 0.12 
2M 1 
6 1 ND 
lID 0.12 0.12 
1A 2 4 
llC 0.12 0.12 
7 2 0.5 
SXT, ERY, TET 
SXT,ERY,TET 
SXT, ERY, TIT 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, CHL 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, CHL 
D I 11C 0.12 0.12 SXT, ERY, TET 
B B 23F 2A 4 2 SXT, ERY, CHL 
A A 1A 4 2 SXT, ERY, TET 
A A 1A 4 8 SXT, ERY, TET 
A A lA 2 4 SXT, ERY, TET 
B B 2D 2 SXT, ERY, CHL 
B B 3B ND SXT 
A A 1A 4 8 SXT, ERY, TET 
A A 1A 2 1 SXT, ERY, TET 
A A 1A 2 1 SXT, ERY, TET 
A A lA 2 1 SXT, ERY, TET 
B B 2G 2 SXT, ERY, ClI 
A A lA 2 SXT, ERY, TET 
B B 3D 1 0.5 SXT 
B B 2A 2 SXT, ERY, CHL 
A A lA 4 1 SXT,ERY, TET 
A A 1A 2 8 TET 
Sp174 1O-Jun-98 
SpI77 I2-Jun-98 
Sp180 l2-Jun-98 
Sp 182 18-Jun-98 
Sp183 17-Jun-98 
Sp19l 29-Jun-98 
Sp 192 29-Jun-98 
Sp194 30-Jun-98 
Sp198 01-Jul-98 
Sp202 02-Jul-98 
Sp206 06-Jul-98 
Sp2II 09-Jul-98 
Sp212 09-Jul-98 
Sp214 1O-Jul-98 
Sp217 13-Jul-98 
Sp22l 10-Jul-98 
Sp226 16-Jul-98 
Sp228 17 -Jul-98 
Sp237 23-Jul-98 
Sp239 23-Jul-98 
Sp240 24-Jul-97 
Sp242 27-Jul-98 
Sp243 27-Jul-98 
Sp247 29-Jul-98 
Sp249 04-Aug-98 
Sp254 06-Aug-98 
Sp256 07-Aug-98 
Sp257 07-Aug-98 
Sp258 07-Aug-98 
Sp259 07-Aug-98 
Sp262 10-Aug-98 
Sp269 15-Aug-98 
Sp272 17-Aug-98 
Sp273 18-Aug-98 
Sp280 25-Aug-98 
Sp281 26-Aug-98 
Sp284 27-Aug-98 
Sp288 20-Jul-98 
Sp289 19-Nov-97 
Sp303 09-Sep-98 
Sp304 10-Sep-98 
Sp306 11-Sep-98 
Sp307 14-Sep-98 
Sp312 17-Sep-98 
Sp324 25-Sep-98 
Sp330 02-0ct-98 
Sp332 05-0ct-98 
§J)"~_8~, 08-0ct-98 
2 F Nose 
43 F Nose 
4 M 
37 FEar 
2 M Ear 
13 F Eye 
11 F Eye 
1 FEar 
71 M Sputum 
85 FEar 
75 M Sputum 
52 F Nose 
33 F Nose 
2 M Ear 
81 F Sputum 
69 M Sputum 
2 M Nose 
II M Eye 
2' FEar 
32 M Sputum 
81 F Sputum 
? FEar 
43 M Sputum 
II mth F Eye 
5 M Adenoid 
5 FEar 
9mth M Ear 
6 F Eye 
2 M Ear 
M Nose 
2 M Ear 
12 M Ear 
1 M Ear 
2 M Ear 
6 M Ear 
2 M Ear 
4 M Nose 
69 M Sputum 
4 F Nose 
2wk M Eye 
34 F Pus 
2 FEar 
7mth M Ear 
6 mth M Eye 
3mth M Eye 
1 wk F Eye 
14 M Eye 
43 F Nose 
A A lA 4 1 SXT, ERY, TET 
A A 19F lA 2 1 SXT, ERY, TET 
A A lA 2 2 SXT,ERY,TET 
A A 19F lA 4 4 SXT, ERY, TET 
A A lA 4 1 SXT, ERY, TET 
D 1 III 0.12 0.12 SXT, ERY, TET 
D I lID 0.12 0.12 SXT, ERY, TET 
A B IA 4 0,5 SXT, ERY, TET 
A A lA 4 8 SXT, ERY, TET 
A A lA 2 1 SXT, ERY, TET 
B B 3B 2 
B B 3C 0.5 ND SXT 
B B 2A 4 SXT, ERY, CHL 
B B 3A 4 
B B 
B B 
A A 
D I 
A' A 
B B 
B B 
L 0 
A B 
A A 
I L 
B B 
A A 
D 1 
A A 
B B 
A A 
A A 
A B 
A A 
B B 
A A 
A A 
A A 
B B 
A A 
B B 
A A 
A A 
A A 
B B 
B B 
A A 
A A 
2E 2 
ID 2 
IA 4 
SXT, TET, CHL 
2 SXT, ERY, TET 
8 SXT, ERY, TET 
llJ 0.12 0.12 
lA 8 8 SXT,ERY,TET 
3A 2 2 
2A 4 SXT, ERY, CHL 
5B 0.5 ND SXT 
lA 4 2 SXT, ERY, TET 
IA 2 0.5 SXT, ERY, TET 
12B 0.12 0.06 SXT 
3B 
IA 
1 
4 
ND SXT 
8 
lID 0.12 0.12 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT 
lA 4 2 
3A 
lA 
IB 
lA 
lA 
3C 
lA 
lA 
IA 
3B 
IA 
3B 
IA 
lA 
lA 
21 
3C 
lA 
1 
4 
4 
4 
4 
1 
4 
2 
2 
1 
8 
4 
2 
4 
4 
4 
0.5 
4 
ND 
8 
2 
1 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
8 SXT,ERY,TET 
0.5 SXT 
8 
4 
2 
ND 
1 
8 
1 
ND 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT 
SXT, ERY, TET 
ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET, CHL 
SXT 
.••••.• ~ ••••... "." ••••••••••.•.••••• ! ••• " .. 
Sp341 
Sp342 
Sp349 
Sp350 
Sp351 
Sp353 
Sp358 
Sp367 
Sp372 
Sp377 
Sp378 
Sp380 
Sp383 
Sp385 
Sp388 
Sp401 
Sp405 
Sp411 
Sp412 
Sp413 
Sp414 
Sp415 
Sp416 
Sp417 
Sp418 
Sp419 
Sp421 
Sp422 
Sp423 
Sp425 
Sp426 
Sp429 
Sp431 
Sp432 
Sp433 
Sp436 
Sp437 
Sp438 
Sp439 
Sp440 
Sp441 
Sp443 
Sp444 
Sp445 
Sp446 
Sp447 
Sp449 
13-0ct-98 
13-0ct-98 
23-0ct-98 
23-0ct-98 
27-0ct-98 
29-0ct-98 
04-Nov-98 
12-Nov-98 
20-Nov-98 
27-Nov-98 
27-Nov-98 
30-Nov-98 
01-Dec-98 
03-Dec-98 
ll-Dec-98 
14-Dec-98 
15-Dec-98 
19-Dec-98 
22-Dec-98 
22-Dec-98 
16-Feb-99 
05-Mar-99 
05-Mar-99 
05-Mar-99 
08-Mar-99 
23-Mar-99 
26-Mar-99 
26-Mar-99 
22-Mar-99 
08-Apr-99 
09-Apr-99 
20-Apr-99 
28-Apr-99 
06-May-99 
10-May-99 
16-0ct-00 
17-0ct-00 
17-0ct-00 
26-Mar-Ol 
04-Apr-Ol 
09-Apr-Ol 
21-Apr-Ol 
o I-May-O 1 
03-May-Ol 
20-May-Ol 
05-Jun-0l 
07-Jun-Ol 
II-Jun-Ol 
1 M Eye 
45 M Eye 
56 F Ethmoid 
1 M Ear 
18 F Eye 
2 F Eye 
1 M Eye 
2wk F 
62 M 
3 F 
Eye 
Sputum 
Eye 
41 M Sputum 
6wk F Eye 
5 M Eye 
2 M Ear 
1 FEar 
9 mth FEar 
1 M Nose 
53 FEar 
7 M AdenQid 
1 FEar 
6 F Eye 
2 F Nose 
2 F Nose 
91 M Sputum 
1 F 
2 M 
7mth M 
56 F 
Ear 
Nose 
Ear 
Sputum 
1 FEar 
41 F SW 
40 F 
2 M Ear 
16 F 
2mth F 
8mth F 
76 F 
87 F 
44 F 
Sputum 
Eye 
Eye 
Sputum 
Sputum 
Sputum 
3 FEar 
30 F Sputum 
1 F Nasal 
1 FEar 
76 F Eye 
6 wk F Eye 
7 mth M Ear 
1 M Ear 
52 M Ethmoid 
2 ? Nasal 
A B 
D I 
A A 
A A 
D I 
A A 
A A 
A A 
A A 
B B 
B B 
A A 
D I 
B B 
A A 
A A 
A A 
A A 
B' B 
A B 
D I 
A A 
A A 
B B 
B B 
A A 
A A 
B B 
I L 
B B 
D I 
B B 
A B 
B B 
A A 
G D 
B B 
A A 
A B 
A A 
C B 
A A 
A A 
B B 
A A 
A B 
B B 
A A 
IA 1 2 
lIE 0.12 0.12 
lA 4 1 
IA 4 2 
lIE 0.12 0.12 
1A 
lA 
lA 
IE 
2N 
2G 
1A 
2 
2 
4 
4 
2 
2 
4 
1 
4 
8 
1 
1 
2 
2 
lID 0.12 0.06 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, TET, CEL 
SXT, ERY, TET, CRL 
SXT, ERY, TET 
SXT, ERY, TET 
3E 
1A 
1A 
lA 
IA 
3E 
0.5 
4 
4 
2 
2 
0.5 SXT 
2 
8 
8 
1 
1 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
SXT, ERY, TET 
1A 2 SXT, ERY, TET 
llC 0.12 0.12 SXT, ERY, TET 
lA 4 1 SXT, ERY, TET 
lA 4 1 SXT, ERY, TET 
2A 4 2 SXT, ERY, CHL 
2A 2 1 SXT, ERY, CRL 
IA 4 16 SXT, ERY, TET 
lA 8 16 SXT, ERY, TET 
3A 2 1 SXT 
17 0.12 0.06 SXT 
3C 1 SXT 
lID 0.12 0.12 SXT, ERY, TET 
3D 1 ND SXT 
18 1 1 SXT, TET 
3D 0.5 SXT 
19 2 0.5 SXT, ERY, TET 
2M 0.5 0.25 SXT, ERY, TET, CRL 
2A 1 1 SXT, ERY, TET, CRL 
lA 4 8 SXT, ERY, TET 
lA 1 SXT, ERY, TET 
lA 0.5 SXT, ERY, TET 
25 0.12 0.12 SXT, ERY, TET 
lA 2 SXT, ERY, TET 
lA 1 0.5 ERY, TET 
20 1 ND SXT 
lA 1 SXT, ERY, TET 
lA 1 SXT, ERY, TET 
3E ND SXT 
1A 2 1 
20-Jun-Ol 20 M D I 0.12 ERY, TET 
20-Jun-Ol 1 F Ear A B lA 2 ERY, TET 
20-Jun-Ol 1 F Ear E B 13 0.12 ,TET 
26-Jun-Ol 6mth F Eye A A lA 1 2 ERY, TET 
27-Jun-0l 83 F Sputum D I lIH 0.2S ERY, TET 
28-Jun-Ol 34 F Sputum A A lA 2 ERY,TET 
29-Jun-Ol S4 F Sputum A A lA ERY,TET 
29-Jun-Ol 72 M Sputum A A lA ERY, TET 
04-Jul-01 48 ML A A lA 1 ERY,TET 
OS-Jul-01 66 M Sputum A A lA 1 2 ,ERY,TET 
OS-Jul-Ol 70 M Sputum A A IE 1 
06-Jul-Ol 1 M Ear A B lA 2 
06-Jul-Ol 3 F Vulva B B 3D 0.5 
12-Jul-Ol Smth F Eye A A lA 1 2 
13-Jul-Ol 1 M Ear A B lA 2 1 
23-Jul-Ol 2 F Eye N B 22 1 
23-Jul-Ol 74 M Ear A L 23 1 
23-Jul-Ol S F Ear I . L 24 0.12 
24-Jul-Ol F Ear A A IE 1 
24-Jul-01 F Ear A A lA 2 
24-Jul-Ol 10 mth F Eye A A lA 1 
2S-Jul-0l 38 F Eye D I lIe 0.12 
2S-Jul-Ol 2 M Ear A A lA 1 
Table A.I. ii Isolate data on invasive isolates characterised by MLST. 
Pen, penicillin; Ctx, cefotaxime (both detennined by Etest); ERY, erythromycin, SXT, co-trimoxazole, TET, 
tetracycline, CHL, chloramphenicol; CSF, cerebral spinal fluid; PDF, peritoneal dialysis fluid; ACF, abdominal 
cavity fluid; Dashes (--) signify susceptibility to all four antibiotics, (*) resistance to tetracycline not determined, (* *) 
resistance to tetracycline and co-trimoxazole not detennined, 
,'" ~ ~" ='C' " DenMI(0~t~m~, 
Isolate Source, Regioii ' 'SelZot~Re (lr!c '{mil f-~ _~ml Resistance llrofile ' 
P92-095 Blood Auckland 14 0.016 0.016 ERY 
P92-247 Blood Hamilton 19A 0.25 0.6 SXT 
P93-060 Blood Auckland 19F 1 0.12 
P93-075 Blood Auckland 9N 0.016 0.016 
P93-116 Blood Auckland 14 0.016 0.016 ERY 
P93-216 Blood Christchurch 19A 0.016 0.016 
P93-241 Blood Whakatane 6B 2 1 ERY, SXT, TET, CHL 
P93-295 CSF Palmerston North 23F 0.12 0.12 
P93-308 Blood Auckland 19F 0.016 0.016 TET 
P93-316 Blood Christchurch 23F 0.016 0.016 
P93-345 Blood Dunedin 19A 0.12 0.06 SXT 
P94-001 Blood Auckland 14 0.016 0,016 SXT 
P94-008 Blood Auckland 23F 2 1 TET,CHL 
P94-015 Blood Auckland 9V 0.03 0.016 
P94-054 Blood Christchurch 19F 0.016 0.016 
P94-055 Blood Christchurch 14 0.016 0.016 
P94-099 Blood Auckland 23F 2 1 SXT, TET, cm~ 
P94-115 Blood Auckland 9V 0.016 0.03 
P94-212 Blood Auckland 23F 2 1 ERY, SXT, CHL 
P94-271 CSF Christchurch 19 0,016 0.016 
P95-066 Blood Christchurch 19A 0.12 0.06 SXT 
P95-194 Blood Christchurch 14 0.016 0.016 
P95-213 Blood Palmerston North 9V 0.016 0.016 
P95-255 Blood Auckland 14 0.5 0.12 
P95-298 Blood Auckland 9N 0.03 0.016 
P95-347 Blood Auckland 9V 2 1 SXT 
P96-165 Blood Rotorua 19F 2 1 ERY, SXT, CHL 
P96-466 Blood Auckland 6B 2 1 ERY, SXT, TET, CHL 
P97-036 Blood Whangarei 14 2 1 ERY, SXT, TET, CHL 
P97-076 Blood Auckland 19F 2 1 ERY* 
P97-083 Blood Auckland 23F 2 1 CHL* 
P97-291 CSF Dunedin 19F 4 2 ERY, SXT* 
P97-350 Blood Auckland 23F 2 1 ERY, SXT, CHL* 
A97-359 CSF Dunedin 19F 4 1 ERY, SXT, TET 
P97-377 Blood Auckland 9V 2 1 * 
P97-552 Blood Auckland 9V 2 1 * 
P97-626 Blood Christchurch 191<' 4 8 ERY, SXT* 
P98-120 PDF Hamilton 19F 2 0.5 ERY** 
P98-122 ACF Hamilton 23F 2 1 CHL** 
P98-136 CSF Wellington 23F 2 1 CHL** 
P98-206 Blood Dunedin 9V 2 1 --** 
P98-263 Blood Hawera 9V 2 0.5 ** 
~' , ' ~ n~~'M[(inifim~' " 
Jsolate Source Regjon _ ~ero~:p~ ,~ijgziil~ ~f.!g~m:I Resistance Brnfile 
P98-283 Blood Auckland 19F 4 2 ERY,CHL** 
P98-286 Blood Christchurch 14 2 1 --** 
P98-299 Blood Christchurch 23F 2 1 ERY, CHL** 
P98-356 Blood Whangarei 9V 2 1 ** 
P98-475 Blood Auckland 23F 2 1 ERY, CHL** 
P98-555 Blood Christchurch 14 2 1 ** 
A99-074 CSF Auckland 23F 2 4 CHL 
Table A.I. iii Isolate data on non-invasive isolates characterised by MLST. 
Pen, penicillin; Ctx, cefotaxime (both detennined by Etest), ERY, erythromycin, SXT, co-trimoxazole, TET, 
tetracycline, CHL, chloramphenieoL 
~ -"", ~ ~" ~ ~'" if < 
~ : ,:'~ _~ Re!l'MIClH.&ltX'MI(8 
'lsolate Source Region Sero~pe ~MgZmlJc -( 'gZmll [Resistance [Rr!;tlle I, 
A93-380 Nasopharynx Auckland 19F 2 1 ERY, SXI', I'EI' 
A93-431 Sputum Wellington 19F 2 1 ERY, SXI', I'EI' 
A93-612 Ear Auckland 19F 4 1 ERY, SXT, I'EI' 
A94-993 Sputum Christchurch 19F 2 1 ERY, TET 
A95-061 Eye Christchurch 19F 2 1 ERY, SXT, TET 
A95-109 Ear Wanganui 19F 4 1 ERY,SXT 
A95-176 Ear Christchurch 19F 4 2 ERY, SXT, TET 
A95-235 Sputum Christchurch 19F 2 1 ERY, SXT, TET 
A96-755 Ear Christchurch 19F 2 1 ERY, SXI', TET 
A97-006 Ear Christchurch 19F 2 1 ERY, SXT, TEI' 
A97-066 Ear Hastings 19F 2 1 ERY, I'ET 
A97-503 Ear Wellington 19F 2 1 ERY, SXT, TET 
A97-550 Eye Hamilton 23F 2 1 ERY, SXI', CHL 
A97-635 Eye Palmerston North 19F 4 2 ERY, SXT, TET 
A97-724 Ear Palmerston North 19F 8 32 ERY, SXT, TET 
A98-370 Sputum Christchurch 19F 4 1 ERY, SXT, TET 
A98-441 Ear Christchurch 19F 4 0.5 ERY, SXI', I'ET 
A98-537 Sputum Invercargill 19F 0.5 16 ERY, SXT, TET 
A98-619 Ear Christchurch 19F 4 1 ERY, SXT, TET 
A99-539 Eye Christchurch 19F 4 8 ERY, SXT, TET 
A99-909 Eye Palmerston North 14 4 8 ERY, SXT, TET 
A99-1014 Sputum Hamilton 19F 4 4 ERY, SXT, TET, CHL 
AOO-058 Eye Whangarei 19F 4 8 ERY, SXT, TET, CHL 
A00-499 Sputum Palmerston North 19F 4 8 ERY, SXT, TET 
AOO-716 SEutum Christchurch 19F 8 16 ERY, SXT, CHL 
Appendix 
Media 
II.i General media 
Unless otherwise stated, media were sterilised by autoc1aving for 20 min at 121°C at 103.4 kPa. 
Solutions that were unstable at this temperature were filter sterilised by passing through a 0.22 
I-lm filter and added to sterile media. Solid media was stored at 4°C while broths were stored at 
ambient temperature. 
Tryptic Soya Agar (TSA) + 5% Sheep Blood 
Typical Formula 
Pancreatic digest of casein 
Papaic digest of soyabean meal 
NaCI 
Bacteriological agar 
Defibrinated sheep blood 
Per litre 
15 g 
5g 
5g 
15 g 
50ml 
Halfvolumes of the above was mixed with 475 ml of dH20 and sterilised by autoclaving. Agar 
was cooled to 50°C before addition of 25 ml defibrinated sheep blood. Components were 
thoroughly mixed and dispensed into sterile petri dishes. 
Mueller Hinton + 5% Sheep Blood Agar 
Typical Formula 
Acid digest of casein 
Beef extract 
Starch 
Bacteriological agar 
Defibrinated sheep blood 
Per litre 
17.5 g 
2.0 g 
1.5 g 
17 g 
50ml 
19 g of the agar base (Remel, Lexena, KS) was mixed with 475 ml of dH20 and sterilised by 
autoclaving. Agar was cooled to 50°C before addition of 25 ml defibrinated sheep blood. 
Components were thoroughly mixed and dispensed into sterile petri dishes. 
Brain Heart Infusion (BID) Broth 
Typical Formula 
Beefheart infusion 
Calf brain infusion 
Protease peptone 
NaCl 
Na2HP04: 12H20 
Per litre 
25 g 
20 g 
10 g 
5g 
2.5 g 
Glucose 2 g 
19.0 g of broth base (Oxoid, Hampshire, England) was mixed with 500 ml of dH20 and 
sterilised by autoclaving. 
Todd Hewitt (TH) Broth 
Typical Formula 
Infusion from 450 g fat free minced meat 
Tryptone 
Sodium bicarbonate 
NaCl 
Na2HP04: 12H20 
Per litre 
109 
20 g 
2g 
2g 
0.4 g 
17 g of broth base (Oxoid, Hampshire, England) was mixed with 500 ml of dH20 and sterilised 
by autoclaving. Where stated in the text, TH broth was supplemented with 0.5% (w/v) yeast 
extract, added prior to autoclaving. 
Appendix 
Buffers and Solutions 
Buffers and solutions requiring sterilisation were autoclaved for 20 min at 121°C at 103.4 kPa 
or filter sterilised by passing tln'ough a 0.22 11m filter. Unless stated otherwise, all buffers and 
solutions were stored at ambient temperature. 
III.i General stock solutions and buffers 
0.9% Saline 
0.15 MNaCl 
Dissolved in dH20 to a final volume of 1 litre. 
Phosphate Buffered Saline 
145 mMNaCI 
1.7 mM KH2P04 
4.2 mM Na2HP04 
Dissolved in dH20 to a final volume of 1 litre, pH adjusted to 7.4. 
Phosphate buffer, pH 6.0 
50mMKH2P04 
5.7mMNaOH 
Dissolved in dH20 to a final volume of 1 litre, pH checked. 
Per litre 
9.0 g 
Per litre 
8.5 g 
0.3 g 
0.6 g 
Per litre 
6.8 g 
0.23 g 
10% Sodium Dodecyl Sulphate (SDS) 
SDS 
Per litre 
100 g 
Dissolved in dH20 at 68°C to a final volume of 1 L. pH was adjusted to 7.2 with concentrated 
hydrochloric acid. 
III.ii Standard agarose electrophoresis buffers & solutions 
SOx TAE 
50 mM Tris base 
0.11 % v/v glacial acetic acid 
1 mMEDTA(pH 8.0) 
Made up to 1 Lin dH20 and pH adjusted to 8.0. 
Ix TAE 
20 ml of SOx TAE made up to 1 L with dH20. 
6x DNA Loading Dye for Agarose Gel Electrophoresis 
50% (v/v) Glycerol 
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene eyanol 
Made up to 10 m1 in dH20. 
III.iii Chromosomal DNA Purification Solutions 
Ix TEBuffer 
10 mM Tris-HCl 
1 mMEDTA 
50 m1 of 20x TE buffer made up to 1 L with dH20. 
Per litre 
242 g 
57.1 m1 
46.5 g 
GES Lysis Solution 
Guanidium thiocyanate 
0.1 M EDTA (pH 8.0) 
dH20 
Per 100 ml 
60 g 
20 ml (0.5 M stock) 
20ml 
10% v/v N-lauroyl sarcosine 5 ml 
Guanidium thiocyanate and dH20 heated at 65°C and mixed until dissolved. 10% N-lauroyl 
sarcosine added after cooling. Made up to 100 ml with dH20 and passed through a 0.45 Ilm 
filter. 
7.5 M Ammonium Acetate 
NH4C2H30 2 
Dissolved in dH20 to a final volume of 1 L. 
24:1 Chloroform/lAA 
Chloroform 
Isoamyl alcohol (IAA) 
Mixed thoroughly and stored at 4°C in a dark glass bottle. 
III.iv PFGE Buffers And Solutions 
Per litre 
577.5 g 
Per 50 ml 
48 ml 
2ml 
Molecular biology grade reagents and distilled water were used wherever possible for all 
solutions and buffers. PFGE buffers and solutions were either autoclaved at 121°C at 120 kPa or 
filter sterilised through a 0.22 Ilm filter. 
lII.iv.i PFGE Stock Solutions 
1 M Tris-HCL 
Tris base 
Per 200 ml 
24.22 g 
Dissolved in 150 ml dH20 with gentle heat, pH adjusted to 7.6 by addition of concentrated HCI. 
Made up to final volume of 200 ml and stored at 4°C. 
O.SMEDTA 
EDTA 
NaOH pellets 
Per litre 
186.1 g 
22g 
Dissolved in 800 rnl dH20 with gentle heat. pH adjusted to 8.0 by addition of more NaOH 
pellets. Made up to [mal volume of 1 L and stored at 4°C. 
5 M Sodium Chloride 
NaCl 
Dissolved in 800 rnl dH20 by heating. Made up to 1 L final volume. 
20x TE Buffer 
200 mM Tris-HCI 
2mMEDTA 
Dissolved in dH20, pH adjusted to 8.0. 
lOx PFG-TBE (Tris-borate-EDTA) 
1 M Tris-HCL 
1 M Boric Acid 
2mMEDTA 
Per litre 
295 g 
Per litre 
24.22 g 
4 rnl (0.5 M stock) 
Per litre 
121.1 g 
61.83 g 
4 rnl (0.5 M stock) 
Dissolved in 800 ml dH20 with gentle heat. Made up to 1 L and stored at 4°C. 
llI.iv.ii PFGE worldng solutions 
EC Lysis Buffer 
6 mM Tris-HCI 
1 MNaCl 
100mMEDTA 
0.5% Brij-58 
0.2% Sodium deoxycholate 
Per 400 ml 
2.4 ml (1 M stock) 
80 ml (5 M stock) 
80 ml (0.5 M stock) 
2g 
0.8 g 
0.5% N-Lauroyl sarcosine 2 g 
Dissolved in 100 ml dH20 with gentle heat, Made up to 400 m! and filter sterilised in 20 ml 
aliquots. Stored at -20°C. Before use, 1 mglml (final cone.) lysozyme and 20 Jlg/ml (final 
cone.) of heat-treated RNase was added. 
ESP Buffer 
0.5MEDTA 
Per 400 ml 
400ml 
1 % N-Lauroyl sarcosine 4 g 
N-Lauroyl sarcosine was added to sterile 0.5 M EDTA solution and shaken vigorously to 
dissolve. 0.5 mglml (final cone.) Proteinase K was added prior to use. 
PETT IV Buffer 
10 mM Tris-HCI (PH 7.6) 
1 MNaCl 
Made up to 1 Lin dHzO and stored at 4°.C. 
1x TE Bufl"er 
50x TE stock buffer 
Made up to 500 ml in dH20 and stored at 4°C. 
Per litre 
10 ml (1 M stock) 
200 ml (5 M stock) 
Per 500 ml 
25ml 
O.5x PFG-THE 
lOx PFG-TBE stock 
Made up to 2 L in dH20 immediately prior to use. 
III.v Southern Hybddisation Buffers and Solutions 
Depurination Solntion 
0.2 M HCI 
Prepared using concentrated HCI diluted with dH20. 
Denaturation Solution 
0.5MNaOH 
1.5MNaCI 
Dissolved in dH20. 
Neutralisation Solution 
0.5 M Tris-HCI (pH 7.0) 
3 MNaCI 
Dissolved in dH20, adjusted to pH of 7.0. 
20x SSC (Standard Saline Citrate) 
3 MNaCI 
0.3 M Trisodium citrate 
Dissolved in dH20, adjusted to pH of 7.0 with citric acid. 
Transfer Solution 
20x SSC, pH 7.0 
Per 2 L 
100ml 
Per litre 
17.2 m1 
Per litre 
20 g 
87.7 g 
Per litre 
76.9 g 
175.5 g 
Per litre 
175 g 
88 g 
DIG Buffers and Solutions 
1 M Maleic Acid 
Maleic acid 
Made up to 1 L in dH20 and stored at ambient temperature. 
Maleic Acid Buffer 
0.1 M maleic acid 
0.15 M NaCI 
Adjusted to pH of 7.5 with NaOH pellets. 
Washing Buffer 
Maleic Acid buffer 
0.3% v/v Tween 20 
Blocking Solution 
10% v/v blocking reagent (kit-stored in freezer) 
90% v/v maleic acid buffer. 
Prepared freshly for each hybridisation, heated to 37°C to dissolve 
Post-Hybridisation Low Stringency Wash I 
2x SSC 
0.1% SDS 
Made up to 1 L with dH20 
Detection Buffer 
0.1 M Tris-HCI 
0.1 MNaCI 
Adjusted to pH of9.5 with NaOH pellets, made up to 1 L with dH20 
Per litre 
116.1 g 
Per litre 
100 ml (1 M stock) 
30 ml (5 M stock) 
Per litre 
100 ml (20x stock) 
10 ml (10%) 
Per litre 
100 ml (1 M stock) 
20 ml (5 M stock) 
III.vi Protein Extraction and Labelling Buffers and Solutions 
Protein Extraction Buffer 
140:mNI NaCI 
20 mM K.H2P04 
Dissolved in dH20 to a final volume of 1litre, pH adjusted to 7.5. 
ITI.vi.i SDS-PAGE stock solutions 
1.5 M Tris-HCL (pH 8.8) 
Per litre 
8.2 g 
3.5 g 
Per 100 m1 
Tris base 18.15 g 
Dissolved 75 m1 dH20 with gentle heat, pH adjusted to 8.8 by addition of concentrated HCI. 
Made up to final volume of 100 m1 and stored at 4°c' 
0.5 M Tris-HCL (pH 6.8) 
Tris base 
Per 100 m] 
6.05 g 
Dissolved in 75 m1 dH20 with gentle heat, pH adjusted to 6.8 by addition of concentrated HCi. 
Made up to final volume of 100 m1 and stored at 4°C. 
30% w/v Acrylamide/Bis solution (37.5:1 ratio) stock (BioRad) 
Acrylamide 
N, N' -methylene-bis-acrylamide 
Purchased commercially from BioRad. 
Ammonium persulphate solution (Iml) 
10% Ammonium persulphate 
Made in 1 m1 dH20 prior to use, stored short tenn at -20°C. 
Per 500 m1 
146.1 g 
3.9 g 
0.1 g 
SDS-PAGE running buffer 
mMTris 
10 mM Glycine 
0.1 % SDS 
Make up to volume with dH20, stored at 4°C. 
Sample buffer 
0.125 M Tris 
4%SDS 
5% beta-mercaptoethanol 
5% Glycerol 
0.25% (w/v) Bromophenol blue 
Made up to 10 mls dH20, stored in 1 ml aliquots at -20GC 
IU.vi.ii SDS-PAGE gel formulations 
7.5°/6 Resolving gel 
7.5% AcrylamidelBis 
375 mM Tris-HCl (PH 8.8) 
1% SDS 
dH20 
TEMED 
0.5%APS 
Per litre 
3g 
14.4 g 
1 g 
Per 10 ml 
8.3 ml (l.5 M stock) 
OAg 
500 f-ll 
1 ml 
Per 10 ml 
2.5 ml (30% stock) 
2.5 ml (1.5 M stock) 
100 ) ..11 (10% stock) 
4.85 ml 
5 JlI 
50 ~Ll (10% stock) 
4.0% Stacking gel 
4.0% AcrylamidelBis 
125 mM Tris-HCl (pH 6.8) 
1% SDS 
dII20 
TEMED 
0.5%APS 
Per 10 m1 
1.3 m1 (30% stock) 
m1 (0.5 M stock) 
100 ~tl (10% stock) 
6.10 m] 
5 ~l 
50 ~ll (10% stock) 
Appendix IV 
p-Lactam s by Agar Dilution 
Table A.IV. MICs of seven 13-lactam antibiotics; raw data of 43 isolates of New Zealand 
19.F clone. 
Pen, penicillin; Pip, piperacillin; Ceph, cephalothin; Cfux, cefuroxime; Ceft, cefotaxime; Mem, meropenem. 
: 'MIC b~ Agar Dilution (Hglml) . E~e;t MIC 
~train "# Pen Pip (£eph Cclor (£fuX eeft; Mero 1 Pel! (£eft 
pia ~ 1 ~ ~ 
ATCC 49619 0.5 0.5 1 2 0.5 0.12 0.06 ND ND 
98-537 0.5 2 16 264 64 16 0.5 0.5 16 
97-066 1 2 8 264 4 1 0.5 2 1 
97-076 1 2 4 "264 4 1 0.5 2 1 
98-542 2 2 8 264 4 1 0.5 2 0.5 
96-755 2 4 16 264 4 1 0.5 2 1 
97-291 2 4 8 264 8 1 0.5 4 2 
97-769 2 4 32 264 16 4 1 ND ND 
97-816 (Sp038) 2 4 16 264 4 1 0.5 4 
98-120 2 4 16 264 4 1 0.5 2 0.5 
98-370 2 4 8 264 4 1 0.5 4 1 
98-491 (Sp202) 2 4 8 264 4 1 0.5 2 0.5 
98-618 (Sp272) 2 4 16 264 8 1 1 4 1 
98-619 2 4 16 264 8 1 0.5 4 1 
98-740 2 4 16 264 8 1 0.5 4 1 
98-779 2 4 8 264 4 1 0.5 4 1 
98-997 2 4 16 264 8 1 0.5 ND ND 
00-482 4 4 32 264 32 8 0.5 8 16 
00-486 4 4 32 264 32 8 0.5 4 16 
00-761 4 4 16 64 32 8 1 4 16 
00-903 4 4 32 264 32 8 1 4 16 
95-176 (Sp042) 4 4 32 264 32 8 1 4 2 
97-469 4 4 16 264 32 8 0.5 2 8 
97-626 4 4 16 264 32 8 1 4 8 
97-838 4 4 16 264 32 8 1 4 8 
98-509 4 4 32 264 32 8 1 8 8 
98-558 4 4 32 264 32 8 1 4 8 
98-560 (Sp262) 4 4 32 264 32 8 1 4 8 
98-653 4 4 16 264 32 8 1 4 8 
98-698 4 4 16 264 8 1 0.5 2 2 
98-853 4 4 32 264 32 8 1 2 4 
~ i ~~ ~ ! _;: ! ~- ""«,, ~ 
~ Mi~ by :A'gar Dilution (MgZmt~, ~ llltest NII(JJ 
Strain '# :Ben Rip ~ ~epli (JJclOl1 (JJfux ~ l!.ieft j Mero' R~n (JJeft 
~ \: "" ,",-4 " 0( J!! - "\ ~ 
98-886 4 4 16 264 32 8 1 4 8 
99-1014 4 4 32 264 32 8 1 4 4 
99-205 (Sp419) 4 4 16 264 32 8 1 4 16 
00-716 4 8 32 264 32 8 1 8 16 
00-879 4 8 32 264 32 8 1 4 16 
00-942 4 8 32 264 32 8 1 4 16 
97-724 4 8 32 64 32 8 1 8 32 
98-097 (Sp059) 4 8 32 264 32 8 1 4 16 
98-259 4 8 16 264 32 8 1 2 4 
98-441 (Sp194) 4 8 16 264 8 1 1 4 0.5 
99-206 (Sp421) 4 8 32 264 32 8 1 8 16 
99-539 4 8 32 64 32 8 1 4 8 
99-909 4 8 16 264 32 8 1 4 8 
